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ABSTRACT 
 
 
 
Mouse cytomegalovirus (MCMV), a β-herpesvirus, encodes the m145 family of 
glycoproteins. Several members of this family are predicted to adopt the MHC-I fold 
although their amino acid sequences exhibit less than 30% identity to classical MHC-I 
(MHC-Ia) proteins. Our aim was to determine how related the viral proteins are to MHC-
Ia and characterize them in terms of cellular expression, structure and function. We 
studied the cellular localization of FLAG-tagged m17, M37, m145, m151, m152, m153 
and m155 in transfected mouse fibroblasts. Flow cytometry analysis of transfected cells 
showed that M37, m145, m151 and m153 localize predominantly to the cell surface, 
whereas the majority of m17, m152 and m155 remain inside the cell. MHC-Ia proteins 
require assembly with β2-microglobulin (β2m) and peptide for stable cell surface 
expression. Transient transfection studies with β2m- or transporter associated with 
antigen (TAP)-deficient cell lines revealed that M37, m145, m151 and m153 could be 
expressed stably at the cell surface in the absence of β2m or TAP expression.  
 
To generate protein material for crystallization screening we evaluated both bacterial and 
insect cell expression systems. Although most m145 family members could be expressed 
in bacteria in insoluble inclusion bodies, none of the proteins could be accurately 
refolded. Since M37, m151 and m153 are cell surface molecules with the potential to 
bind receptors on host cells, we focused our structure determination efforts on them and 
evaluated their expression in Drosophila S2 insect cells. The extracellular domains of all 
three proteins expressed at significant levels, however, m151 tended to aggregate and 
 iii 
precipitate over time. M37 and m153 were stable and could easily be purified to 
homogeneity. Size exclusion chromatography and SDS-PAGE analysis of m153 
suggested that it forms a non-covalent homodimer. Analytical ultracentrifugation 
experiments confirmed this observation and provided an estimated molecular mass of 
78.8 kDa. Enzymatic and mass spectrometry analyses showed that insect-expressed m153 
is highly glycosylated. We tested a wide range of crystallization conditions for m153. It 
formed very fragile crystals and after optimization we obtained several that diffracted to 
2.3 Å. To determine the structure of m153, we prepared a seleno-methionine derivative in 
insect cells, collected data on a single crystal and solved the phases by the single 
anomalous dispersion method. The m153 model was refined at 2.4 Å resolution to final 
Rcryst and Rfree of 23% and 27.9%, respectively.  
 
The m153 homodimer is formed by two MHC-I-like heavy chains, each consisting of two 
α-helices arranged on a platform of seven β-strands and an Ig-like α3 domain. The 
monomers are arranged “head-to-tail”, with the α1α2 platform domain of one chain 
interacting with the Ig-like α3 domain of the other.  The α1 and α2 helices are closely 
juxtaposed and do not form a peptide binding groove. Three N-linked carbohydrate 
residues were visualized in the crystal structure. Major deviations from the MHC-I fold 
include an extended N-terminus, which originates next to the α3 domain, and an 
elongated α2 helix (designated H2b) that reaches down towards the α3 domain. In 
addition, m153 has two unique disulfide bonds, one between strands of the platform 
domain and another that links the extended N-terminus to the H2b helix. Both unique 
disulfide bonds were verified by mass spectrometry. The canonical Ig-fold disulfide bond 
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is present in the α3 domain. Alanine mutation of four amino acids involved in interface 
hydrogen bonds abolished m153 dimer formation, validating the dimer interface 
visualized in the structure. The crystal structure of m153, together with the recently 
reported m157 structure, confirms the MHC-I fold for the MCMV m145 family and 
highlights shared structural features in the m145 family. We have demonstrated 
dimerization of full-length m153 in mammalian cells by bimolecular fluorescence 
complementation and co-immunoprecipitation studies. Further, we have shown that m153 
is expressed at the surface of MCMV-infected cells at early times after infection.  
 
To initiate a search for host ligands of m153, we generated a reporter cell line by 
introducing an m153-human zeta chain fusion protein into 43.1 cells that contain an 
NFAT-driven GFP construct. While a variety of mouse cell lines were unable to stimulate 
the m153-reporter cells, coculture with mouse splenocytes specifically induced GFP 
production in m153-reporters but not in the parental or control reporter cell lines. We 
identified conventional CD11c+ and plasmacytoid dendritic cells (DCs) as the most 
potent m153-reporter cell stimulating populations in the spleen. The stimulation was 
shown to be m153-specific, dose- and cell contact-dependent. DCs derived from bone-
marrow cultures also potently stimulated the m153-reporter cells. Macrophages and NK 
cells exhibited weaker stimulation of the reporter cells, indicating lower levels of ligand 
or that only small subsets of the cells express a ligand. DCs from several mouse strains, 
but not from the rat, stimulated m153-reporter cells. We evaluated DC surface phenotype 
and migratory capacity after coculture with m153-reporter cells or on m153-coated 
plates, but could not detect any changes induced specifically by the presence of m153. 
 v 
The functional consequences of an interaction between MCMV m153 and mouse DCs 
remains to be explored. A viable approach to identify the m153 ligand/s is the generation 
and screening of DC-specific cDNA libraries with the m153-reporter cell line. 
Identification of a ligand will facilitate studies to establish m153’s function during virus 
infection and provide greater insight into the immune manipulation strategies of 
herpesviruses. 
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 CHAPTER 1 
 
LITERATURE REVIEW 
 
1.1 Introduction 
 
Viruses follow one of two strategies to propagate themselves successfully and survive 
within the host population. In the first strategy, the infection is of short duration, the host 
cells are often killed as a consequence of the infection and the virus is easily transmitted 
to a series of successive hosts. In the second strategy, the virus establishes a long-term 
persistent infection in one host from which virus may spread at frequent or infrequent 
intervals to other hosts. Viruses with a small coding capacity, such as the RNA-viruses 
influenza or rhinovirus, adopt the first strategy and rely on high antigenic variation to 
escape the host immune response. Viruses that have larger DNA genomes, like the pox- 
or herpesviruses, follow the long-term strategy and often co-exist with their hosts for 
life. Larger genomes enable DNA viruses to encode numerous proteins that can interact 
with the host immune response and tip the balance in favor of the virus and result in the 
establishment of persistent infections. The main aim of persistent viruses is to avoid 
detection by the immune system. Viruses use many different mechanisms to achieve this 
goal. Some viruses, such as herpes simplex, hide from the immune system by infecting 
non-permissive cell types that act as reservoirs for their genetic material. Little or no 
transcription takes place until certain events reactivate the virus and allow for its 
replication and spread (Steiner et al., 1990). Other pathways of viral interference include 
blockade of antigen presentation, evasion of natural killer (NK) cell responses, 
disruption of normal cytokine signaling networks, inhibition of apoptosis in virus-
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infected cells and evasion of antibody and complement responses (Finlay and McFadden, 
2006; Tortorella et al., 2000). The herpesvirus family provides examples of virus-
encoded proteins that target each of these different pathways.  
 
1.2 The Herpesviridae 
 
The herpesvirus family is divided into the alpha-, beta- and gamma-herpesvirinae. 
Historically the division was based on biological characteristics but more recent 
sequence-based phylogenetic analyses confirmed the major lineages (McGeoch et al., 
1995). The DNA genomes range from 125-230 kb and encode 70-200 genes. All three 
subfamilies share a set of around 40 genes that have similar genomic positions and 
nucleotide sequences. The viruses share a common evolutionary origin and molecular 
phylogeny of the family suggests that the virus sublineages had developed by co-
speciation with their hosts (McGeoch et al., 2006). Human pathogens are found in all 
three herpesvirus subfamilies. The α-herpesvirus HSV-1 causes cold sores, HSV-2 is the 
main cause of genital herpes, β-herpesviruses include the cytomegaloviruses and Epstein 
Barr virus and Kaposi’s sarcoma-associated herpesvirus are γ-herpesviruses that are 
associated with the onset of several malignancies.  
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1.2.1 β-herpesvirinae 
 
1.2.1.1  Human cytomegalovirus (HCMV) 
 
The β-herpesvirus subfamily consists of human herpes virus (HHV)-6, HHV-7 and the 
cytomegaloviruses. These three groups have a similar genome organization and content. 
The cytomegaloviruses exhibit strict host-specificity and are characterized by a slow 
replication cycle and tropism to secretory glands and hematopoietic cells (Krmpotic et 
al., 2003).  Cytomegaloviruses of many different species have been isolated. HCMV is 
the prototypic cytomegalovirus and derives its name from the characteristic enlargement 
of CMV-infected cells. Antibodies to HCMV can be detected in 50% to 90% of 
individuals and prevalence of the infection is linked to the socio-economic status of the 
population (Sissons et al., 2002). In healthy individuals the virus causes no clinical 
disease but infection of the immunocompromised host (transplant recipients, AIDS 
patients, neonates) can lead to serious and even fatal disease. Annually between 1% and 
3% of infants in the United States are affected by congenital CMV infection that causes 
mortality and permanent disabilities (Pereira et al., 2006). Development of a vaccine to 
prevent congenital CMV infection is therefore a high priority. Immunocompromised 
individuals that suffer from HCMV disease benefit from anti-viral treatment with several 
nucleoside analogs that target the viral polymerase. The available drugs however, have 
poor oral bioavailability and toxic side effects, and development of improved drugs and 
identification of novel drug targets is needed.  
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The strict host specificity of HCMV has complicated the study of its pathogenesis. 
Several rodent models have been utilized (mouse (Simon et al., 2006), rat (Kaptein et al., 
2006) and guinea pig (Schleiss and Lacayo, 2006)) and more recently non-human 
primates  (chimpanzee and rhesus macaque (Britt, 2006)), the results of the latter would 
presumably be easier to translate to the human disease than findings from the rodent 
models. However, the rodent models will probably still be widely used because the 
primate models have disadvantages such as high cost and ethical considerations.   
 
1.2.1.2  Mouse cytomegalovirus (MCMV) 
 
MCMV causes acute, persistent and latent infection in mice (Sweet, 1999). The dsDNA 
genome of MCMV is 230 kb and encodes at least 170 genes. The MCMV virion consists 
of three major layers (Figure 1.1). The genome is surrounded by an icosahedral capsid. 
The tegument, a proteinaceous layer, covers the capsid and a host-derived lipid bilayer 
forms the envelope. Viral glycoproteins are found in the envelope and they act as 
receptors that facilitate virus entry into cells.  
 
 
 
 
 
 
 
 
Figure 1.1. Cartoon representation of the MCMV virion. 
Viral glycoproteins 
Envelope 
Nucleocapsid 
dsDNA genome 
Tegument  
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The organization of the MCMV genome is such that the central genomic region encodes 
the genes essential for virus replication, which tend to be conserved among the CMVs of 
different species. The terminal genomic regions are more divergent and encode genes 
whose products are involved in immune evasion and are generally dispensable for virus 
growth in vitro (Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Schematic representation of the MCMV genome. Genes encoded in the 
central region of the genome are conserved between different herpesviruses and are often 
essential for virus replication. Genes found at the terminal regions of the genome are less 
conserved and contribute to immune evasion. Two of the best-studied immunoevasin 
families of MCMV are highlighted. The majority of the predicted MCMV MHC-I 
homologs are found within the m145 glycoprotein family. Positions in the genome are 
indicated in kb. 
 
MCMV genes can be divided into three classes, α, β, and γ, based on the timing of their 
expression. The genes are expressed at immediate early (IE), delayed early (E) and late 
(L) stages of the replication cycle in infected cells. After virus entry into the host cells, 
IE transcription occurs independent of de novo viral protein synthesis. A second E phase 
then follows but the expression of these genes is dependent on the prior expression of 
one or more IE genes which transactivate E promoters. The L phase of expression begins 
m145, m146, m150-155, m157,m158 m144 
m145 family 
 
202  
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m02 – m16 m17 
m02 family 
 
1  
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with the onset of virion DNA replication and viral structural proteins are then 
synthesized (Sweet, 1999).  
 
1.3 MCMV pathogenesis 
 
1.3.1 Acute infection 
 
Natural transmission of MCMV is most likely through contact with saliva from infected 
animals. The routes by which the virus enters the host have not been clearly established. 
It has been shown that newborn mice can be infected via the oral route and that the virus 
spread is similar to that observed after intraperitoneal inoculation (Krmpotic et al., 
2003), therefore it is likely that the virus enters the host via the upper respiratory and 
gastrointestinal tracts. Sexual transmission of MCMV could also be an important type of 
horizontal transmission (Krmpotic et al., 2003). Virus dissemination after intraperitoneal 
inoculation has been characterized well. Initially the virus replicates in macrophages and 
mesothelial cells that line the peritoneal cavity. From these sites the virus is spread by 
large mononuclear phagocytes to the spleen, liver and various other organs (Stoddart et 
al., 1994). MCMV can infect various cell types including different types of epithelial 
cells (glandular epithelial cells of the salivary gland, hepatocytes), endothelial cells, 
dendritic cells and tissue macrophages. In the spleen MCMV preferentially targets 
endothelial cells of the splenic stroma and induces changes in the microarchitecture of 
the spleen (Benedict et al., 2006).  
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In immunocompetent mice acute MCMV infection is usually controlled, whereafter a 
life-long persistent infection is established that is characterized by periods of latency and 
reactivation. The type of disease caused by MCMV infection in laboratory mouse 
models is highly dependent on the source of infectious virus (tissue culture-derived 
(TCV) or salivary gland extract-derived (SGV)), route and dose of inoculation, age and 
strain of mouse as well as the immune status of the animal. Infection of day-old BALB/c 
mice leads to ∼ 40% mortality in the third week post infection with virus replication 
detectable in several organs. Survivors display growth retardation until they are 4-6 
weeks of age. At this time virus replication is restricted to the salivary glands, where the 
virus persists for 4-6 months. After 6 months the infection becomes latent. In contrast, 
MCMV infection in adult immunocompetent mice does not cause mortality, significant 
organ damage is not observed and virus replication seems to be confined mostly to the 
salivary glands. After about two months the infection in the salivary glands is cleared 
and a latent infection is established (Reddehase et al., 1994). Disease manifestations in 
immunodeficient mice include interstitial pneumonia (Reddehase et al., 1985), adrenal 
necrosis (Reynolds et al., 1993; Shanley and Pesanti, 1986), bone-marrow aplasia 
(Mutter et al., 1988) and retinitis (Zhang and Atherton, 2002). These all correlate with 
clinical manifestations of HCMV infection in immunocompromised humans (Vancikova 
and Dvorak, 2001).  
 
1.3.2 Latency 
 
The mechanisms by which the MCMV genome enters into and is maintained in the latent 
state are not well understood. Latency is defined as a persistent infection in which the 
viral genome is present but gene expression is limited and infectious virus is not 
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produced (Roizman and Sears, 1987). In mice, several organs (liver, kidney, heart, lungs, 
spleen, adrenal and salivary glands) as well as whole blood have been shown to be sites 
of latent MCMV infection (Reddehase et al., 2002). The lungs are a major site of latency 
in the mouse and have an up to 10-fold higher burden of viral DNA than other tissues 
(Balthesen et al., 1993). Stromal and / or parenchymal cells are sites of MCMV latency 
in most organs. In addition endothelial cells, lung alveolar macrophages and bone 
marrow cells have been shown to contain MCMV DNA during latency (Koffron et al., 
1998). Reactivation of MCMV from latency occurs in vitro in tissue explants (Jordan 
and Mar, 1982) and in vivo when latently infected mice are immunosuppressed 
(Balthesen et al., 1993). The reactivated virus replicates in salivary gland epithelial cells 
and recurring and persistent shedding from the salivary gland can be detected.  
 
1.4 The immune response to MCMV infection 
 
1.4.1 Innate response 
 
The innate immune response coordinates the initial attack on invading pathogens, 
containing viral infections until the adaptive response is generated and able to clear the 
infection. Cells such as dendritic cells, macrophages and NK cells combine forces to 
limit CMV infection. IFN-α/β cytokines are produced early after MCMV infection. They 
are crucial in establishing an antiviral state and are required for the survival of the host 
(Dalod et al., 2002).  A specialized subset of dendritic cells, the plasmacytoid DCs, are 
the main producers of IFN-α/β (Dalod et al., 2003) in response to MCMV infection. It 
seems that IFN-α/β cytokines play a central role in regulating both innate and adaptive 
immune responses to MCMV challenge. Apart from the induction of an antiviral state, 
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IFN-α/β induce NK cell cytotoxicity and they control the maturation and cytokine 
production of the various dendritic cell subsets, thereby indirectly contributing to CD8 T 
cell activation (Dalod et al., 2003).  
 
1.4.1.1 Dendritic cells 
 
Dendritic cells (DCs) are a heterogeneous group of cells of hematopoietic origin. They 
occur at a low frequency and are found throughout the peripheral tissues, primary and 
secondary lymphoid organs, and are specialized to capture, process and present antigens 
to naïve T cells. In the classical description of DCs, peripheral DCs are in an immature 
state, which is characterized by low surface levels of MHC class II and co-stimulatory 
molecules, and the cells are highly efficient in antigen uptake and processing. Upon 
encounter with foreign antigen or upon entering a milieu rich in pro-inflammatory 
cytokines, these cells undergo phenotypic changes and migrate to the lymph nodes where 
they interact with naïve or resting T cells and initiate an immune response (Banchereau 
et al., 2000). More recently, studies in mice have revealed that most of the DCs in the 
spleen and thymus and about half of the lymph-node DCs develop from bone-marrow 
precursor cells within the lymphoid organs and do not traffic throughout the peripheral 
tissues (Villadangos and Heath, 2005). Therefore not all DCs follow the classical 
pathway.  
 
The nomenclature of mouse DC subtypes in the literature varies. In a recent review it 
was suggested that DCs should be divided into conventional DCs (cDCs), which already 
have a dendritic form and function, and precursors of DCs (pre-DCs), cells that require 
further development to acquire full DC function and the typical dendritic form 
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(Shortman and Naik, 2007). The conventional DCs are subdivided into migratory and 
resident cells. The migratory cDCs include interstitial DCs and Langerhans cells that 
migrate from the dermis and epidermis, respectively, to subcutaneous lymph nodes. 
Three different types of resident cDCs can be distinguished based on their expression of 
CD4 and CD8: CD4+, CD8+ and double negative (i.e. CD4-CD8-) DCs. Plasmacytoid 
dendritic cells (pDC), also known as natural interferon-producing cells, are a type of pre-
DC. The pDCs circulate as spherical cells, have a relatively long life span and produce 
large amounts of type I interferons in response to viral and bacterial stimulation. They 
acquire a dendritic shape and an enhanced ability to take up and present antigen after 
activation.  
 
Both cDC and pDC play pivotal roles in orchestrating the immune response to virus 
infection. Several groups have shown that DCs can be infected by HCMV and MCMV 
(Andrews et al., 2001; Jahn et al., 1999; Mathys et al., 2003; Moutaftsi et al., 2002; 
Raftery et al., 2001), but the reports differed on the effects of CMV infection on the 
surface phenotype and T cell priming activity of infected DC. The most recent study by 
Mathys and colleagues (Mathys et al., 2003) revealed that although both immature and 
mature DC are permissive to MCMV infection, only immature DC support virus 
replication. They further showed that the expression of MHC class I, class II, CD40, 
CD80 and CD86 increased during early times after MCMV infection of immature and 
mature DC, but at 48 h after infection these surface molecules were significantly 
downregulated from the cell surface. The viral Fc receptor, m138, was subsequently 
identified as the molecule responsible for the downregulation of CD80 from the surface 
of infected DC (Mintern et al., 2006).  
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Infected DC were able to prime autologous naïve T cells against MCMV at early times 
after infection. By 48 h after infection however, the DC were unable to prime T cells, 
consistent with the marked downregulation of MHC and costimulatory molecules from 
the cell surface (Mathys et al., 2003).  Thus MCMV infection induces the activation of 
DC and first initiates and then restricts T cell activation. It has been proposed that 
productive infection of immature DC, which will migrate upon activation, could aid the 
dissemination of the virus (Mathys et al., 2003). 
 
1.4.1.2               NK cells 
 
Patients that lack NK cells suffer from severe HCMV infections (Biron et al., 1989) and 
mice that have been depleted of NK cells or genetically lack NK cells are also highly 
susceptible to MCMV infection. Furthermore, adoptive transfer of NK cells can prevent 
MCMV disease in both adult and newborn mice (Bukowski et al., 1985; Bukowski et al., 
1988). Therefore NK cells must play an important role in the innate immune response to 
MCMV. As mentioned earlier, the genetic makeup of a mouse strain has a profound 
effect on susceptibility to MCMV infection. Mice can be divided into susceptible (e.g. 
BALB/c) or resistant strains (e.g. C57BL/6 (B6)) based on their ability to control 
MCMV replication at early times after infection. Studies in the early eighties indicated 
that there are both MHC- (H2) as well as non-H2 loci that confer resistance to MCMV 
infection (Grundy and Melief, 1982; Grundy et al., 1982). The non-H2 loci were 
identified in the B6, C3H and CBA mouse strains. The Cmv1 resistance locus was 
identified by analysis of the genetic basis of the differences in MCMV susceptibility of 
BALB/c and B6 mice. The locus was subsequently mapped to the NK cell gene complex 
(NKC) on mouse chromosome 6. The NKC region encodes both activating and 
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inhibitory NK cell receptors. By further genetic and physical mapping studies Cmv1 was 
identified as Ly49h (Klra8) (Forbes et al., 1997; Lee et al., 2003).  
 
Ly49h encodes a lectin-like activating NK cell receptor, which is expressed on 
approximately 50% of B6 NK cells (Smith et al., 2000). The viral ligand that binds 
Ly49H and activates B6 NK cells was identified as m157, which is a member of the 
m145 glycoprotein family encoded by MCMV (Arase et al., 2002; Smith et al., 2002). 
B6 mice are thus resistant to MCMV infection because m157 engages the activating 
receptor Ly49H and this interaction leads to the activation and expansion of Ly49H+ NK 
cells and clearance of virus-infected cells. It does not make sense for the virus to encode 
a ligand for activating NK cell receptors. However, m157 was also shown to bind Ly49I, 
which is an inhibitory NK cell receptor expressed in the 129/J strain (Arase et al., 2002; 
Smith et al., 2002). Therefore the more logical function of m157 would be to engage 
inhibitory receptors. Notably, in an experiment where MCMV was serially passaged 
through resistant B6 (Ly49H+) mice, several virus clones could be isolated that contained 
mutations in the m157 gene. The mutations all prevented the expression of m157 or its 
binding to Ly49H (Voigt et al., 2003). These results indicate that the virus quickly adapts 
under selective pressure from the host innate immune system.  
 
Recently it was shown that early control of MCMV replication by NK cells attenuates 
the IFNα/β response by pDCs. Thus, rapid control of MCMV prevents IFNα/β-related 
immunosuppressive effects and enables earlier development of an effective CD8+ T cell 
response (Robbins et al., 2007). Mice that are deficient only in the adaptive immune 
response but have normal NK cells can limit early MCMV replication, but they cannot 
sustain virus control and eventually succumb to disseminated viral infection. Thus NK 
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cells play an important role during the initial stages of infection but the adaptive 
response is essential for resolution of the infection. 
 
1.4.2 Adaptive response 
 
The first studies implicating T cell subsets in the protective response to MCMV infection 
utilized adoptive transfer of T cells. T lymphocytes, obtained from the draining lymph 
nodes of MCMV-infected immunocompetent mice, were transferred into syngeneic 
sublethally irradiated mice either 2 h prior to infection or 6 days after infection of the 
recipients. Both prophylactic and therapeutic T cell transfers were able to prevent 
mortality (Reddehase et al., 1985). Furthermore it was shown that the CD8+ T cell subset 
is protective and that CD4+ T cells are not required to prevent mortality. This kind of 
preemptive CD8+ T cell immunotherapy has been applied successfully to 
immunosuppressed patients after bone marrow transplantation (Riddell et al., 1992).   
Although CD4+ T cells are not essential to prevent death, mice depleted of CD4+ T cells 
were unable to eliminate virus production in the salivary glands even though large 
numbers of CD8+ T cells had infiltrated the salivary glands (Jonjic et al., 1989). 
Antibodies are not crucial to the resolution of MCMV infection, since B-cell deficient 
mice clear primary infection and establish latency with the same kinetics as wild type 
mice (Jonjic et al., 1994). It can be concluded that CD8+ T cells represent the major 
protective part of the adaptive immune response to MCMV but that CD4+ T cells are 
necessary for the elimination of virus from the salivary glands. The salivary gland is the 
site of persistent infection and virus shedding, therefore CD4+ T cells are important in 
preventing horizontal transmission of MCMV.  
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In the B cell-deficient mouse model of MCMV latency, it has been shown that stringent 
immune surveillance, rather than cell intrinsic factors, maintains the CMV genome in the 
latent state. In latently infected mice, stepwise or combined depletion of NK cells or 
different T cell subsets, is followed by productive virus replication, indicating that the 
virus frequently initiates productive replication cycles that are kept in check by the 
immune response. Antibodies to MCMV seem to play a protective role when 
reactivation from latency occurs, since mice devoid of B cells and antibodies develop 
higher MCMV titers when NK and T cells are depleted and reactivation takes place 
(Polic et al., 1998).  
 
In conclusion, the immune response to MCMV infection is a complex process involving 
many different innate and adaptive cytokines and cell types and may vary in different 
organs and during the different stages of virus infection.  
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1.5 The m145 gene family of MCMV 
 
The genome sequence of the Smith strain of MCMV was determined by Rawlinson and 
colleagues (Rawlinson et al., 1996). The authors grouped eleven putative transmembrane 
glycoproteins together in the m145 family (m17, m145, m146, m150-155, m157, m158). 
Ten genes are found towards the right end of the genome arranged in tandem on the 
complementary strand. One family member, m17 lies at the opposite end of the genome 
adjacent to the m02 glycoprotein family (see Figure 1.2). All genes contain putative 
signal peptides, transmembrane regions and potential N-linked glycosylation sites, 
except for m157, which is predicted to be glycophosphatidylinositol (GPI)-linked. A 
homologous but expanded family is encoded by the rat CMV (RCMV), however all 
members of the mouse m145 family are not conserved. Rat homologs with both 
sequence and positional homology are r145, r150, r151, r152, r155 and r157 (Vink et 
al., 2000). An interesting feature of the mouse m145 family is that eight members are 
predicted to adopt an MHC-I-like fold despite no significant sequence similarity to 
MHC-I molecules (Smith et al., 2002). A multiple alignment of the predicted MHC-I-
like m145 proteins and their rat homologs (including signal peptide, transmembrane and 
intracellular domains) is shown in Figure 1.3. The viral proteins share low levels of 
amino acid similarity (7-28%) and there are very few amino acid residues conserved in 
all family members. The predicted extracellular regions of the proteins are most similar, 
whereas the N-terminal and C-terminal (predicted intracellular domain) regions show 
very little conservation. A number of cysteine residues, which are presumably involved 
in disulfide bonds, are conserved. Several important immune evasion functions of 
MCMV are attributed to members of the m145 family. These will be discussed in the 
following section. 
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1.6 Interplay between MCMV and the host immune response  
 
A wide variety of immune evasion strategies have been described for MCMV. Notably, 
the virus has evolved multiple proteins that interfere with the activation of NK cells and 
subvert antigen presentation (Lodoen and Lanier, 2005; Pinto and Hill, 2005).  
 
1.6.1 MCMV interference with NK cell activation 
 
Four members of the m145 family of MCMV interfere with the NK cell response. m145, 
m152 and m155 have all been shown to downregulate distinct ligands of the activating 
NK cell receptor NKG2D. m145 targets MULT-1 (murine UL-16 binding protein-like 
transcript 1), m152 affects the Rae-1 family of ligands and m155 is specific for H60 
(Figure 1.4, (Hasan et al., 2005; Krmpotic et al., 2005; Lodoen et al., 2003; Lodoen et 
al., 2004)). Rae-1 (α, β, γ, δ, ε  isoforms), H60 and MULT-1 are NKG2D ligands that are 
induced in cells subjected to stress, cancerous transformation or virus infection 
(Cerwenka and Lanier, 2003). Whether the viral proteins directly interact with the 
NKG2D ligands or effect their retention/degradation in an indirect way is not yet known. 
Rae-1, H60 and MULT-1 are related to MHC-I in structure, but consist of only the α1 
and α2 domains of classical MHC-I and lack the Ig-like α3 domain (see section 1.8). 
MCMV m157 was the first viral ligand to be identified for an activating NK cell receptor 
(Arase et al., 2002; Smith et al., 2002). The interaction of m157 with activating and 
inhibitory receptors of the Ly49 lectin-like NK cell receptors was discussed in detail in 
the preceding section on the innate immune response to MCMV. Another MCMV 
encoded protein interferes with NKG2D ligand expression. The viral Fc receptor (fcr-1) 
encoded by the m138 gene was recently shown to reduce the surface expression levels of 
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H60 and MULT-1 in MCMV-infected cells (Lenac et al., 2006). The study revealed that 
fcr-1 uses distinct domains and possibly different mechanisms to downregulate H60 and 
MULT-1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. MCMV encoded glycoproteins downregulate ligands of the activating 
NK cell receptor NKG2D. m138 interferes with surface expression of H60 and MULT-
1, m145 targets MULT-1, m152 retains members of the Rae-1 ligand family and m155 
affects H60 cell surface expression. 
 
1.6.2 Manipulation of the MHC-I antigen presentation pathway by MCMV 
 
MCMV encodes three different proteins that target antigen presentation by MHC class I 
molecules (Figure 1.5). They were named VIPRs -Viral proteins that Interfere with 
antigen Presentation- to distinguish them from other immunoevasins. The m04 and m06 
genes encode gp34 and gp48 respectively and they affect MHC-I trafficking in different 
ways. The m152 gene encodes the gp40 glycoprotein and has a dual function. In addition 
to the downregulation of Rae-1, which was described in the preceding section, m152 
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reduces MHC-I surface expression. The VIPRs all use different mechanisms to regulate 
MHC-I. m04/gp34 associates with MHC-I in the ER and these complexes are transported 
to the cell surface where the proteins remain associated (Kleijnen et al., 1997). m06/gp48 
redirects MHC-I molecules to lysosomes, where they are subsequently degraded. 
m06/gp48 has a di-leucine motif in its cytoplasmic tail that facilitates binding to adaptor 
proteins AP-1A and AP-3A and sorting into the lysosomal pathway. Both m04 and m06 
belong to the m02 gene family of MCMV. Other m02 family members have not been 
characterized functionally. m152, which is part of the m145 family, was the first MCMV 
VIPR to be described (Krmpotic et al., 1999). Initial observations showed that an MHC-I 
presented epitope derived from the IE protein pp89 was presented during immediate 
early MCMV gene expression but not when early genes were expressed (Del Val et al., 
1989; Reddehase et al., 1989). Further studies revealed that the virus blocks antigen 
presentation by retaining the tri-molecular MHC-I complex (heavy chain, β2-
microglobulin and peptide) in the ER/cis-Golgi compartment (del Val et al., 1992). The 
region affecting MHC-I transport was mapped to the HindIII E fragment of the viral 
genome (Thale et al., 1995), and m152 was identified as the gene responsible for MHC-I 
downregulation (Ziegler et al., 1997). The luminal domain of m152 was implicated in 
catalyzing the retention of MHC-I molecules (Ziegler et al., 2000). There is no evidence 
of a stable m152/MHC-I interaction and the exact mechanism of retention remains a 
mystery.  
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Figure 1.5. Schematic representation of the interference with MHC-I trafficking in 
MCMV infected cells. m04 associates with MHC-I and the complex is transported to 
the cell surface. m06 reroutes MHC-I molecules from the secretory pathway into 
lysosomes for their degradation. m152 catalyzes the retention of MHC-I in the ER Golgi 
Intermediate Compartment (ERGIC).  
 
 
The biological consequences of the concerted action of m04, m06 and m152 are not well 
understood. A complex picture has emerged from studies utilizing viruses that have had 
individual or combinations of immunoevasins deleted. All three viral genes exhibit 
different efficiencies in targeting different MHC-I alleles (Pinto et al., 2006). Early 
studies indicated that m04 could inhibit CTL lysis of MCMV infected cells (Kavanagh et 
al., 2001). It was proposed that m04 prevents the T cell receptor (TCR) from recognizing 
MHC-I, thereby reducing CTL activity. m04 was thus considered a negative regulator of 
antigen presentation (Lilley and Ploegh, 2005). More recently, a comprehensive analysis 
of the effect of m04 on antigen presentation both in vitro and in vivo was undertaken 
(Holtappels et al., 2006). These experiments provided important new insight, namely that 
m04 instead acts as a positive regulator of antigen presentation. Cells that were infected 
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with a mutant MCMV, in which m04 and m06 were deleted, successfully evaded CTL 
stimulation and lysis. Thus, m152 expression is sufficient to block antigen presentation 
and evade CTL attack. However, when m04 was expressed in combination with m152, 
the infected cells became susceptible to CTL lysis, suggesting that m04 restores antigen 
presentation by escorting MHC-I to the cell surface. Wild type MCMV-infected cells, 
where m04, m06 and m152 are expressed in combination, were able to evade CTL 
responses. Therefore, m06 counters the positive effect of m04 and allows escape from 
immune recognition (Holtappels et al., 2006).  
 
It was assumed that VIPR function was essential for MCMV to establish persistent 
infection in mice. However, a deletion mutant for m04, m06 and m152 did not differ in 
its ability to establish acute, persistent and latent infection in adult B6 mice. 
Furthermore, the size and effector memory phenotype of the CD8+ T cell response 
elicited after infection with the triple mutant virus was comparable to the response 
against wild type virus (Gold et al., 2004). As mentioned before, MCMV infection in 
salivary gland acinar epithelial cells cannot be controlled by CD8+ T cells and is only 
cleared by CD4+ T cells. The effect of deleting all three VIPRs on virus replication in the 
salivary gland was recently tested. Mice infected with the m04+m06+m152 knockout 
virus had 10-fold lower salivary gland titers than mice infected with wt MCMV. The 
virus titers could be restored to the levels reached in a wt MCMV infection by depleting 
CD8+ T cells (Lu et al., 2006). Taken together, it seems that the MCMV VIPRs affect 
antigen presentation to CD8+ T cells in the salivary gland epithelial cells and may be 
important to sustain virus production in the salivary glands and promote transmission to 
new hosts.  
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1.6.3 Additional immune evasion mechanisms 
 
Early after infection with MCMV, IL-10 is prematurely and transiently activated. This 
causes substantial downregulation of MHC class II molecules from the cell surface from 
infected macrophages and prevents antigen presentation to CD4+ T cells (Redpath et al., 
1999). MCMV further encodes two molecules that influence chemokine function during 
infection. MCK-2, a CC chemokine homolog, promotes dissemination of the virus to the 
salivary glands (Fleming et al., 1999) and M33, a viral chemokine receptor, has been 
shown to be very important for successful virus replication in the salivary glands (Davis-
Poynter et al., 1997). MCMV can infect dendritic cells and encodes the modB7-2 protein 
that selectively downregulates CD86 in antigen presenting cells (Loewendorf et al., 
2004).  Other viral products that modulate the complement pathway (Nomura et al., 
2002) and prevent apoptosis in infected cells have also been described (Menard et al., 
2003).  
 
1.7 Major Histocompatability Class I (MHC-I) molecules  
 
MHC-I molecules are type I transmembrane cell surface receptors that are expressed on 
most cell types and consist of a heavy chain, a β2-microglobulin (β2m) light chain, and 
peptides of 8-10 residues (Figure 1.6). They are poised for recognition by clonotypic αβ 
receptors on CD8+ T cells or by inhibitory or activating receptors on NK cells.  MHC-I 
are classified as classical (Ia) or non-classical (Ib) molecules based on their amino acid 
sequence polymorphism, function, and tissue-specific expression.  The heavy chain 
consists of an α1α2 domain unit containing two α-helices set atop an eight-stranded β-
sheet platform and an Ig-like α3 domain (Figure 1.6A) (Bjorkman and Parham, 1990). 
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The peptide-binding groove is formed by the α1 and α2 helices (Figure 1.6B). β2m 
associates with the heavy chain below the platform domain adjacent to the α3 domain.  
Two conserved disulfide bonds stabilize the heavy chain, one bond is found in the α1α2 
domain (strand β5 - α2 helix) and the second bond links the B and G strands of the Ig-
like α3 domain. MHC-Ib molecules exhibit less polymorphism than the classical 
molecules, most do not bind peptide, and they vary in their association with β2m 
(Natarajan et al., 1999). MHC-Ib proteins function both in immune recognition and in 
other physiological settings (Margulies et al., 2007). The Rae-1 family of stress-induced 
molecules are examples of MHC-Ib proteins that are expressed in mouse cells. In 
humans, MICA and MICB molecules are induced by stress signals and they are also non-
classical MHC-I proteins. These molecules act as ligands for the activating NK cell 
receptor NKG2D. The structures of Rae-1β and MICA have been determined (Li et al., 
2002; Li et al., 2001). These molecules do not bind peptide, Rae-1β is truncated with no 
α3 domain (Figure 1.6C) and MICA consists of a full-length heavy chain but does not 
associate with β2m (Figure 1.6D).    
 
Figure 1.6. Crystal structures of classical and non-classical MHC-I molecules. A) 
Structure of the classical MHC-I molecule H-2Kb in complex with a peptide derived 
from the VSV nucleoprotein (Fremont et al., 1992). Ribbon diagram of MHC heavy 
chain (cyan) α1, α2 and α3 domains, β2m (magenta) and peptide (red). B) Top view of 
the peptide binding groove. Disulfide bonds are shown in yellow. C) Rae-1β, an example 
of an MHC-I-like protein that consists only of the α1α2 domain (Li et al., 2002). D) 
MICA, a non-classical MHC-I protein that has the α1α2 and α3 domains, but does not 
associate with peptide or β2m and displays an unusually large angle between the α1α2 
and α3 domains (Li et al., 2001).  
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1.8 MHC-I homologs encoded by human and murine CMVs  
 
1.8.1 Homologs with significant amino acid sequence similarity 
 
HCMV encodes two different MHC-I homologs. UL18 shares 25% identity and 40% 
similarity with classical MHC-I molecules and it associates with β2m and peptide 
(Figure 1.7A). UL18 is a ligand for the leukocyte Ig-like receptor 1 (LIR-1) (Cosman et 
al., 1997), an inhibitory receptor that is expressed on some NK cells, T cells, dendritic 
cells, monocytes and B cells. LIR-1 binds to UL18 with a 1000-fold higher affinity than 
to other MHC-I molecules. A recent report indicated that UL18 inhibits LIR-1+ NK cells 
but has an activating effect on LIR-1- NK cells (Prod'homme et al., 2007).  Another 
study revealed that soluble UL18 protein can affect the phenotype of monocyte-derived 
dendritic cells and impairs their capacity to migrate and stimulate T cells (Wagner et al., 
2008). However, the function of UL18 during HCMV infection is not yet well 
understood. UL142 is the other identified MHC-I homolog expressed by HCMV. This 
protein is shorter than the classical MHC-I heavy chain and is predicted to consist of 
only an α1 and α2 domain (Wills et al., 2005). UL142 downregulates some alleles of the 
human stress-induced ligand MICA and thereby protects the infected cell from NK cell 
cytotoxicity (Chalupny et al., 2006). m144 is the counterpart of UL18 expressed by 
MCMV. m144 differs from UL18 in several respects, it does not bind peptide and can be 
stably expressed in the absence of β2m (Natarajan et al., 2006). MCMV lacking m144 is 
attenuated in vivo and the attenuation can be reversed by depletion of NK cells (Cretney 
et al., 1999; Farrell et al., 1997). The mechanism by which m144 affects NK cell 
function is not known, since no ligand has been identified. The crystal structure of m144 
has been determined (Natarajan et al., 2006). It revealed a peptide-free, class I-like heavy 
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chain, associated with β2m (Figure 1.7B). Crystal structures of UL18 and UL142 have 
not yet been determined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIR-1 normally binds to a range of  
 
 
 
 
Figure 1.7. Structures of viral MHC-I homologs (MHC-Iv). A) Side and top views of 
a molecular model of HCMV UL18 based on the crystal structure of the HLA-A2/LIR-1 
complex (Wagner et al., 2007) (PMDB access code PM0074971). Heavy chain (pink), 
β2m (cyan). No peptide was included in the model. B) Crystal structure of MCMV m144 
(PDB ID = 1U58). Heavy chain (purple), β2m (cyan). Disulfide bonds are shown in 
yellow.  
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1.8.2 Distant viral homologs of MHC-I - Homology based on structural 
predictions 
 
Protein structure prediction from amino acid sequence is complicated by a low level of 
sequence identity between the target protein and proteins of known structure. The 
majority of programs for secondary structure prediction use multiple sequence 
alignments to predict regions of alpha helix, beta sheet and coil. When working with 
sequences within the “twilight zone” (<30% homology), multiple alignments often do 
not provide reliable predictions. The 3D-PSSM method incorporates structural 
alignments of homologous proteins with standard multiple sequence alignments and is 
therefore able to detect distant relationships between proteins (Kelley et al., 2000). Smith 
and colleagues subjected the MCMV genome to structural prediction analysis using 3D-
PSSM (Smith et al., 2002). The program uses one- and three-dimensional sequence 
alignments in combination with secondary structure and solvation potential information 
to assign a protein fold. Twelve MCMV open reading frames in total were predicted to 
encode proteins with MHC-I-like folds (Smith et al., 2002).  Eight of these proteins form 
part of the m145 family of MCMV. The other proteins were m144, the known MHC-I 
homolog, and M37, m90 and m159, all proteins of unknown function. The confidence of 
the fold prediction ranged from 70-95% and a variety of MHC-I molecules made out the 
top hits.  
 
Of the predicted MHC-I-like proteins, only m144, m145, m152, m155 and m157 have 
established functions. The exact mechanism of action has only been determined for 
m157. It is intriguing that MCMV should encode MHC-I-like molecules that interact 
with either host MHC-I molecules (m152), endogenous MHC-I-like proteins (m145, 
m152 and m155) or receptors that usually recognize MHC-I proteins (m157). The unique 
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functions of m145, m152, m155, and m157 suggest that each member of the m145 
family is important in modulating the response of the host to MCMV infection. The low 
degree of sequence similarity within the m145 family implies that the members of the 
m145 family may have evolved significant structural deviations from typical MHC-I to 
solve novel difficulties in their encounter with the immune system.  
 
1.9 Aims of the study 
 
An understanding of the evolution and function of the MHC-I-like molecules of MCMV 
demands examination of the cellular expression, immunological function, and molecular 
structure of each of these molecules.  The aims of this study were to characterize the 
MCMV MHC-I-like proteins in recombinant and mammalian cell expression systems, 
select a suitable candidate and determine its crystal structure. Structural information on 
the m145 family could confirm the validity of the MHC-I fold prediction, help to 
evaluate how closely related these proteins are to host MHC-I and to each other, and 
possibly yield insight into other members of the family. Since the functions of several 
family members are still unknown, structural characterization may be complementary to 
functional characterization of this important MCMV protein family.   
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Specific objectives: 
1. To characterize the predicted MHC-I-like proteins encoded by MCMV in terms 
of cellular localization and cell surface expression requirements for β2m and 
peptide 
 
2.  To evaluate recombinant expression systems for yield and quality of the viral 
 proteins for structural studies 
 
3.  To screen the proteins for crystallization and determine the crystal structure of a 
 successful candidate  
 
4.  To construct a reporter cell line for the specific MCMV MHC-I-like protein  
 
5.  To screen primary cells and cell lines for possible ligands  
 
 
The characterization of several MCMV MHC-I-like proteins in terms of cellular 
localization and association with β2m and peptide as well as their recombinant 
expression is presented in Chapter 3. m145 family member m153 presented a suitable 
candidate for structure determination, since it could be expressed at high levels in 
recombinant form, is of a very stable nature and could be crystallized. We have studied 
m153 in both transfected and MCMV-infected cells in detail and this is presented in 
Chapter 4.  We demonstrate that m153 is a functional gene that directs the expression of 
its encoded protein to the surface of MCMV-infected cells.  Surface expression of m153 
is independent of the transporter associated with antigen processing (TAP) or β2m.  In 
surprising contrast to MHC-I molecules, recombinant soluble m153 is homodimeric. The 
crystal structure of m153 described in Chapter 5 confirms that m153 adopts an MHC-I-
like fold and reveals the mode of dimerization in addition to other distinguishing 
features. In Chapter 6 we report the m153-reporter cell construction and the 
identification of dendritic cells as a cell type that can stimulate m153-specific reporter 
cells.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Cell lines 
 
COS-7 (ATCC CRL-1651), NIH3T3 (ATCC-1658), RMA, RMA-S and Phoenix E cells 
were grown in DMEM containing 10% fetal bovine serum, 5 x 10-5 M 2-
mercaptoethanol, 1x non-essential amino acids (Biowhittaker, Lonza, Allendale, NJ, 
USA) and 50 µg/ml gentamicin at 37 °C in 5% CO2. R1.1, R1E and 43.1 and its 
derivatives 153z_43.1, 153z_43.1_H, 144z_43.1 and 144z_43.1_H, mouse bone marrow 
and spleen cells were cultured in RPMI containing the same supplements as above. 
RMA-S cells have a defect in the Ham-2 gene and do not express a functional transporter 
associated with antigen processing (Attaya et al., 1992). R1E cells do not express β2m 
(Allen et al., 1986). 43.1 cells contain an NFAT-driven GFP construct and express GFP 
upon cross-linking of the T cell receptor (Ohtsuka et al., 2004). Drosophila S2 cells were 
maintained in Insect Express medium (BioWhittaker) supplemented with 50 µg/ml 
gentamicin except where mentioned otherwise. SF9 cells were cultured in BacVector 
Insect Cell Medium (Novagen, Madison, WI, USA) supplemented with 50 µg/ml 
gentamicin.  
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2.2 Mice 
 
BALB/cJ, BALB/cByJ, CBA/J, C3H/HeJ, C57BL/6, DBA2/J, FVB/NJ and NOD/ShiLtJ 
mice were obtained from NIH-NCI-DCT (Frederick, MD, USA). Male and female mice, 
ranging from 6 weeks to 3 months of age were used in the experiments. Dr. Anderson 
Nunes (LVMR, NIAID) kindly provided female Wistar rat spleens. All animal based 
studies were performed under an approved protocol of the NIH Animal Care and Use 
Committee under AAALAC guidelines.  
 
2.3 Antibodies 
 
Rabbit antiserum was produced against m153 expressed as inclusion bodies in E. coli. 
Reduced, denatured SDS-gel purified m153 was emulsified in complete Freund adjuvant 
prior to immunization. The mouse monoclonal antibody mAb153.16 was generated with 
the extracellular domain of mature m153 (amino acids 1-314) expressed in S2 cells, and 
stains m153 transfected cells and immunoprecipitates m153 from transfected or virus-
infected cells. The mouse monoclonal antibody to MCMV m144, 15C6, was obtained 
from the American Type Culture Collection (Cat. No. CRL-2431, ATCC - Manassas, 
VA, USA).  
 
2.4 Vector constructs 
 
The PCR primer sequences are listed at the end of this Chapter under section 2.26. 
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2.4.1 Bacterial expression 
 
The extracellular regions of the MCMV proteins (m17, M37, m90, m145, m150, m151, 
m152, m153, and m155) were predicted using the Signal P 3.0 server (Bendtsen et al., 
2004; Nielsen et al., 1997) and hydrophilicity plots from the Macvector program (Olson, 
1994). Restriction enzyme sites for BamHI and NdeI were incorporated in the DNA 
primers designed to amplify the extracellular domains from MCMV genomic DNA 
(Smith strain, catalog no. VR-1399, American Type Culture Collection, Manassas, VA, 
USA). These sites were used to insert the PCR products in the bacterial expression 
vector pET21b (Novagen, Madison, WI, USA). A termination codon was inserted in all 
the 3’-oligos to prevent addition of the vector encoded His-tag to the proteins. The 
primers used to amplify the MCMV proteins are listed under Section 2.26 on page 51. 
All constructs were sequence verified.  
 
2.4.2 Insect cell expression  
 
cDNAs encoding the predicted mature extracellular domain of M37 (residues 1-246), 
m151 (residues 1-317) and m153 (residues 1-315) were PCR-amplified from MCMV-
infected cell culture supernatants (Smith strain, ATCC, catalog no. VR-1399). BamHI 
(m151, m153) or BglII (M37) restriction sites were incorporated in the forward primers 
and a thrombin cleavage site (LVPRG, m151 and m153) or an enterokinase site 
(DDDDK, M37), a 6xHis tag, a termination codon, and a KpnI restriction site were 
incorporated in the reverse primers. The PCR products were directly cloned into the 
pCR4-Topo-TA vector (Invitrogen, Carlsbad, CA, USA), the sequences verified, and 
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then the M37, m151 and m153 fragments were inserted in the BglII and KpnI sites of 
pMT-Bip-V5-His (Invitrogen).  
 
To generate the interface mutant, alanine mutations were introduced at four residues 
(T128, S131, R225 and S241) in the m153-N-YFP construct using the QuickChange 
Multi mutagenesis kit (Stratagene, La Jolla, CA, USA). An alanine mutation was 
introduced at a site distant from the interface at Asp 194 in the control mutant. The wild 
type and mutated forms of m153 (residues 1-315) were PCR-amplified from the wt 
m153-N-YFP or the mutated plasmids and cloned in the pIEx-4 SF9 expression vector 
(Novagen, Madison, WI, USA). 
 
2.4.3 Mammalian cell expression  
 
2.4.3.1  FLAG- and HA-tagged constructs 
 
The FLAG-tag DYKDDDDK was inserted two amino acids after the predicted signal 
peptide cleavage site of each MCMV protein. Overlapping primers were designed to 
encode the FLAG sequence and the N-terminal sequence of the proteins. Three to five 
sequential PCRs were performed using MCMV Smith strain (ATCC VR-1399) DNA as 
template to amplify the full-length gene and insert the FLAG-tag in ORFs, m17, M37, 
m90, m144, m145, m150, m151, m152, m153, m155 and m159. The PCR products were 
inserted in the TOPO-TA vector (Invitrogen, Carlsbad, CA, USA) and sequence verified. 
EcoRI or MfeI and BamHI or BglII restriction enzyme sites were incorporated in the 5’ 
and 3’ oligonucleotides, respectively, to facilitate cloning of the tagged genes in the 
EcoRI and BamHI sites of the pIRES-hr-GFP-II vector (Stratagene, La Jolla, CA, USA). 
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This vector will be referred to as pIRES-GFP. The HA-tag YPYDVPDYA was inserted 
at the N-terminus of m153 by sequential PCR with m153-pcDNA as template. The HA-
tagged m153 was then inserted in the EcoRI and BamHI sites of pIRES-GFP.  
 
2.4.3.2 m153-EYFP fusion construct 
 
EYFP was fused to the C-terminus of full-length m153. Residues minus 22-383 of m153 
were amplified from an existing construct using forward and reverse primers with 
BamH1 and EcoRI restriction sites respectively. The PCR product was then inserted into 
the corresponding sites of pEYFP-N1 (Clontech, Mountain View, CA, USA). Expression 
of the fusion protein is driven by the CMV IE promoter.  
 
2.4.3.3             Bimolecular fluorescence complementation constructs 
 
Mammalian expression vectors encoding the N-terminal 1-154 residues (N-YFP) or the C-
terminal 155-238 residues (C-YFP) of YFP were a kind gift from Dr. Keiko Ozato, NICHD, 
NIH. m153 and m144 were amplified from existing full-length constructs. The PCR 
products were digested and inserted in the BglII and EcoRI sites of N-YFP and C-YFP and 
the sequences verified. The resulting constructs encode fusion proteins of m153 and m144 
linked at their C-termini to either the N- or C-terminal fragments of YFP. A 12-13 amino 
acid spacer separates the viral proteins from the YFP fragments. 
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2.4.3.4  m144-human zeta and m153-human zeta fusion constructs 
 
The transmembrane and cytoplasmic domain of the human T cell receptor zeta chain was 
fused to the extracellular domain of m153 using splicing by overlap extension (SOE) 
PCR. The extracellular domain (residues minus 22-315) of m153 and the human zeta 
chain (residues 30-163) were amplified from existing constructs. The resulting PCR 
products were used as template for the SOE reaction using the outer primer pairs. The 
fused m153-human zeta PCR product was cloned in the TOPO-TA vector (Invitrogen, 
Carlsbad, CA, USA) and sequence verified. The construct was then excised from the TA 
vector with BamHI and EcoRI and inserted in these sites of the pMXs retrovirus vector 
(a kind gift of Dr. Toshio Kitamura, University of Tokyo, Tokyo, Japan) (Onishi et al., 
1996). A construct consisting of the extracellular domain of m144 (residues minus 20-
249) fused to the transmembrane and cytoplasmic domain of the human zeta chain was 
obtained from Dr. Kannan Natarajan, NIAID, NIH. This fusion construct was amplified 
and inserted in the BamHI and EcoRI sites of pMXs.  
 
2.5 Transfection and FACS analysis of FLAG-tagged MCMV proteins 
 
Fugene 6 (Roche Diagnostics, Indianapolis, IN, USA) was used according to the 
manufacturer’s instructions to transfect COS-7 cells with the parental pIRES-hr-GFP-II 
vector (Stratagene, La Jolla, CA, USA) or pIRES-hr-GFP-II constructs encoding FLAG-
tagged versions of m17, M37, m144, m145, m151, m152, m153 and m155. Forty-eight 
hours after transfection the surface expression of the viral proteins was assessed. One 
million cells were stained with 0.5 µg anti-FLAG M2 (Sigma-Aldrich, St. Louis, MO, 
USA) in PBS, 5% FCS, 0.1% NaN3 for 30 min. on ice. After washing, the bound 
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antibodies were detected with sequential 30 min. incubations with anti-mouse IgG1–
Biotin and Streptavidin-PE (BD Pharmingen, San Jose, CA, USA). 
 
For intracellular staining of m152- and m155-transfected samples the cells were fixed 
with 4% paraformaldehyde for 20 min. at room temperature, washed twice with PBS and 
permeabilized in PBS, 0.1% BSA, 0.5% Triton X-100. One million cells were stained 
with 1 µg M2 for 30 min. at room temperature, and after washing the bound antibodies 
were detected with anti-mouse IgG1-PE (Southern Biotech, Birmingham, AL, USA). 
Cells transfected with the pIRES-hr-GFP-II vector served as a negative control for non-
specific staining in all experiments. The stained cells were analyzed with a Becton 
Dickenson FACScan (BD Biosciences, San Jose, CA, USA). 
 
To assess the effect of the MCMV proteins on MHC-I expression in mouse cells, 
NIH3T3 cells were transfected with FLAG-tagged versions of m17, M37, m144, m145, 
m151, m152, m153 and m155 in the pIRES-hr-GFP-II vector. The Amaxa nucleofector 
(Amaxa Biosystems, Cologne, Germany) was used to introduce 2 µg of DNA into 1 x 
106 NIH3T3 cells (Solution R, program U30). Eighteen hours after transfection the cells 
were stained for MHC-I expression with the anti-H-2Dl/q antibody followed by anti-
mouse IgG-APC (BD Biosciences, San Jose, CA, USA) and analyzed with a 
FACSCalibur (BD Biosciences).  
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2.6 β2m and TAP-dependence  
 
The Amaxa nucleofector (Amaxa Biosystems, Cologne, Germany) was used to introduce 
the pIRES-hr-GFP-II vector (Stratagene, La Jolla, CA, USA) encoding the different 
FLAG-tagged MCMV genes or H-2Dd into R1.1 and R1E cells (solution V, program 
A30) or into RMA and RMA-S cells (solution T, program A30) according to the 
manufacturer’s instructions. In the RMA and RMA-S experiments serum-free medium 
was used after transfection, to avoid stabilization of MHC-I molecules by peptides 
derived from serum proteins in the medium.  Eighteen to 24 h post transfection the cells 
were stained for surface expression of the FLAG-tagged viral proteins with the M2 
monoclonal antibody (Sigma-Aldrich, St. Louis, MO) and a PE labeled anti-mouse IgG1 
antibody (Southern Biotech, Birmingham, AL, USA). H-2Dd was detected using the PE-
labeled 34-5-8S antibody (BD Biosciences, San Jose, CA, USA). Propidium iodide 
staining was used to exclude dead cells from the analysis. 
 
2.7 MCMV infection, cell surface staining and FACS 
 
Seventy percent confluent NIH3T3 cells were infected with MCMV-GFP at a 
multiplicity of infection (m.o.i) of two. Twenty-four hours post infection (p.i.) the cells 
were detached with a non-enzymatic cell dissociation solution (Cellstripper, Cellgro, 
Herndon, VA, USA) and resuspended in PBS containing 5% FCS and 0.1% NaN3. 
F(ab’)2 fragments were generated from monoclonal antibody mAb153.16 with the 
Immunopure IgG1 F(ab’)2 kit (Pierce, Rockford, IL, USA). Infected and uninfected cells 
were incubated with the F(ab’)2 followed by anti-mouse IgG-APC. Dead cells were 
excluded by propidium iodide gating. Cells were analyzed with a FACSCalibur (Becton-
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Dickinson, Franklin Lakes, NJ, USA) and virus-infected cells were gated on GFP 
expression.  
 
For time-course analysis of m153 expression in MCMV-infected cells, cells were 
infected as described above and harvested at 3, 6, 12, 24 and 48 h p.i. The cells were 
processed for immunoprecipitation and Western blot as described in Section 2.10.  
 
2.8 Bimolecular fluorescence complementation 
 
NIH3T3 cells were transfected with 153-N-YFP and 153-C-YFP or 144-N-YFP and 144-
C-YFP using the Amaxa nucleofector (Amaxa Biosystems, Cologne, Germany, solution 
R, program U30). Cells were then seeded on chambered coverslides and incubated for 48 
h at 37 °C. A Leica TCS AOBS SP2 confocal microscope (Leica Microsystems, 
Bannockburn, IL, USA) equipped with a 63x 1.4 NA PL APO objective was used to 
examine live cells at room temperature for YFP fluorescence complementation. Leica 
TCS v2.1547 software was used to capture the images. After analysis the cells were 
detached with trypsin and the YFP positive cells were quantified by flow cytometry.  
 
2.9 Localization studies of m153 
 
NIH3T3 cells (1 x 106) were transfected with 1 – 2 µg of m153-EYFP-pcDNA or 153-
pcDNA using the Amaxa nucleofector (Solution R, Program U30) and seeded in Lab-
Tek coverglass chambers (Nalge Nunc International). Eighteen hours post transfection 
the cells were fixed for 15 min. at room temperature with 4% paraformaldehyde and 
washed once with PBS. All subsequent steps were performed at room temperature. The 
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intracellular staining samples were permeabilized with 0.1% Triton X-100 for 15 min. 
and washed once with PBS. Both surface and intracellular staining samples were then 
treated with Image It Enhancer (Molecular Probes, Invitrogen Carlsbad, CA, USA) for 
30 min., washed with PBS and blocked for 30 min. with 10 mg/ml goat serum. After 
rinsing in PBS the cells were incubated with mAb153.16 for 1 h, washed three times in 
PBS, and incubated with anti-mouse IgG-Alexa 594 for 30 min. The staining patterns 
were then studied by confocal microscopy as described in section 2.8. 
 
m153-EYFP (2 µg) was transfected in 1 x 106 NIH3T3 cells (Amaxa nucleofector, 
solution R, program U30) and the cells were seeded on Lab-Tek chambered coverglass 
(Nalge Nunc International, Rochester, NY, USA). Eighteen to 24 h after transfection the 
cells were fixed with 4% paraformaldehyde (15 min. room temperature), stained for the 
Golgi apparatus (anti-human Golgin, Molecular Probes) or early endosomes (anti-EEA1, 
Abcam, Cambridge, MA, USA) and detected with anti-mouse or -rabbit Alexa 594 
secondary antibodies (Molecular Probes). For visualization of mitochondria and 
lysosomes, live cells were treated with Mitotracker-Red and Lysotracker-Red (Molecular 
Probes) according to the manufacturer’s instructions. Nuclei were stained with DAPI 
(Molecular Probes). The confocal microscope and image capturing software described in 
section 2.8 were used.  
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2.10 Immunoprecipitation and Western blots 
 
NIH3T3 cells (2 x 106) were co-transfected with FLAG-m153-pcDNA (1 µg) and HA-
m153-pcDNA (1 µg) (Amaxa Nucleofector, solution R, program U30) and seeded in 10 
cm plates. For infection experiments 70-80% confluent NIH3T3 cells seeded in 10 cm 
plates were infected with MCMV-GFP at an m.o.i. of two. After overnight incubation for 
transfections and 24 h incubation for infections, the cells were washed twice in ice-cold 
PBS and lysed in the plates with 1 ml of 1% NP40, 50 mM Tris-HCl pH 8, 300 mM 
NaCl, 5 mM EDTA, 1x protease inhibitor cocktail (Pierce, Rockford, IL, USA), 10 mM 
iodoacetamide, 0.02% sodium azide. The cells were removed from the plate with a cell 
scraper and incubated for 15 min. on ice. All subsequent steps were performed on ice or 
at 4 °C. The lysate was centrifuged for 15 min. at 13,000 rpm, and supernatants were 
precleared by incubating with 50 µl of anti-mouse IgG beads (eBioscience, San Diego, 
CA, USA) for 30 min. For transfected cells the precleared cell lysates were divided into 
three aliquots, and either 5 µg of FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO, 
USA), anti-HA  (Sigma-Aldrich) or mAb153.16 were incubated with the lysates for 1 h. 
For infection experiments 5 µg of mAb153.16 were incubated with infected and 
uninfected cell lysates for 1 h. Then 50 µl of anti-mouse IgG beads were added to the 
lysates and incubated for 1 h with rotation. The beads were washed 5x with lysis buffer 
containing 0.1% NP40. Reducing SDS-PAGE sample buffer (Pierce) was added to the 
beads and the samples heated to 100 °C for ten minutes prior to electrophoresis on an 8-
20% gradient Tris-Glycine SDS-PAGE gel (Invitrogen, Carlsbad, CA, USA). The 
proteins were transferred to polyvinylidene fluoride (PVDF) membranes using standard 
protocols. The membrane was blocked overnight with 5% non-fat dried milk in 0.1% 
Tween 20/PBS. The proteins were detected by incubation with either anti-FLAG M2, 
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anti-HA (Sigma-Aldrich) or anti-m153 rabbit serum for 1 h at room temperature. After 
washing in 0.1% Tween 20/PBS the membranes were incubated with secondary antibody 
for 1 h at room temperature (anti-mouse or anti-rabbit Trublot-eBioscience), and washed 
again. The blots were developed with the Supersignal West Dura Extended Duration 
substrate (Pierce) and exposed to Biomax XAR film (Kodak, Rochester, NY, USA).  
 
To determine whether m153 is glycosylated, immunoprecipitated samples on beads were 
incubated with 1000 U PNGaseF (New England Biolabs, Ipswich, MA, USA) in PBS at 
37 °C overnight before processing for SDS-PAGE and Western blot analysis as 
described above.  
 
2.11 Bacterial expression in E.coli and refolding of proteins from inclusion bodies 
 
The MCMV constructs were evaluated for expression in bacterial inclusion bodies in 
Rosetta DE3 cells (Novagen, Madison, WI, USA). One liter of LB medium with 250 
µg/ml carbenicillin and 34 µg/ml chloramphenicol was inoculated with a 50 ml 
overnight culture of the MCMV/pET21 construct and grown at 37 ºC and 250 rpm until 
an OD600 of 0.8 was reached. The cultures were then induced with 0.5-1 mM IPTG. 
After two hours the cells were harvested by centrifugation at 5000 x g for 5 min. The cell 
pellet was resuspended in 100 mM Tris-HCl, 2 mM EDTA pH 8, 0.1% deoxycholate and 
0.5 mg/ml lysozyme and the cells were lysed overnight at 4 ºC. The viscous mixture 
obtained after lysis was sonicated 4 x 20 sec with a Sonicator cell disruptor set at output 
= 7 and duty cycle = 50% (Misonix, Inc. Farmingdale, NY, USA). The inclusion bodies 
were pelleted at 20,000 x g for 20 min. and washed three times with TE/0.1% DOC and 
once with TE. The final pellet was dissolved in 6 ml TE to which 5.7 g guanidine-HCl or 
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4.8 g urea was added to produce a final concentration of 6 M GdHCl or 8 M urea 
respectively. The inclusion bodies were incubated for several hours at room temperature 
until the solution was clear.  
 
The solubilized proteins were then diluted drop-wise with rapid stirring in one liter of a 
0.4 M arginine-HCl, 100 mM Tris-HCl, 2 mM EDTA, 4 mM reduced glutathione, 0.4 
mM oxidized glutathione pH 8 buffer, that was pre-chilled to 4 °C. The refolding 
mixture was incubated for 4 days at 4 ºC. Precipitates were removed by filtering through 
a 0.45 µm membrane and the solution was dialyzed against TBS pH 8. After dialysis, 
precipitated material was removed by filtration and the protein solution concentrated 
using a 10 000 MW cutoff membrane (Millipore, Danvers, MA, USA) in a stir-cell 
concentrator (Amicon-Millipore). The concentrated proteins were analyzed on a size 
exclusion column (Shodex KW 802.5, Thomson Instrument Company, Clear Brook, VA, 
USA) to assess the efficiency of refolding. 
 
 
The Research Technology Branch of the NIAID provided N-terminal sequencing 
services. Liquid or blotted protein samples were sequenced by automated Edman 
degradation. 
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2.12 Drosophila insect cell expression and purification of m153  
 
The pMT-Bip-His constructs encoding M37, m151 or m153 were transfected, together 
with puromycin and blasticidin resistance-encoding plasmids (10:1:1 ratio by weight), 
into S2 cells using Fugene6 (Roche, Indianapolis, IN, USA) according to the 
manufacturer’s protocol. Forty-eight hours after transfection the cells were transferred to 
selective medium containing 5 µg/ml puromycin (Sigma-Aldrich, St. Louis, MO, USA) 
and 5 µg/ml blasticidin (Calbiochem, San Diego, CA, USA). Resistant cells were 
maintained in selective medium in shaker cultures (28 °C, 100 rpm). Expression of M37, 
m151 or m153 was induced with 1 mM CuSO4 at a cell density of 2 x 107 /ml. The 
proteins were purified on Ni-NTA columns (Qiagen, Valencia, CA) and then subjected 
to SEC (Shodex KW802.5 or Pharmacia Superdex 75). The His-tags were removed by 
thrombin or enterokinase (M37) cleavage at 37 °C for 2 h, and the proteins were purified 
by anion exchange chromatography (Mono Q, Pharmacia, Uppsala, Sweden). For 
preparation of a SeMet derivative of m153, the m153/S2 cells were grown in Orbigen 
insect cell medium to 2 x 107 cells/ml. The cells were then washed in methionine-free 
medium (Orbigen, San Diego, CA, USA) and starved in this medium for 6 h under 
normal growth conditions. Protein expression was induced by simultaneous addition of 1 
mM CuSO4 and 60 µg/ml SeMet (Sigma-Aldrich). The SeMet labeled protein was 
purified as described for the native protein.  
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2.13 Transient expression of wild type and mutant m153 in SF9 cells 
 
Two hundred micrograms of m153-pIEx-4, interface mutant-m153-pIEx-4 or control 
mutant-m153-pIEx-4 were transfected into 1 x 108 exponentially growing SF9 cells in 
100 ml with 1 ml of Insect GeneJuice transfection reagent (Novagen, Madison, WI, 
USA).  Seventy-two hours after transfection the cell supernatants were collected.  Wild 
type and mutant proteins were then purified on Ni-NTA and SEC columns as described 
for S2 insect cell expression.  
 
2.14 Crystallization, structure determination and refinement 
 
Crystal Screen, Crystal Screen 2 (Hampton Research, Aliso Viejo, CA, USA) and the 
PEGs Suite (Qiagen, Valencia, CA, US) were used to screen for m153 crystallization 
conditions. Both native m153 and the SeMet derivative of m153 crystallized in 25% 
PEG 2000 MME, 0.1 M Tris-HCl pH 8. The crystals were grown in 2 µl hanging drops 
at 18 ºC. The crystals were very fragile and did not diffract well. We used an additive 
screen (Hampton Research) and found that addition of 0.5% β-D-maltoside to the drops 
yielded crystals that diffracted to 2.3 Å. Diffraction data for SAD phasing were collected 
on a single SeMet derivative crystal on beamline X29A at the NSLS, Brookhaven, at a 
wavelength of 0.9791 Å and processed with HKL2000 (Otwinowski and Minor, 1997). 
The automated SOLVE/RESOLVE scripts as incorporated in the AutoSol module of the 
PHENIX suite (Adams et al., 2002) were used with data truncated at 2.8 Å to obtain 
SAD phases followed by automated model building and docking to the m153 sequence. 
Ambiguously placed residues were rebuilt manually into the SAD-phased map in COOT 
as alanines (Emsley and Cowtan, 2004).  To extend the resolution to 2.4 Å a molecular 
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replacement search was carried out in Phaser (Read, 2001) with the partially built model 
yielding Z-scores of 11.0 and 23.7 for the rotation and translation functions, respectively, 
for one dimer in the asymmetric unit. Rigid body refinement specifying α1α2 and α3 as 
separate domains yielded a model with initial R and Rfree of 36.9% and 38.6%, 
respectively. Refinement at 2.4 Å was continued in Refmac5 (Murshudov et al., 1997) 
with tight NCS restraints between chains A and B with further model building guided by 
2Fo-Fc and Fo-Fc maps generated in COOT 0.1.3. Residues in the 231-237 loop which 
had little or no electron density were omitted from the NCS restraints. Optimal domains 
for TLS refinement were identified and input files for TLS refinement were generated 
using the TLSMD web server (Painter and Merritt, 2005). TLS refinement using 10 TLS 
groups per chain decreased Rfree from 29.9% to 28%. Finally, waters were added with 
CNS 1.1 (Brunger et al., 1998) and a final round of refinement was performed without 
NCS restraints. The final model has Rcryst=23% and Rfree=27.9%, includes residues 2-230 
and 238-277 of chain A and residues 5-277 of chain B and has 57 waters. The atomic 
coordinates and structure factors have been deposited in the Protein Data Bank (Berman 
et al., 2000) under accession number 2O5N. Buried surface area calculations were 
performed in CNS. Hinge angles were calculated using HINGE, a program written by 
Peter Sun. HINGE calculates an ellipsoid (defined by axes a, b and c) for each indicated 
domain, and reports the angle between the long axes of the adjacent domains as the hinge 
angle. HINGE is available at: http://sis.niaid.nih.gov/programs/hinge.html. 
The following residue ranges were used to define the α1α2 and α3 domains in the 
respective proteins: m153 (20-178, 179-277), m157 (20-175, 176-268), m144 (1-142, 
143-242), H-2Kb (1-180, 181-274), CD1d (1-184, 185-279), T22 (1-180, 181-276), ZAG 
(1-182, 183-277), MICA (1-175, 176-274). Figures were generated using PyMOL 
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(DeLano, 2002). Sc values were calculated using the default settings of the Sc program 
(Lawrence and Colman, 1993) of the CCP4 Suite. 
 
2.15 Analytical ultracentrifugation 
 
Sedimentation velocity experiments were conducted with a ProteomeLab XLI 
ultracentrifuge (Beckman Coulter, Fullerton, CA, USA). 400 µl samples were loaded at 
concentrations of 0.3 mg/ml for m153 wild type and 0.5 and 0.1 mg/ml for the m153 
mutant and centrifuged at 50,000 rpm at 20 °C.  Sedimentation data were acquired with 
the Rayleigh interference optical system at 1 min. intervals, and data were analyzed 
using SEDFIT software (Schuck, 2000). Additional details on experimental and data 
analysis protocols can be found at http://www.analyticalultracentrifugation.com. 
 
2.16 Mass spectrometry 
 
For mass spectrometry infusion experiments, samples were diluted with ultrapure water 
(LC-MS-Chromasolv grade, Sigma-Aldrich, St. Louis, MO, USA), heated to 65 °C for 5 
min. and desalted twice in ultrapure water using Centri•Sep™ desalting spin columns 
according to the manufacturer’s procedures (Princeton Separations, Inc. Adelphia, NJ, 
USA). After further enzymatic or chemical treatment with 0.1 µg trypsin (Promega, 
Madison, WI, USA), 0.5 mU PNGaseF (QA-Bio, Palm Desert, CA, USA), 2 µg tris-
(carboxyethyl)-phosphine hydrochloride (TCEP, Sigma-Aldrich) or 2 µg dithiothreitol 
(DTT, Sigma-Aldrich) and incubation at 37 °C for 1 – 48 h, the respective samples were 
diluted 1:1 in spraying buffer (40% Isopropanol, 40% Acetonitrile, 20% Ultrapure Water 
and 0.2% formic acid, all Sigma-Aldrich). Infusion nano-electrospray was performed 
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using the TriVersa™-NanoMate chip technology (Advion Biosystems, Ithaca, NY, 
USA) coupled to an LTQ-FT™ ICR mass spectrometer (Thermo Electron, Thermo 
Scientific, Waltham, MA, USA).  
 
Five microliters solution pick-up (ca. 2-15 pmol/µL) was sufficient for ~ 45 min. 
analysis time (1.5 kV, 0.3 bar pressure assistance). MS and MSn fragmentation data 
were recorded applying collision-induced dissociation (CID, 35% energy), electron 
capture dissociation (ECD, 5 x 105 energy, 10 ms delay, 70 ms duration) or infrared 
multi photon dissociation (IRMPD, 90% energy, 10 ms delay, 90 ms duration) of 
indicative precursor ions. MS spectra recorded were the average of three or more FT-MS 
scans (max. ion injection time 3000 ms, resolution 100,000 to 500,000, ion accumulation 
values according to the manufacturer’s standard values). MSn spectra were recorded as 
the average of three FT-MS scans (5 Da window for precursor ion selection).  
 
2.17 Retrovirus production and generation of reporter cell lines 
 
The m144-zeta-pMX and m153-zeta-pMX (2 µg) constructs were transfected in the 
Phoenix E packaging cell line (a kind gift of Dr. Toshio Kitamura, University of Tokyo, 
Tokyo, Japan) using Fugene 6 (Roche, Indianapolis, IN, USA) according to the 
manufacturer’s protocol. Retrovirus containing supernatants were collected 48 h after 
transfection and stored at -80 °C. The 43.1 cell line (Ohtsuka et al., 2004) contains an 
NFAT-driven GFP construct and was used as the parental reporter cell line. One and a 
half million 43.1 cells were suspended in 3 ml of m144-zeta or m153-zeta retroviral 
supernatants in one well of a 6 well plate. Polybrene (hexadimethrine bromide, Sigma-
Aldrich, St. Louis, MO, USA) was added to a final concentration of 4 µg/ml and the 
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cells were centrifuged at 1000 x g for two hours at room temperature to enhance the 
infection efficiency. Forty-eight hours after infection the cells were stained for surface 
expression of m144 and m153 using anti-m144 15C6 or mAb153.16 followed by anti-
mouse IgG-PE and FACS analysis to determine the infection efficiency. Forty-three 
percent of m144-zeta infected cells expressed m144 and 70% of m153-zeta infected cells 
expressed m153. Limited dilution cloning was then performed to obtain cell lines in 
which all cells express the respective viral molecules at high levels. 153z_43.1 or 
144z_43.1 cells were seeded at different concentrations in 96 well plates (50, 25, 10 and 
1 cell per well) and cultured at 37 °C / 5% CO2. The cells that grew out were expanded 
and stained for m153 or m144 expression and the populations with homogeneous viral 
protein expression were selected for further use.  
 
2.18 Control antibody stimulation of reporter cell lines 
 
Control stimulation of 43.1, m144z_43.1 and m153z_43.1 cell lines was performed in 
flat bottom 96 well plates coated overnight with the TCR specific antibody H57 (1 
µg/ml), anti-m144 15C6 (1 µg/ml) or anti-m153 mAb153.16 (4 µg/ml) in PBS. Reporter 
cells (1 x 105/well) were incubated for 16-18 h at 37 °C / 5% CO2 before the cells were 
harvested by centrifugation and analyzed for GFP expression by FACS.  
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2.19 Reporter cell coculture assays 
 
Screening of cell lines and primary cells was performed in round-bottom 96 well plates. 
One hundred thousand reporter cells were cocultured with different numbers of 
stimulator cells ranging from 1 x 105 to 1 x 106 in a total volume of 250 µl for 18 h. 
Reporter cells were discriminated from stimulator cells based on forward- and side-
scatter profiles or by staining with a PE-labeled antibody to the Vβ3 TCR chain (clone 
KJ25, BD Pharmingen, BD Biosciences, San Jose, CA, USA) and analyzed by FACS 
(FACSCalibur, BD Biosciences, San Jose, CA, USA). The number of Vβ3 positive cells 
that express GFP represents the percentage of cells stimulated by the “test” cell line or 
primary cells. Dead cells were excluded from the analysis by gating on propidium iodide 
negative cells.  
 
2.20 Isolation of mouse or rat splenocytes 
 
Each freshly isolated spleen was flushed three times with 3 ml of 6 mg/ml Liberase 
Blendzyme 2 (Roche, Indianapolis, IN, USA) and 0.5 mg/ml DNAse (Roche) in 
complete RPMI. The spleen was then cut into fine pieces and combined with the 
cell/enzyme suspension and incubated at 37 °C for 30 min. and vortexed every 5 min. 
The cells were passed through a 45 µm cell strainer (BD Falcon) and the remaining 
pieces of tissues dissociated with a plunger. The cells were then centrifuged for 10 min. 
at 300 x g at 4 °C. The red blood cells were lysed by addition of ACK lysing buffer (155 
mM NH4Cl, 0.1 mM EDTA, 10 mM KHCO3, Quality Biological Inc., Gaithersburg, 
MD, USA) and were subsequently washed twice in RPMI medium containing 50 µg/ml 
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gentamicin and 10% fetal bovine serum. The yield of cells per spleen ranged from 1.2 to 
1.6 x 108.  
 
2.21 Isolation of different cell subsets from mouse or rat splenocytes 
 
2.21.1  Dendritic cells (mouse – CD11c+, rat – OX62+) 
 
CD11c+ cells were isolated by positive selection with anti-CD11c microbeads from 
Miltenyi Biotec (Auburn, CA, USA). Cells were resuspended at 108 cells/400 µl in ice-
cold PBS containing 0.5% BSA and 2 mM EDTA. To increase the purity of the final 
CD11c+ population, the cells were incubated with anti-CD32/CD16 (clone 2.4G2, 4 
µg/ml, BD Pharmingen, San Jose, CA, USA) for 10 min. on ice, to block Fc receptor on 
the spleen cells. Then 100 µl anti-CD11c+ beads were added per 108 cells and the cells 
were incubated for 15 min. at 4-8 °C. The cells were subsequently washed with the 
PBS/BSA/EDTA buffer (1-2 ml/ 108 cells) and resuspended at 108/500 µl. The CD11c+ 
cells were then isolated using an LS positive selection column and MACS separator 
(Miltenyi Biotec) according to the manufacturer’s instructions. The purity of the 
population was determined by staining with an anti-CD11c-PE antibody (clone HL3, BD 
Pharmingen) and FACS analysis (FACSCalibur, BD Biosciences). Routinely, CD11c+ 
populations with purity of  ≥ 90% were obtained. 
 
Rat (Wistar strain) dendritic cells were isolated by positive selection using rat anti-DC 
(OX62) Microbeads (Miltenyi Biotec), according to the manufacturer’s instructions.  
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2.21.2  Plasmacytoid dendritic cells  
 
For plasmacytoid DC (pDC) isolation spleen single cell suspensions were prepared by 
mechanical disaggregation. The pDC were isolated using the plasmacytoid dendritic cell 
isolation kit II from Miltenyi Biotec according to the manufacturer’s instructions. This 
kit allows the isolation of untouched pDC from single cell suspensions of the spleen. The 
purity of the population, as assessed by staining with the anti-mPDCA-1-PE antibody 
(Miltenyi Biotec), was usually ~ 90%. 
 
2.21.3  B cells, CD11b+ cells, NK cells, CD4+ and CD8+ T cells 
 
For B cell and monocyte/macrophage (CD11b+) isolation the spleen cell suspensions 
were prepared by enzymatic disaggregation as described for CD11c+ cells. The cells 
were isolated using positive selection with CD19 or CD11b microbeads from Miltenyi 
Biotec. NK, CD4+ and CD8+ cells were isolated from spleen cell suspensions prepared 
by mechanical disaggregation. NK cells were isolated by positive selection using anti-
NK (DX5) microbeads (Miltenyi Biotec) or by a combination of first negative selection 
using the NK cell isolation kit from Miltenyi Biotec followed by positive selection. 
CD4+ and CD8+ T cells were isolated by negative selection using the CD4 and CD8-
specific T cell isolation kits from Miltenyi Biotec. The purity of the final populations 
was 98% for B cells, 80% for CD11b+ cells, 70% for NK cells by positive selection), 
91% by combination, 94% for CD4+ T cells and 89% for CD8 T cells as determined by 
staining for specific cell markers and FACS analysis.  
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2.22 Generation of dendritic cells from mouse bone marrow cells 
 
Bone marrow cells were flushed from the femora of BALB/c mice and the cells were 
treated with ACK buffer to remove red blood cells. The cell suspension was then 
incubated with PE-labeled antibodies to B220, MHC class II (IE/IA), CD90.2 and 
CD11b (all from BD Pharmingen) for 10 min. at 4-8 °C. Anti-PE magnetic beads 
(Miltenyi Biotec) were added to the cell suspension and a further incubation of 15 min. 
at 4-8 °C was performed. The labeled cells were removed using an LS MACS separation 
column (Miltenyi Biotec). The unlabeled fraction was seeded at 3 x 106 cells per well in 
a 6 well plate in RPMI containing GM-CSF (5 ng/ml, Chemicon International, Millipore, 
Danvers, MA, USA). The medium was changed every 2 days and after 6 days of culture 
CD11c+ cells were isolated from the bone-marrow cultures using the CD11c Microbeads 
as described above.  
 
2.23 Cell-cell contact assay 
 
CD11c+ cells were isolated from BALB/c spleens as described in section 2.21.1. As a 
positive control for reporter cell stimulation, 1.2 x 106 CD11c+ cells were cocultured in 
24 well plates overnight with 5 x 105 153z_43.1_H reporter cells in 700 µl complete 
RPMI medium at 37 ºC / 5% CO2. As a negative control, the parental 43.1 reporter cells 
were cocultured with CD11c+ cells under the same conditions. To test whether cell-cell 
contact was required for reporter cell stimulation, the cocultures were performed in 24 
well plates with 0.4 µm polycarbonate membrane 6.5 mm transwell inserts (Costar, 
Corning, NY, USA) that separated the reporter and stimulator cells. CD11c+ cells (1.2 x 
106) were incubated in 100 µl in the transwell (upper chamber) and 5 x 105 reporter cells 
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were added in 600 µl to the well of the 24 well plate (lower chamber) and vice versa. 
The assay was performed in duplicate wells. After overnight incubation at 37 ºC / 5% 
CO2 the reporter cells were collected, stained for Vβ3 expression and analyzed by FACS 
to determine the number of GFP+ cells. Dead cells were excluded by propidium iodide 
gating.  
 
2.24 Dendritic cell migration assay 
 
The migration assay was performed using polycarbonate transwell inserts with a 6.5 mm 
diameter and a pore size of 5 µm (Costar, Corning, NY, USA). CD11c+ cells were 
isolated as described and cultured overnight in complete RPMI at a concentration of 1 x 
106 cells/ml on 24 well plates coated in PBS, 10 µg/ml m152 in PBS or 10 µg/ml m153 
in PBS. Half of the cells cultured on the PBS coated plates were stimulated with 1 µg/ml 
lipopolysaccharide (LPS, Sigma-Aldrich, St. Louis, MO, USA). Two hundred and fifty-
thousand cells were then added to the transwell inserts in 100 µl. The bottom chambers 
were filled with 600 µl complete RPMI medium or medium supplemented with 200 
ng/ml recombinant mouse CCL19 (also known as MIP-3β, R&D Systems, Minneapolis, 
MN, USA). The cells were incubated at 37 °C / 5% CO2 for 6 h. Cells that had migrated 
to the bottom chamber were collected, stained for CD11c and counted by FACS. The 
migration is expressed as the ratio of cells migrating in CCL19 to cells migrating in 
medium alone. The assay was performed in triplicate.  
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2.25 DC surface phenotype analysis by FACS 
 
One million CD11c+ cells were cultured alone or with 1 x 106 43.1 or m153z_43.1H 
cells for 16-18 h. The surface phenotype of the CD11c+ cells after the coculture was 
assessed by staining with anti-CD11c-PE and FITC-labeled antibodies to CD40 (3/23), 
CD80 (16-10A1), CD86 (GL1) or I-Ad (AMS-32.1) and appropriate isotype controls 
followed by FACS analysis (FACScan, BD Biosciences). All antibodies were from BD 
Pharmingen (BD Biosciences, San Jose, CA, USA). 
 
2.26 Primer sequences 
 
Table 2.1. Primer sequences 
Bacterial expression 
MCMV ORF Primer sequence 
m17 A 5' GCTAGGGCTAGCCGTGCGCAGAACTGCGGCGTCAGTTTC  
B 5' GAGTCAGGATCCTTAGCTCGCGCAGCGTTTTGTTTTTGACTT  
M37 A 5' GCTAGGGCTAGCCTCGGGGCCCGAATCGGGCGTCTTCGA  
B 5' GAGTCAAGATCTTTACTTGGGCAGGGGATCGCCGGCCACGTA  
m90 A 5' GCTAGGGCTAGCGGCACGGCGGACTTATATACCTGGATA  
B 5' GAGTCAGGATCCTTAGGTGTAAGCCTCCTGGGGTTCTCTGCC  
m145 A 5' GCTAGGGCTAGCAGCTACGATCAACGTACCCCCGGCGAC  
B 5' GAGTCAGGATCCTTACGTATCTACCGAATAGCCCGAGTAATA  
m150 A 5' GCTAGGGCTAGCTCCCTGAACGATAGCTTTCCCCTCGTA  
B 5' GAGTCAGGATCCTTAGGCCGGCTCCCTCTCTGTCGTCGTTGC  
m151 A 5' GCTAGGGCTAGCGCCGGGCTTCATGATGCGGTCACAAAG  
B 5' GAGTCAGGATCCTTAACAAGATCTTTTGCGACCGACATGCGA  
m152 A 5' GCTAGGGCTAGCGGCGAGACGGCGGGCAGCAGCTATATG  
B 5' GAGTCAGGATCCTTACGCGGAGACGGGAGGAGCGTGCTTGAG  
m153 A 5' GCTAGGGCTAGCGTCGTGCGGCCCGAAGTTAACAGGACG  
B 5' GAGTCAGGATCCTTAGGTCAGTCTCGAATCGTTGATCGTCCT  
m155 A 5' GCTAGGGCTAGCATCGATTTACAAGACTATGATGATGAC  
B 5' GAGTCAGGATCCTTAGGCGTCGTTTAGGTACGGAACCACTTT  
m159 A 5' GCTAGGGCTAGCTTCAGTCAGGAGTGTCTATACATGCCT   
B 5' GAGTCAGGATCCTTAGCTGCCCATGGGTAGCGGTCCGTAAGG  
 
Insect cell expression 
pMT-Bip-V5-His / Drosophila S2 cells 
M37 A 5’AGATCTGGGCCCGAATCGGGCGTCTTCG 
B 5’GGTACCTCAATGGTGATGGTGATGATGCTTGTCATCGTCATCCTTGGGCAGGGGATCGCCGGCCAC 
m151 A 5’GGATCCTCTGTGTGTGAGTCGCCGGTCCTCG 
B 5’GGTACCTCAATGGTGATGGTGATGATGGCTGCCGCGCGGCACCAGACAAGATCTTTTGCGACCGACATG 
m153 A 5’GGATCCGAGGTCGTGCGGCCCGAAGTTAAC 
B 5’GGTACCTCAATGGTGATGGTGATGATGGCTGCCGCGCGGCACCAGGGTCAGTCTCGAATCGTTGATCGTC 
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pIEx-4 / SF9 cells 
m153 5’CGTCACCCATGGCAATTCCCCTTCTCCTTCTGCCGTTGGTTCTC 
5’ACTTCGCTCGAGGGTGAGTCTCGAATCGTTGATCGTCCTCTG 
Interface 
Mutation 
primers 
5’GACGGTGCTATACAGGCCATACGAGCCGTGACATCGGAATAC (T128A, S131A) 
5’AGCGCCGGCCGGGACTCCGCTGCGATAGCCTTGTCCGCG (R225A) 
5’ATCGAAGTGGCTGCCTATCTGCCGGTC (S241A) 
Control 
mutation 
primers 
5’ GAAGATGACATTCTAGAAGCTGACATCGAGATGGATATCG (D194A, forward) 
5’ CGATATCCATCTCGATGTCAGCTTCTAGAATGTCATCTTC (D194A, reverse) 
Mammalian expression 
Insertion of N-terminal FLAG tags 
ORF Primer Sequence 
m17 A 5’TCTAGTGGATCCATGGGGACGGGAGGAAAGGCGGACGGTACGTTCTCGGGTTTCTATCTG 
B 5’ACGTTCTCGGGTTTCTATCTGCTGTTCTGGCTCGCCCTCGCCGTGCGTGCGGACTACAAG 
C 5’GCCGTGCGTGCGGACTACAAGGATGACGATGACAAGCAGAACTGCGGCGTCAGTTTC 
D 5’TCGACTGAATTCTTAGACTTGGGGCAGACGCTGAAATCG 
M37 A 5’CCTGCCAGATCTATGGTCCTGACACATAAGTCCGAATCTCGGGCGGATTCTCTCGTC 
B 5’TCTCGGGCGGATTCTCTCGTCAGGATGACAGCGGGGGGGCTCGGGATCGCGGCGGTG 
C 5’GGGCTCGGGATCGCGGCGGTGGCCACGCGTGCCACCACTCTCTGTTGTTGCCTCGCGATCGCC 
D 5’TGTTGTTGCCTCGCGATCGCCGCGCGGACGGCGGTCTCGGGGCCCGAATCGGACTAC 
E 5’TCGGGGCCCGAATCGGACTACAAGGATGACGATGACAAGGGCGTCTTCGAGTGCTCCTAC 
F 5’AGCGTCGAATTCTTACACGTTTTCCGCGGCGAAATC 
m144 A 5’GCTACGGGATTCATGAGGGCTCTGGCGCTGATATGCGTGGTGTGGGTGTGTTGGCGAGAG 
B 5’GTGTGGGTGTGTTGGCGAGAGAGTTGCGCTCGCCACGGGGACTACAAGGATGACGAT 
C 5’CACGGGGACTACAAGGATGACGATGACAAGACAGAGGACTCGTCCGAGTCCGGACTG 
D 5’TACGCTGAATTCTTAAATGCTGGGATCCGGGACCGTGACGAT 
m145 A 5’ACGGCTGGATCCATGGACCGTCGGGTGGTCTCATACCTAATGTGCGCCTTG 
B 5’TCATACCTAATGTGCGCCTTGGCGGTTTCGTTCGCTAGCTACGATTAC 
C 5’TCGTTCGCTAGCTACGATTACAAGGATGACGATGACAAGCAACGTACCCCCGGCGACGTA 
D 5’ACAGTTGAATTCTTACGCCTCTATCGTCTTATACCA 
m152 A 5’GCTACGGGATTCATGATTGGCGTGATACGTGCGCTCGTGTGGTGGACTTTGGTG 
B 5’CTCGTGTGGTGGACTTTGGTGAAGACGACCGCAGCCTCTGTGGACTACAAG 
C 5’GCAGCCTCTGTGGACTACAAGGATGACGATGACAAGTGTGAGTCGCCGGTCCTCGTT 
D 5’TACGCTCAATTGTTATCGAAAGCTGAGCTCGCTGTGGGA 
m152 A 5’GGATCCATGCTGGGCGCTATCACCTACTTGCTCCTCTCGGTTCTCATAAAC 
B 5’CTCCTCTCGGTTCTCATAAACCGAGGCGAGACGGCGGGCGACTACAAG 
C 5’GAGACGGCGGGCGACTACAAGGATGACGATGACAAGAGCAGCTATATGGACGTGCGC 
D 5’GAATTCTTACCACACGCGGCAGTTGATGTA 
m153 A 5’GCTACGGGATCCATGATTCCCCTTCTCCTTCTGCCGTTGGTTCTCATCTCAGGAGGG 
B 5’TTGGTTCTCATCTCAGGAGGGTTCTGGGCGTGCGGCTCAGCGGAGGTCGACTACAAG 
C 5’TCAGCGGAGGTCGACTACAAGGATGACGATGACAAGGTGCGGCCCGAAGTTAACAGG 
D 5’TACGCTGAATTCTTACACCACATTCTCCTCCGTATCCGAGCA 
m155 A 5’GGATCCATGTCTGTACGAGTATGTGCTCTCCTGCTCTTGATCGCT 
B 5’CTCCTGCTCTTGATCGCTTGTGCCTACGCCTACATCGATTACAAG 
C 5’TACGCCTACATCGATTACAAGGATGACGATGACAAGTTACAAGACTATGATGATGAC 
D 5’CAATTGTTATTTGTAGACGGGCGGGACGCT 
Insertion of N-terminal HA-tag 
m153 A 5’GCTACGGGATCCATGATTCCCCTTCTCCTTCTGCCGTTGGTTCTCATCTCAGGAGGG 
B 5’TCAGCGGAGGTCTACCCATACGATGTTCCAGATTACGCTGTGCGGCCCGAAGTTAACAGG 
C 5’TTGGTTCTCATCTCAGGAGGGTTCTGGGCGTGCGGCTCAGCGGAGGTCTACCCATAC 
D 5’TACGCTGAATTCTTACACCACATTCTCCTCCGTATCCGAGCA 
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m153-EYFP fusion 
Forward  
Reverse 
A 5’ACGGGATCCATGATTCCCCTTCTCCTTCTGCCG 
B 5’ACGGAATTCGCACCACATTCTCCTCCGTATCCG 
BiFC constructs 
m144_5YFP 
m144_3YFP 
A 5’ACGAGATCTATGAGGGCTCTGGCGCTG  
B 5’ACGGAATTCGCAATGCTGGGATCCGGGACCGTG 
m153_5YFP 
m153_3YFP 
A 5’ACGGGATCCATGATTCCCCTTCTCCTTCTGCCG 
B 5’ACGGAATTCGCCACCACATTCTCCTCCGTATCCG 
m144 and m153 – human zeta chain fusion constructs 
153_YFP 
153-hzeta-reverse 
5’ACGGGATCCATGATTCCCCTTCTCCTTTCTGCCG 
5’TCCATCCAGCAGGTAGCAGAGTTTGGTCAGTCTCGAATCGTTGATCGTCCTCTGG 
153_hzeta_forward 
human_zeta_reverse 
5’CCAGAGGACGATCAACGATTCGAGACTGACCAAACTCTGCTACCTGCTGGAT 
5’GAATTCTTAGCGAGGGGGCAGGGCCTGCATGTGAAC 
m144_5YFP 
human_zeta_reverse 
5’ACGAGATCTATGAGGGCTCTGGCGCTG 
5’GAATTCTTAGCGAGGGGGCAGGGCCTGCATGTGAAG 
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CHAPTER 3 
 
 
CHARACTERIZATION AND RECOMBINANT EXPRESSION OF PREDICTED 
MHC-I-LIKE PROTEINS ENCODED BY MCMV  
 
3.1 Introduction 
 
The predicted MHC-I-like proteins of MCMV comprise m144, eight members of the 
m145 family (m17, m145, m150, m151, m152, m153, m155 and m157) and three 
additional proteins of unknown function M37, m90 and m159. We did not include m157 
in our characterization experiments, since several other groups were already studying it. 
m144, previously studied in the laboratory, was used as a control in some experiments. 
 
The MCMV MHC-I-like proteins all have putative N-terminal signal sequences, 
transmembrane regions or in the case of m157, a GPI-anchor signal sequence, and N-
linked glycosylation sites (Rawlinson et al., 1996). It is therefore likely that they are cell 
surface expressed molecules, similar to classical MHC-I proteins. However, the capacity 
of proteins like m145, m152 and m155 to cause downregulation of host proteins argues 
that the family members may localize either to the surface or remain inside the cell, in 
the secretory/surface pathway, depending on their function. To learn more about the 
cellular expression of the MCMV m145 family we used transient transfection studies in 
mammalian cells. As a first step to examine the relationship of these proteins to classical 
MHC-I molecules, we determined whether the proteins are expressed predominantly 
inside the cell or at the cell surface. MHC-Ia proteins are only stably expressed at the cell 
surface when they have peptide bound in the α1α2 domain groove and are associated 
with the β2m light chain. We therefore evaluated whether the viral proteins are 
 
59 
dependent on association with β2m or the availability of peptides in the ER for stable 
surface expression.  
 
We applied bioinformatics to predict the soluble extracellular domain of the viral MHC-
I-like molecules and tested different recombinant expression systems to identify the 
optimal expression system for this protein family, identify the best candidates for 
structure determination and obtain suitable material for crystallization trials.  
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3.2 Results 
 
3.2.1 Localization of MCMV MHC-I-like proteins in transfected cells 
 
The cellular localization of several members of the m145 family as well as M37 was 
studied in transfected cells. Constructs encoding N-terminally FLAG-tagged molecules 
were transfected into COS-7 cells and the surface expression of the proteins was 
assessed 48 h post transfection by staining with the FLAG-specific monoclonal antibody 
M2 and flow cytometry analysis. Due to technical difficulties m90, m150 and m159 
could not be studied in the transfection experiments. Of the six m145 family members 
tested, m145, m151 and m153 were localized predominantly at the cell surface. M37 was 
also detected readily at the cell surface (Figure 3.1A). m144, which is expressed on the 
surface of MCMV-infected cells (Andrews et al., 2001), was used as a positive control 
for surface localization. The percentage of cells that expressed m17, m152 and m155 at 
detectable levels at the cell surface ranged from 10 to 36%. Subsequent intracellular 
staining for m152 and m155 confirmed that these proteins are more abundant inside the 
cell than on the surface (Figure 3.1B), consistent with the observation that they cause the 
retention of NKG2D ligands Rae-1 and H60 in MCMV infected cells (Hasan et al., 2005; 
Lodoen et al., 2003). Thus even though the m145 family members all have predicted 
signal peptides and transmembrane regions, their localization is not necessarily at the 
cell surface and is probably dictated by their individual functions.  
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Figure 3.1. Cellular localization of MCMV MHC-I-like glycoproteins in transfected COS-7 
cells. A) pIRES-GFP vectors encoding N-terminally FLAG-tagged constructs of the indicated 
proteins were transfected into COS-7 cells. Surface expression was evaluated 48 h after 
transfection by staining with the anti-FLAG M2 monoclonal antibody and anti-mouse IgG1-PE 
followed by FACS analysis. B) Intracellular staining of COS-7 cells transfected with m152- or 
m155-pIRES-GFP using the same antibodies as in A. Experimental details are described in 
Chapter 2, section 2.5. 
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3.2.2 Cell surface expression of M37, m145, m151 and m153 is independent of 
β2m and TAP expression 
 
Since the MHC-I fold was predicted for all members of the MCMV m145 family as well 
as M37 (Smith et al., 2002), we next determined whether the MCMV proteins that 
localize to the cell surface (m145, m151, m153 and M37), share the requirements of 
classical MHC-I molecules for β2m and peptide for stable expression. To investigate 
their requirement for β2m we transfected N-terminally FLAG-tagged constructs into a 
cell line deficient in β2m (R1E (Allen et al., 1986)) as well as its β2m sufficient 
counterpart (R1.1). The surface expression of all four proteins was equivalent in both 
cell types indicating that none of them require β2m for stable surface expression (Figure 
3.2).  
 
To evaluate the requirement for bound peptide we examined surface expression of M37, 
m145, m151 and m153 in RMA-S, a TAP deficient cell line that fails to transfer peptides 
from the cytosol to the ER (Townsend et al., 1989). MHC-Ia molecules expressed in 
such cells are unstable at the cell surface. We transfected RMA-S and RMA (TAP+) cells 
with each of the four FLAG-tagged constructs and evaluated surface expression of the 
viral proteins in comparison to transfected H-2Dd, an MHC-Ia molecule (Figure 3.3). 
TAP deficiency had no effect on M37, m145, m151 or m153 surface expression, whereas 
expression of H-2Dd was clearly reduced. We conclude that these MCMV proteins do 
not require β2m or bound peptide for stable surface expression. The structural 
implication of this finding is that these MCMV proteins fold properly and have a 
compact three-dimensional structure in the absence of peptide or β2m.  
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Figure 3.2. Surface expression of 
MCMV MHC-I-like proteins is 
independent of β2m. 
R1.1 (β2m+) and R1E (β2m-) cells 
were transfected with the indicated 
FLAG-tagged viral genes in pIRES-
GFP or H-2Dd-pIRES-GFP as a 
control. Eighteen hours post 
transfection surface levels of the viral 
proteins and H-2Dd were determined 
as described in Chapter 2, section 2.6. 
The number of GFP positive cells 
indicates transfection efficiency. The 
percentage surface expression is 
indicated in bold in the upper right 
quadrant (percentage of GFP+ cells 
that stain for either FLAG-M2 or H-
2Dd). The results are representative of 
at least two independent experiments.  
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Figure 3.3. TAP-independent cell surface expression of M37, m145, m151 and 
m153. RMA (TAP+) and RMA-S (TAP-) cells were transfected with the indicated 
FLAG-tagged viral genes in pIRES-GFP or H-2Dd-pIRES-GFP as a control. Eighteen 
hours post transfection surface levels of the viral proteins and H-2Dd were determined as 
described in Chapter 2, section 2.6. The number of GFP positive cells indicates 
transfection efficiency. The percentage surface expression is shown in the upper right 
quadrant in bold (percentage of GFP+ cells that stain for either FLAG-M2 or H-2Dd). 
The results are representative of at least two independent experiments.  
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3.2.3 Cell surface MHC-I levels are downregulated by m152 and to a lesser extent, 
by m153 
 
It has long been known that m152 downregulates surface MHC-I in MCMV-infected 
cells. To determine whether any of the other m145 family members have an effect on 
MHC-I expression, we transfected NIH3T3 fibroblasts with the FLAG-tagged constructs 
encoding the individual family members and 18 h after transfection stained the cells for 
H-2Dq expression (Figure 3.4). As expected, m152 reduced the surface levels of H-2Dq 
significantly in the majority of transfected cells. The only other family member that 
affected MHC-I expression was m153. 
 
 
 10
0 101 102 103 104
GFP
100
101
102
103
104 0.51 0.3
6.6192.6
 10
0 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
62.1 36.6
0.440.82
 10
0 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
73.5 22.7
0.323.41
100 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
75.4 19.3
0.434.94
 
 
100 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
51.8 46.5
0.770.95
100 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
62.3 33.3
2.162.26
100 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
60.7 38.3
0.330.68
 
 
100 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
44.4 23.5
30.61.57
100 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
60.9 35.3
3.10.64
100 101 102 103 104
GFP
100
101
102
103
104
M
H
C
-I
65.8 33.4
0.20.56
 
 
Figure 3.4. Effects of different m145 family members on MHC-I surface expression. 
FLAG-pIRES-GFP constructs of the indicated viral proteins were transfected in NIH3T3 
cells. Eighteen hours after transfection the cells were surface stained for MHC-I (H-2Dq) 
expression (for details see Chapter 2, section 2.5) and analyzed by flow cytometry.   
 
Untransfected 
 NIH3T3 cells 
 No stain Vector control m17 M37 
m144 m145 m151 
m152 m153 m155 
GFP 
(Transfection efficiency) 
M
H
C
-I 
 
66 
The effect of m153 on MHC-I surface expression levels was only observed in GFP-
bright cells (Figure 3.4). Since GFP and m153 expression is linked in the pIRES-GFP 
vector, the GFP-bright population should represent cells that express high levels of 
m153. MHC-I expression is thus only affected when a very high concentration of m153 
is present. This effect was not observed for any of the other family members, and is 
therefore unlikely to be an artefact of the transfection system. In conclusion, even though 
m153 causes significant reduction in the surface MHC-I levels, it does not downregulate 
MHC-I expression to the same extent as m152 (Figure 3.5).  
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Figure 3.5. Comparison of the MHC-I expression levels on the GFP-bright 
populations in m152-, m153- or vector control-transfected NIH3T3 cells.  
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3.2.4 Optimization of recombinant expression of MCMV MHC-I homologs for 
 structural characterization 
 
Bacterial expression in insoluble inclusion bodies is a widely used approach to generate 
protein material for structural studies (Yokoyama, 2003) and the majority of the protein 
structures available in the Protein Data Bank (PDB) were determined from bacterially 
expressed recombinant proteins. Inclusion bodies, the insoluble product of the highly 
expressed recombinant protein, are frequently highly enriched with the recombinant 
protein accounting for as much as 75-90% of their content. If a protein can be refolded 
successfully from bacterial inclusion bodies, relatively high yields of protein can be 
prepared in a short time. Since bacterially expressed proteins lack glycosylation, the 
preparations are highly homogeneous and therefore more likely to crystallize than 
glycosylated insect- or mammalian-cell expressed proteins. Another advantage of 
bacterial expression is that it allows for the quick generation of various mutant proteins. 
 
MHC-I molecules can be expressed in bacteria and refolded from inclusion bodies in 
combination with β2m and peptide (Garboczi et al., 1992). Thus, we first tested 
expression of the predicted MCMV MHC-I homologs in bacteria.  
 
3.2.4.1  Expression in bacterial inclusion bodies 
 
The extracellular domains (ECD) of the MCMV encoded MHC-I homologs were 
predicted with the SignalP 3.0 server, that recognizes signal peptides (Bendtsen et al., 
2004), and the Kyte/Doolittle hydrophilicity plots of the MacVector program (Olson, 
1994) that predicts the transmembrane regions (Table 3.1). The ECD of each of the 
proteins were cloned in the pET21b bacterial expression vector. 
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Table 3.1. Predicted extracellular domains of the MCMV MHC-I homologs. 
 
 
*The SignalP 3.0 server: http://www.cbs.dtu.dk/services/SignalP 
 
 
The expression of the MHC I-like proteins listed in Table 3.1 was evaluated in BL21 
DE3 E. coli cells. Only m90 could be expressed in the BL21 DE3 cells (data not shown). 
We next tested expression in the Rosetta DE3 strain of E. coli. The Rosetta strain 
contains the pRARE plasmid, which encodes tRNAs for six rare mammalian codons, and 
enables the expression of proteins that are limited by codon usage (Brinkmann et al., 
1989; Kane, 1995). Seven of the viral proteins could be expressed at varying levels in the 
Rosetta DE3 strain of E. coli (Figure 3.6).  
 
 
 
 
 
MCMV 
ORF 
Predicted extracellular domain 
 
 Size 
(kDa) 
Signal peptide 
(SignalP 3.0 server)* 
Transmembrane domain 
(Macvector) 
m17 33.7 MGTGGKADGTFSGFYLLFWLALAVR GQLCVHLGQILNLALIFLPIFAICLILNLCI 
M37 27.3 MVLTHKSESRADSLVRMTAGGLGIAAVATRA
TTLCCCLAIAARTAVS 
KMVGMFFFVFGGLALLILFCFMT 
m90 23.3 MDSARRNTSSRVSCSMPAFLSSPRITFMLLG
VLLCFALASGGTA 
TFLHVLIAFLFCIGTGLIVCLYAIL 
m145 44.9 MDRRVVSYLMCALAVSFA TPTLVAMFVAVTALCICAMVFCYYC 
m150 27.4 MCIVAVLSHSLSTSVVMAVVRVRTWGVILVC
YFIVRNASA 
ACGMELSLVTVVAIVSTFTVLKGVLCAYVF 
m151 33.3 MIGVIRALVWWTLVKTTAA CSLLYLLAVPAVLLVVLSSVVIF 
m152 33.9 MLGAITYLLLSVLINRGET EYSIFFMDVWSLIAIGVVFVIVFMYLVKLRVVWIN 
m153 37.4 MIPLLLLPLVLISGGFWACGSA TTVTIAITVAAFVALFVVVGLLVHGIV 
m155 34.1 MSVRVCALLLLIACAYAYIDL AELIINVTYTLLVVLCVLLVVMCWM 
m159 37.2 MWTTSYFLIGLGTLVLS EVPVMLVAAIVAVLVVFLMIGCIGFCSFV 
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Figure 3.6. SDS-PAGE analysis of MCMV MHC-I-like proteins expressed in 
Rosetta DE3 E. coli.  Inclusion bodies were solubilized in SDS-PAGE sample buffer 
and separated on a 20% acrylamide gel. The proteins were visualized by Coomassie 
brilliant blue staining. The sizes of the molecular weight markers (MM) are indicated in 
kDa. Experimental details in Chapter 2, section 2.11. 
 
The identity of the dominant protein present in each inclusion body preparation was 
confirmed by N-terminal sequencing (Table 3.2) 
 
Table 3.2.  Summary of expression of MCMV MHC-I homologs in bacterial  
  inclusion bodies. 
 
MCMV ORF BL21 DE3 Rosetta DE3 N-terminal sequence * 
m17 - - - 
M37 - + # 
m90 + + XTADLYT(T)IQATP 
m145 - - - 
m150 - + XLNDSFPLVRIDG 
m151 - + AGL(H)DAVTK 
m152 - - - 
m153 - + VV(I)PEVN(N)TGXVD 
m155 - + IDLQDYXDDNNX(Y) 
m159 - + FSQE(I)LYMPQINL 
 *The identity of each expressed protein was verified by N-terminal sequencing  
 X – no amino acid identified, ( ) – possible amino acid 
 # Due to low yields the N-terminal sequence could not be determined 
 
We attempted to refold the proteins from inclusion bodies by rapid dilution into a 0.4 M 
arginine refolding buffer generally used to refold MHC class I molecules (Garboczi et 
al., 1992). After 4 days of refolding at 4 °C the proteins were dialyzed against Tris-
buffered saline, pH 8 and concentrated before analysis of the efficiency of refolding with 
97 
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size exclusion chromatography (SEC).  The proteins precipitated from the refolding 
solution at different stages as summarized in Table 3.3.  
 
Table 3.3. Behavior of the MCMV proteins during the different steps of refolding. 
MCMV 
Protein 
Dilution in 
Arginine 
Dialysis  
against TBS 
Concentration 
of refolded 
protein 
M37 Small precipitates Lots of fine 
precipitation 
Large precipitate 
m90 Clear Small precipitates Large precipitate 
m150 Clear Small precipitates Large precipitate 
m151 Clear Small precipitates Small precipitate 
m153 Clear Clear Small precipitate 
m155 Clear Large precipitate - 
m159 Large precipitate - - 
 Experimental details are described in Chapter 2, section 2.11. 
 
Analysis of the recovered, refolded proteins by SEC revealed that the majority of every 
protein had aggregated and eluted at a retention time corresponding to a very large size 
(150 – 650 kDa). The SEC profile obtained for m151 is representative of the other 
proteins and is presented in Figure 3.7. No significant elution of protein at the retention 
time corresponding to 30 - 40 kDa was observed for any of the expressed proteins. To 
optimize the refolding conditions we used the FoldIt Screen from Hampton Research. 
We screened a number of refolding conditions for m153 and at a small scale a few 
conditions showed promise, but upon large-scale refolding the proteins again formed 
aggregates (data not shown). Therefore bacterial expression could not be used to 
generate large quantities of the MCMV MHC-I-like proteins for structural 
characterization.  
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Figure 3.7. Size-exclusion chromatography of m151 after refolding from bacterial 
inclusion bodies. The major protein peak elutes at a retention time of 6.6 min. and 
represents aggregated material. The distribution of several size markers (kDa) is 
indicated above the graph. 
 
3.2.4.2  Insect cell expression 
 
Since M37, m151 and m153 were shown to localize to the cell surface (Figure 3.1) and 
are therefore likely to engage cell surface receptors on other cells, we focused on these 
three proteins for further recombinant expression studies. The extracellular domains of 
M37, m151 and m153 were expressed as secreted proteins in stably transfected 
Schneider S2 Drosophila cells. A C-terminal 6x histidine tag facilitated purification of 
the expressed proteins from culture supernatants on nickel-NTA columns. Subsequent 
purification steps consisted of size exclusion chromatography, protease cleavage to 
remove the histidine tag and anion-exchange chromatography. The identity of each 
protein was confirmed by N-terminal amino acid sequencing (Table 3.4).  
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Table 3.4.  N-terminal sequence of M37, m151 and m153 that were expressed in 
insect cells 
 
M37 RSGPESGVFEESYDV 
m151 RSSVXESPVLVLTAS 
m153 EVVRPEVNRTGRVDI 
 
SDS-PAGE analysis of the three proteins confirmed their predicted sizes (Figure 3.8), 
with m151 and m153 migrating at a slightly higher molecular weight, possibly indicating 
glycosylation of the proteins in the insect cells.  
 
 
 
 
 
 
 
 
 
 
Figure 3.8. SDS-PAGE analysis of insect cell-expressed M37, m151 and m153. The 
His-tagged MCMV proteins were purified from S2 supernatants on Ni-NTA affinity 
columns as described in Chapter 2, section 2.12. Fractions eluted from the nickel 
columns were analyzed on 20% SDS-PAGE gels and visualized by Coomassie staining. 
The size markers (kDa) are indicated.  
 
 
M37 and m153 expressed at very high levels in the S2 cells and could easily be purified 
to homogeneity (Figures 3.9 and 3.10). Although m151 was expressed at appreciable 
levels, SEC analysis revealed that a significant amount of the protein had formed 
aggregates (Figure 3.9, upper right panel). Some m151 of the predicted size of 30 kDa 
could be purified, but the yield was very low and the protein also tended to aggregate 
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upon storage (data not shown). M37 eluted at the expected retention time during SEC 
analysis (Figure 3.9). SEC analysis of m153 indicated a larger than expected size for the 
protein. This result will be addressed in more detail in the following chapter. Final anion-
exchange purification yielded highly homogeneous protein suitable for crystallization 
trials for both M37 and m153 (Figure 3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Size-exclusion chromatography 
of M37, m151 and m153.  After purification 
on Ni-NTA columns the proteins were 
concentrated and further purified by size-
exclusion HPLC. M37 and a portion of the 
m151 sample eluted at retention times 
corresponding to their predicted size. m153 
eluted at a retention time representing more 
than double its predicted size. The 44 and 
158 kDa markers are indicated for each 
panel. The respective protein peaks are 
indicated by arrows. M37 and m153 were 
analyzed on a Shodex KW802.4 column and 
m151 was analyzed on a Superdex 75-60 gel 
filtration column.  
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Figure 3.10. Anion-exchange chromatography of M37 and m153.  The proteins were 
eluted from a Mono Q column with a 0-1 M NaCl gradient from 5 to 25 minutes.  
 
 Insect cell expression thus seems to be a more successful approach to express the 
MCMV viral MHC-I molecules than bacterial expression, and we have since also 
expressed m152 successfully in this system (data not shown).  
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3.3 Discussion 
 
As a basis for studying the structure and function of the MCMV MHC-I-like proteins we 
have analyzed their expression and localization in transfected mammalian cells. Our 
results indicate that of the m145 family, m17, m152 and m155 are predominantly 
intracellular proteins. In contrast, m145, m151 and m153 are detected at the cell surface 
in the majority of transfected cells. m157 has been shown to be a GPI-linked, surface-
expressed molecule (Tripathy et al., 2006). Apart from the m145 family members, we 
have also studied M37 and found that it is mostly expressed at the cell surface. The 
cellular localization of the individual viral proteins to some extent correlates with their 
known functions. In the case of m152 and m155, their intracellular location is probably 
linked to the mechanisms they use to retain MHC-I and/or NKG2D ligands in infected 
cells. The cell surface localization of m145, on the other hand, suggests that it uses a 
distinct mechanism from the other immunoevasins to downregulate MULT-1 from the 
cell surface.  
 
We have used cell lines deficient for either β2m or TAP to show that M37, m145, m151 
and m153 can be expressed stably at the cell surface in the absence of these molecules. 
In support of this, it has been reported that m157 cell surface expression is also 
independent of β2m and TAP expression (Tripathy et al., 2006). So far, m144 is the only 
MCMV MHC-I-like protein that does associate with β2m and the crystal structure of 
m144 was determined in complex with β2m. The initial characterization of the MCMV 
MHC-I-like molecules suggests that they have adapted the MHC-I fold to achieve 
stability in the absence of β2m and peptide, like several other non-classical MHC-I 
molecules. We have also tested the effect of transfection of the different MCMV proteins 
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on endogenous MHC-I surface expression levels in mouse fibroblasts. Apart from the 
expected substantial downregulation by m152 (Ziegler et al., 1997), the only family 
member that reduced MHC-I surface expression is m153. The effect is much less 
pronounced than that of m152 and is only observed in cells expressing very high levels 
of m153. It is interesting though, because m152 and m153 are most related to each other 
within the m145 family.  
 
Our first approach to generate protein material for structural studies was to express the 
viral proteins as insoluble inclusion bodies in bacteria. This strategy proved 
unsuccessful. Although several proteins could be expressed in the bacterial system, we 
were unable to refold any of the viral proteins. Since we had established by this time that 
M37, m151 and m153 are surface expressed proteins we decided to focus on them and 
tested the expression of these three proteins in Drosophila insect cells. The S2 system 
provides the advantage that disulfide-containing proteins are expressed faithfully. We 
selected an expression vector that utilizes the signal sequence of the BiP chaperone 
(Kirkpatrick et al., 1995) and directs the expression of the foreign gene from a copper-
inducible promoter (Johansen et al., 1989). One drawback of the system is the long time 
it takes to generate stable clones that express the protein of interest. In addition, proteins 
expressed in insect cells are glycosylated, and that could adversely affect crystallization.   
 
All three proteins expressed at significant levels in S2 cells. m151 had a tendency to 
aggregate and only a small fraction of the correctly folded, soluble protein could be 
isolated. In contrast, the M37 and m153 preparations consisted mostly of the correct 
soluble species and could be purified to homogeneity with ease. To our surprise m153 
seemed to exist as a dimer, based on SEC analysis. We screened a range of 
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crystallization conditions with both M37 and m153. Since we identified several 
promising conditions for m153 we then focused our characterization and structure 
determination efforts on this MCMV protein. The following chapter details the 
characterization of both soluble, recombinant m153 and m153 in transfected and 
MCMV-infected mammalian cells. 
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 CHAPTER 4 
 
BIOCHEMICAL AND CELL BIOLOGICAL CHARACTERIZATION  
OF MCMV m153 
 
4.1 Introduction 
 
Within the MCMV m145 family, m153 is most closely related to m150, m151 and 
m152.  The proteins are 41-44% similar with respect to amino acid sequence and m152 
is the closest relative with 28% amino acid identity to m153. No biological function of 
m153 has been reported, whereas m152 has two well-defined functions, namely the 
downregulation of MHC-I and NKG2D ligands of the Rae-1 family, as detailed in the 
literature overview in Chapter 1. m153 presented a good target for further 
characterization and structure determination since it expressed in high yields in insect 
cells and the protein was very stable.  
 
Initial characterization experiments of MCMV m153 indicated that this protein is 
expressed predominantly at the cell surface of transfected cells, and that this expression 
is independent of the presence of β2m or the activity of TAP (Chapter 3).  In this 
Chapter we report the analysis of the m153 glycoprotein in both soluble recombinant as 
well as native form. The localization of m153 was studied by transfecting both native 
m153 and an m153-EYFP fusion protein in mouse fibroblasts. In addition, we examined 
the expression timeframe and localization of m153 in MCMV-infected cells. 
Recombinant m153 was characterized in terms of its size, glycosylation and 
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multimerization state. Finally we investigate the ability of m153 to homodimerize in 
transfected mammalian cells.  
 
4.2 Results 
 
4.2.1 Localization of m153 in transfected NIH3T3 cells  
 
The open reading frame of the m153 gene predicts a type I transmembrane glycoprotein 
with a core molecular weight of 45 kDa. Initial localization studies of m153 were 
performed with a FLAG-tagged version of m153 in COS-7 cells of monkey origin. These 
experiments confirmed that m153 is a functional gene that directs expression of the 
m153 protein to the cell surface (Chapter 3).  Subsequent generation of a monoclonal 
antibody to m153 enabled us to study the localization of untagged m153 in transfected 
mouse fibroblast cells. In Figure 4.1A the localization pattern of m153 in transfected 
NIH3T3 cells in both surface staining (upper panel) and intracellular staining (lower 
panel) experiments is shown. These confocal images clearly reveal that m153 is 
specifically detected at the cell surface. In the intracellular staining experiment m153 
exhibits a punctate distribution throughout the cytoplasm. In order to study further the 
punctate localization of m153 in living cells we fused EYFP to the C-terminal end of 
full-length m153. In Figure 4.1B the localization pattern of m153-EYFP, detected either 
with mAb153.16 or by EYFP fluorescence is shown. m153-specific staining (Figure 
4.1B, upper left panel), shows surface localization very similar to the native protein in 
Figure 4.1A. When the fusion protein is visualized only by EYFP fluorescence the 
outline of the cell is not visualized as by mAb153.16 staining. This  
 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Localization of m153 in transfected NIH3T3 cells. NIH3T3 cells 
transfected with A) full-length m153 or B) m153-EYFP fusion protein, stained with 
mAb153.16 at 24 h post transfection. Surface staining (upper panel) reveals cell surface 
localization of m153 and intracellular staining (lower panel) shows punctate distribution 
of m153 inside the cell. m153-EYFP displays cellular localization similar to native m153 
in both surface and intracellular staining experiments. The experimental details are 
described in Chapter 2, section 2.9. DIC – differential interference contrast.  
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observation could be explained if the relative levels of m153 at the surface are lower at 
the surface than inside the cell, and hence surface m153 is difficult to visualize above the 
bright cytoplasmic fluorescence. The intracellular staining pattern of m153-EYFP 
(Figure 4.1B, lower left panel) is almost identical to that of native m153 (Figure 4.1A, 
lower left panel). Therefore we could use the fusion protein in localization studies of 
m153. 
 
In NIH3T3 cells transfected with m153-EYFP, the protein displayed punctate 
cytoplasmic distribution as well as some perinuclear localization in the majority of cells 
examined. We performed co-localization experiments with either live-cell organelle 
trackers like Mito- and Lysotracker or antibodies to organelle specific proteins (e.g. anti-
Golgin) to determine whether m153 co-localizes with any subcellular organelles. From 
Figure 4.2 it is evident that m153 does not significantly co-localize with mitochondria, 
lysosomes, the Golgi-apparatus or early endosomes. The punctate distribution may thus 
represent m153 in secretory vesicles destined for cell surface expression.   
 
 
 
 
 
Figure 4.2. Punctate distribution of m153-EYFP fusion protein in transfected 
NIH3T3 cells. The m153-EYFP fusion construct was transfected in NIH3T3 cells. 
Different organelle markers were used to establish whether m153 localizes to a specific 
organelle. Lysosomes – Lysotracker Red, Mitochondria – MitoTracker Red, Nuclei – 
DAPI, Golgi – anti-Golgin mAb staining, Early Endosomes – anti-EEA1 mAb staining. 
For details see Chapter 2, section 2.9. 
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4.2.2 m153 is expressed on the surface of MCMV-infected fibroblasts 
 
To determine whether our transfection studies reflect the localization of m153 during 
virus infection, we examined the expression of m153 in MCMV-infected fibroblasts. 
NIH3T3 cells, infected with MCMV at an m.o.i of 2, expressed readily detectable levels 
of m153 at the cell surface 24 h post infection (p.i.) as detected by the monoclonal 
antibody mAb153.16, specific for the extracellular domain of m153 (Figure 4.3A). 
Uninfected cells did not stain with this antibody. By immunoprecipitation m153 was 
detected in detergent lysates of infected cells as early as 3 h and up to 48 h after infection 
with protein levels peaking at 24 h p.i. (Figure 4.3C).  Immunoprecipitation of cell 
lysates followed by SDS-PAGE and Western blot analysis of m153 revealed an 
unexpectedly high apparent molecular weight of 80 kDa, which is decreased to 45 kDa 
upon deglycosylation with PNGaseF (Figure 4.3B). Such heavy glycosylation is 
consistent with six predicted sites for asparaginyl-carbohydrate addition in the 
extracellular domain of m153. The m153 that was immunoprecipitated from the 
transfected cells (Figure 4.3B, lane 3) migrated in a broad band, which may represent 
heterogeneous glycosylation, and the lower part of this band was not completely 
deglycosylated (Lane 4).  
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Figure 4.3. m153 expression in MCMV-infected cells. A) m153 is detected at the 
surface of MCMV-infected NIH3T3 cells. Cells were surface stained for m153 
expression at 24 h post infection (p.i.). Blue, infected cells + mAb153.16, Black, infected 
cells + control Ab, Dashed, uninfected cells + mAb153.16. B) Immunoprecipitation and 
Western blot analysis of m153 from uninfected (lane 1) and MCMV-infected (lane 2) 
NIH3T3 cell lysates at 24 h p.i. Immunoprecipitation of m153 from transfected NIH3T3 
cells (Immunoprecipitation-mAb153.16, Western blot-anti-m153 rabbit serum). Samples 
were mock-treated (lane 3) or treated with PNGAse F (lane 4) before SDS-PAGE and 
Western blot. C) Time-course analysis of m153 expression in MCMV-infected NIH3T3 
cells. m153 was immunoprecipitated from infected cell lysates with mAb153.16 at the 
indicated times after infection (0-48 h) and analyzed by Western blot as described in 
Chapter 2, section 2.10. Mock-infected NIH3T3 cells were harvested at the same time 
points and served as a negative control. The m153 band (*) migrates just below the 85 
kDa marker and is first detected at 3 h p.i. and peaks at 24 h p.i. The bands at 50 and 25 
kDa represent detection of the heavy and light chains of the immunoprecipitating 
antibody. Another non-specific band is observed at ~ 112 kDa.  
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4.2.3  Glycosylation of m153 in Drosophila S2 cells 
 
There are seven possible N-linked glycosylation sites on m153, six of which are 
predicted to be glycosylated by the NetNGlyc 1.0 server (Table 4.1). m153 expressed in 
transfected cells is glycosylated (Figure 4.3B). We next analyzed the recombinant 
version of m153 that was expressed in Drosophila cells. PNGaseF cleavage releases 
most oligomannose, hybrid and complex N-linked glycans and causes the conversion of 
asparagine to aspartate (Maley et al., 1989). PNGaseF digestion of the soluble 
ectodomain of m153 resulted in increased mobility on an SDS-PAGE gel, which would 
be consistent with the removal of carbohydrates from the protein (Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Recombinant m153, expressed in S2 insect cells, is glycosylated.  
Reducing SDS-PAGE analysis of m153 and a glycosylated control protein (bovine 
fetuin) after mock (-) or PNGaseF (+) digestion overnight. An increase in mobility for 
both bovine fetuin and m153 treated with the enzyme confirms the presence of 
carbohydrates on the proteins. The size markers are indicated in kDa.  
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Mass spectrometry analysis of mass changes induced by the Asn to Asp conversion of 
deglycosylated tryptic peptides of insect-expressed m153 confirmed glycosylation at five 
of the six predicted N-linked sugar addition sites on the ectodomain (data not shown). 
The analysis also revealed glycosylation at a seventh site, which was not predicted by the 
NetNGlyc 1.0 server, and indicated the types of sugar moieties that were added at the 
different positions.  
 
Table 4.1. Analysis of glycosylation positions and content of recombinant m153. 
 
 
Amino acid 
position 
Asn-Xaa-
Ser/Thr 
motif 
Predicted 
N-linked 
site* 
Site 
occupied 
Glycan moieties detected 
8 NRT Yes No - 
65 NES Yes Yes (HexNAc)2(Fuc)1(Hex)3 
107 NCT Yes Yes (HexNAc)2(Hex)1-7 
152 NVT Yes Yes (HexNAc)2(Fuc)0,1(Hex)3-5 
246 NRS Yes Yes not detected 
252 NTT Yes Yes (HexNAc)2(Hex)3 
310 NDS No Yes (HexNAc)2(Fuc)1(Hex)3 
 Hex – hexoses, NAc – N-acetylglucosamine, Fuc – fucose 
* N-linked sites were predicted using the NetNGlyc 1.0 server  
(http://www.cbs.dtu.dk/services/NetNGlyc) 
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4.2.4 Recombinant m153 forms a stable, non-covalent dimer 
 
The extracellular domain of m153 that was expressed in S2 insect cells has a predicted 
mass of 37.4 kDa. SEC analysis of m153 revealed that the protein eluted earlier than 
expected from the column. m153 eluted with a retention time of 8.2 min. which 
corresponds to a molecular weight between 158 kDa and 44 kDa (Figure 4.5A). This 
result suggested that m153 is expressed as a homodimer. SDS-PAGE analysis of insect-
expressed m153 under both reducing and non-reducing conditions showed protein bands 
migrating between the 30 and 45 kDa markers (Figure 4.5B). The faster migration of 
non-reduced m153 implies that the protein contains intrasubunit disulfide bonds and has 
a more compact conformation in the unreduced state. These results also indicate that the 
m153 homodimer is non-covalent, since treatment with SDS-PAGE sample buffer 
breaks up the dimer and the protein migrates at its monomeric size.  
 
 
 
 
 
 
 
 
Figure 4.5. m153 is a non-covalent dimer when expressed in S2 insect cells.  A) Size 
exclusion chromatography analysis of insect cell expressed m153 (extracellular domain – 
1-314). The protein elutes between the 158 kDa and 44 kDa markers, whereas its 
predicted molecular weight is 37.4 kDa. B) SDS-PAGE analysis of recombinant m153 
under reducing (R) and non-reducing (NR) conditions indicates that m153 contains 
intrasubunit disulfide bonds. 
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To confirm that m153 exists as a multimer in solution we performed sedimentation 
velocity analytical ultracentrifugation. In Figure 4.6A the results of a sedimentation 
velocity run performed with m153 at a concentration of 0.2 mg/ml are shown. The 
sigmoid shaped curves that migrate with time to increasing distances from the center of 
rotation are called sedimentation boundaries. The displacement with time of the 
boundary midpoints determines the s-value. The sedimentation data can be described by 
a differential sedimentation coefficient distribution c(s). The distribution describes the 
superposition of boundaries of many species with different s-values. The SEDFIT 
program was used to calculate c(s) (Schuck, 2000)-  
http://www.analyticalultracentrifugation.com.  
 
The sedimentation coefficient distribution c(s) displays one main peak at 4.2 S. This 
indicated that the majority of m153 exists as a single species. (Figure 4.6C). The 
magnitudes of deviation of the model from the data points are shown in Figure 4.6B. 
Since the c(s) distribution contains one major peak it can be transformed to a molar mass 
distribution c(M). The estimated molar mass of m153 is 78 800 Da (Figure 4.6D), thus 
confirming the observation that m153 forms a homodimer.  Similar s values and molar 
mass estimations were obtained in four different sedimentation velocity experiments at 
different protein concentrations (Figure 4.7).  
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Figure 4.6. SEDFIT analysis of m153 sedimentation velocity data. A) Concentration 
profiles that change over time as the protein migrates away from the center of rotation. 
B) Superimposed radial residuals representing the deviation of the model from the 
original data. C) Sedimentation coefficient distribution c(s) from the analysis of the data 
shown in A. The distribution displays one main peak at ~ 4.2 S. D) The molar mass 
distribution c(M) of the peak obtained in C. The estimated molar mass of the single 
major peak (m153) is 78 800 Da. Experimental details are described in Chapter 2, 
section 2.15. 
A 
B 
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Figure 4.7. Sedimentation coefficient distribution c(s) derived from sedimentation 
velocity experiments at four different concentrations of m153.  
 
 
4.2.5 Full-length m153 is dimeric in mammalian cells 
 
To investigate the possibility that dimerization is a result of the engineering of soluble 
m153, we used two approaches to examine m153 in mammalian cells. Bimolecular 
fluorescence complementation (BiFC) can be used to visualize protein-protein 
interactions in cells. The N- and C-terminal domains of a fluorescent protein (e.g. YFP) 
are fused to the target proteins. The constructs are co-transfected and if the target 
proteins interact, the association brings the portions of the fluorescent protein together 
and fluorescence is observed (Hu et al., 2002; Kerppola, 2008). We fused full-length 
m153 to either N- or C-terminal segments of YFP.  While transfectants of either 
construct alone did not show fluorescence, co-transfection of m153-N-YFP and m153-C-
YFP resulted in the complementation of YFP fluorescence in transfected cells, indicating 
that m153 does form dimers. Cells transfected with YFP fusion constructs of m144, a 
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monomeric MHC-Iv protein, showed fewer than 1% YFP positive cells (Figures 4.8A 
and B). In a second approach we co-transfected N-terminal FLAG- and HA-tagged m153 
in NIH3T3 cells. Successful immunoprecipitation of m153 with anti-FLAG antibodies 
and Western blot detection with anti-HA antibodies confirmed that m153 dimerizes in 
transfected fibroblasts (Figure 4.8C). Together these results provide strong evidence that 
m153 is a dimer when expressed as the full-length protein in mammalian cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. m153 forms a homodimer in mammalian cells. A) Bimolecular 
fluorescence complementation analysis. m153 constructs, fused to the N-terminal or C-
terminal portions of YFP, were cotransfected in NIH3T3 cells and the live cells were 
examined by confocal microscopy for fluorescence complementation after 48 h. As a 
negative control YFP-fusion constructs of MCMV m144 were cotransfected. YFP 
channel (left), overlay of the YFP on the differential interference contrast (DIC) channel 
(right). B) Quantification of the number of YFP positive cells. After confocal 
microscopy the YFP-fluorescent cells were detached from the coverslips and counted by 
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FACS. YFP fluorescence was visible in 18% of m153-transfected cells but only in 0.8% 
of m144 transfected cells. C) Co-immunoprecipitation of differentially tagged m153. 
FLAG-m153 (F) or F + HA-m153 (F+HA) constructs were transfected in NIH3T3 cells. 
24 h post transfection post-nuclear cell lysates were immunoprecipitated with anti-FLAG 
antibodies and detected on a Western blot with anti-FLAG (left), anti-m153 rabbit 
antibodies (middle) or HA-specific antibodies (right). Experimental details are described 
in Chapter 2, sections 2.8 and 2.10. 
 
 
 
 
4.3 Discussion 
 
The characterization of m153 has revealed several interesting features of this protein. 
First, we have shown that m153 is expressed in MCMV-infected cells starting at early 
times after infection and that the protein can be detected at the cell surface at 24 h post 
infection. Localization studies in transfected cells have also confirmed surface 
expression of m153 and further revealed that m153 is concentrated in punctate spots 
throughout the cytoplasm. This punctate distribution does not represent localization to 
lysosomes, early endosomes or the Golgi-apparatus. m153 is highly glycosylated when 
expressed in mammalian cells and mass spectrometry analyses confirmed that the 
recombinant ectodomain of m153, which was produced in insect cells, is also 
glycosylated at six of seven possible sites. Surprisingly, recombinant m153 forms a 
stable, non-covalent homodimer. The putative homodimer size estimate, obtained from 
gel filtration results, was clearly confirmed by analytical ultracentrifugation studies. 
These results showed that m153 exists only as a dimer species with an estimated 
molecular weight 78.8 kDa. The dimerization of m153 in transfected mammalian cells 
was studied by both bimolecular fluorescence complementation and co-
immunoprecipitation experiments. Both approaches confirmed that m153 chains 
dimerize in mammalian cells. The functional significance of m153 dimer formation is 
not known at this time. But homodimerization may afford stability to the protein in the 
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absence of β2m and peptide association. In BiFC studies of m152, the m145 family 
member most related to m153, we did not observe any complementation (data not 
shown), therefore m152 does not dimerize in transfected cells.  
 
In general MHC-I molecules do not dimerize, however disulfide linked dimers of 
classical MHC-I molecules have been reported for both human and mouse proteins as 
early as 1973 (Cresswell and Dawson, 1975; Schwartz et al., 1973). More recent work on 
H-2Ld, H-2Db and H-2Dd suggested that the dimerization occurs in the absence of β2m 
and that the disulfide linkage is dependent on a cysteine present in the cytoplasmic 
domain of the class I heavy chain (Capps et al., 1993). The physiological significance of 
such dimers is not known. HLA-B27 is an example of a human class I molecule that 
forms disulfide-linked homodimers in vivo. The HLA-B27 allele has been associated 
with ankylosing spondylitis (Brewerton et al., 1973). The mechanism by which HLA-
B27 is involved in disease pathogenesis remains unknown, however it is possible that the 
tendency of the heavy chain to form β2m-free homodimers via a disulfide linkage at 
cysteine 67 may underlie its effects (Bowness, 2002; Colbert, 2004). m153 would seem 
to form a distinct type of dimer, since no disulfide bonds are involved. 
 
The high yields of recombinant m153, and the stability of the homodimer made this 
protein an ideal candidate for crystallization and structure determination. The following 
chapter describes the crystal structure of m153, explains the mode of dimer formation 
and highlights implications from this structure for other m145 family members.  
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CHAPTER 5 
 
CRYSTAL STRUCTURE OF THE 
MOUSE CYTOMEGALOVIRUS GLYCOPROTEIN, m153 
 
5.1 Introduction 
 
The viral MHC-I homologs encoded by HCMV (UL18) (Beck and Barrell, 1988) and 
MCMV (m144) are clearly related to MHC-I based on amino acid sequence similarity 
(Farrell et al., 1997). UL18 resembles MHC-I the most, since it binds peptide and 
associates with β2m. A structural model of UL18, based on HLA-A2, has been proposed 
(Cerboni et al., 2006). The secondary structure of UL18 is very similar to MHC-I, but 
there are some regions with structural variations, two of which have been implicated in 
interactions of UL18 with its receptor LIR-1 (Cerboni et al., 2006; Wagner et al., 2007). 
The model also predicts a second disulfide bond in the α3 domain that is absent in 
classical MHC-I molecules.  Mutation of the cysteines involved in this bond abolished 
binding of UL18 to β2m (Wagner et al., 2007) confirming the importance of this novel 
bond.  
 
m144 is less related to classical MHC-I than UL18, since it does not require peptide for 
cell surface expression but it does associate with β2m (Chapman and Bjorkman, 1998; 
Natarajan et al., 2006). The crystal structure of m144 showed an MHC-I-like protein, 
bound to β2m but not associated with peptide, confirming predictions based on sequence 
comparison. The molecule is characterized by a large angle between α1α2 and α3, a 
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unique stabilizing disulfide bond in α1α2, and relatively loose association of the heavy 
chain with β2m (Natarajan et al., 2006). 
 
The crystal structure of m157, one of the eight m145 family members with a predicted 
MHC-I fold, was reported recently (Adams et al., 2007). m157 expression does not 
require either β2m or peptide (Arase et al., 2002). Its crystal structure revealed several 
deviations from the MHC-Ia fold:  an extended, helical N-terminus, designated α0, that 
precedes the canonical α1 helix and imparts a three-helix structure to the amino terminal 
α1α2 domain; a long α2 helix that extends into the α3 domain; short interhelical 
distances and close interactions of the α1α2 domain with α3 resulting in a molecule 
significantly more compact than classical MHC-I; and an α3 domain whose Ig fold is 
less twisted than typical Ig folds (Adams et al., 2007).  
 
We have determined the crystal structure of MCMV m153. In contrast to any other 
MHC-I molecules, the soluble ectodomain of m153 forms a stable, non-covalent dimer. 
The crystal structure of m153 reveals the mode of dimerization in addition to other 
distinguishing features, including an extended N-terminus, different from that of m157.  
Thus, although prediction algorithms group members of the m145 family together within 
the broad MHC-I structural family, the details of the individual structures show wide 
variation from MHC-I and demonstrate the robustness and adaptability of the MHC-I 
fold in the service of diverse biological functions.  
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5.2 Results  
 
5.2.1 The MHC-I fold of m153 
 
To elucidate the structure of m153, a selenomethionine (SeMet) derivative was prepared 
by biosynthetic labeling of the protein expressed in Drosophila S2 cells. Size exclusion 
chromatography indicated that soluble m153 was a dimer (Chapter 4, Figure 4.5). 
Diffraction data from a single crystal were collected, the structure was solved by single 
anomalous dispersion (SAD) phasing, and the model was refined at 2.4 Å resolution to 
final Rcryst and Rfree of 23% and 27.9% respectively (Table 5.1). Analysis of the psi/phi 
angles of the m153 backbone was performed with both Procheck (Table 5.1) and 
Molprobity (Figure 5.1). 
 
There is a single dimer in the asymmetric unit with chains designated A and B. We 
observed continuous electron density for residues 2-230 and 238-277 of chain A and 
residues 5-277 of chain B. No electron density was observed for the C-terminal residues 
278-314 of either chain and these were omitted from the model. The average B-factor 
was 42 Å2 for chain A and 32 Å2 for chain B. We selected chain B to describe the 
structural features of the monomer as they relate to the MHC-I fold, because it is more 
complete and has lower B-factor values.    
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Table 5.1. Data collection, refinement and validation statistics. 
 
 
 
Data Collection 
 
Space Group P21 
Unit cell dimensions 
a, b, c 
α, β, γ 
 
61.7, 78.2, 62.7 
90.0, 90.4, 90.0 
Molecules per asymmetric unit 2 
Resolution (Å) 2.3 
Total observations 335, 101 
Unique reflections 26, 191 
Completeness (%)a 97.5 (80.6) 
I/σI a 9.7 (1.54) 
Rsym a/b 0.081 (0.40) 
 
Refinement 
 
Resolution range 62.75 - 2.4 
Reflections 
Working set 
Test set 
 
23443 
1183 
R cryst (%)c 23.0 
R free (%)c 27.9 
Number of non-H protein atoms 4393 
Number of water molecules 57 
Carbohydrate chains 3 
r.m.s deviations from ideality 
Bond lengths (Å) 
Bond angles (deg.) 
 
0.01 
1.318 
Average B values (Å2) 
Main-chain 
Side-chain 
Whole chain 
Overall 
A , B 
42.2 , 32.2 
42.5 , 32.7 
42.4 , 32.4 
37.6 
 
Model Validation 
Ramachandran plot statistics (%) 
Procheck 
Most favored 
Allowed 
Generous 
Disallowed 
 
 
 
 
87.8 
12.2 
0 
0 
 
aValues in parentheses are statistics for the highest resolution shell (2.48–2.38 Å). 
bRsym(I) = ∑ | Ij - <I>| / ∑Ij, where Ij is the intensity of the jth observation of a reflection 
and <I> is the mean intensity from multiple measurements of that reflection. cRcryst = ∑ 
||Fo| - |Fc|| / ∑ |Fo|, where Fo and Fc are the observed and calculated structure factor 
amplitudes, respectively. Rfree is as for Rcryst but calculated for a randomly selected 5.0% 
of reflections not included in the refinement. 
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Figure 5.1. Ramachandran analysis of the m153 model with the Molprobity server 
(http://kinemage.biochem.duke.edu, (Davis et al., 2007)). 
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The structure of m153 (Figure 5.2) reveals basic structural elements of the MHC-I fold. 
The m153 α1α2 domain consists of a unit in which the α1 helix and a discontinuous α2 
helix rest atop a platform of seven β-strands. Three of the strands derive from the α1 
domain and four from α2.  The fourth β−strand of the α1 domain, commonly found in 
MHC-Ia and Ib molecules, is not observed in m153. Unlike either MHC-Ia or Ib 
molecules the C-terminal end of the α2-helix extends downwards into a third helix (H2b) 
that connects the α1α2 domain with the Ig-like α3 domain (Figure 5.2A).  
 
Several structural features of the m153 monomer differ substantially from classical 
MHC-I molecules.  Most striking is the N-terminus, extended by 20 residues, that starts 
adjacent to the G strand of the α3 domain, forming a short β strand. From there it 
extends upwards alongside the H2b helix and continues as the first strand of the platform 
beginning at residue 21 (Figure 5.2A). This feature is absent in all MHC-I molecules 
described thus far and differs substantially from m157, whose extended N-terminus 
forms instead a third, short helix adjacent to the α2 helix (Figure 5.2C). A unique 
disulfide between C16 and C171 anchors the extended N-terminus of m153 to the H2b 
helix (Figure 5.2D). In addition, there are several hydrogen bonds between the extended 
N-terminal strand (residues 6-15) and the loop connecting platform strands β2 and β3. 
Other hydrogen bonds link the extended N-terminus to the H2b helix and the α3 F-G 
loop and serve to further stabilize the structure (Figure 5.2C). The α1 and α2 helices are 
shorter than those observed in MHC-Ia proteins and are closely juxtaposed above the β 
sheet floor. Close interactions between these helices preclude the binding of peptide or 
other ligand (Figure 5.2B), in agreement with cellular expression studies indicating that   
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Figure 5.2. Conserved and unique features of the m153 monomer. A) Side view of 
m153 chain B. The α1, α2 and H2b helices, the α3 domain, N- and C-termini are labeled 
and the disulfide bonds are in yellow. N-terminal residues 2-20 are colored gray. B) Top 
view of the 7 β-strand platform and α1α2 helixes of m153. C) Extended N-terminus of 
m153. Extensive interactions between the N-terminus (gray) and H2b helix, loops in the 
α1α2 domain and the G strand of the α3 domain (cyan). Hydrogen bonds are in black. 
D) Side view of m153 monomer. Two unique disulfide bonds link the N-terminal 
fragment to the H2b helix (C16-C171) and the β5’ platform strand to the loop connecting 
the β5’ and β6’ strands (C101-C108). Electron density around the unique disulfides is 
contoured at 1.25σ. The conserved disulfide bond (C203-C255) is located in the Ig-like 
α3 domain.  
B 
A 
C C’ 
E 
F 
G 
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m153 does not depend on bound peptide for stability (Chapter 3, Figure 3.3). The 
platform is stabilized by a second unusual disulfide  (C101-C108) which connects 
strands β5’ and β6’ of the floor (Figure 5.2D). A similar bond is seen in m157 (C103-
C112) but MHC-Ia molecules preserve a disulfide bond in the same region which links 
β-strand 5 of the platform to the α2 helix (C101-C164) (Bjorkman et al., 1987). We 
examined m153 by mass spectrometry to confirm the presence of the unusual disulfide 
bonds. 
 
Desalted and PNGaseF treated MCMV-m153 was digested with trypsin and nano 
electrosprayed. FT-MS/MS spectra were recorded after electron capture dissociation 
(ECD) fragmentation of indicative peptides to selectively reduce Cys-Cys bonds between 
two tryptic peptides. Alternatively TCEP was added to the solution to obtain mass shift 
experiments of FT-MS survey scans for identification of e.g. internal Cys-Cys bonds in 
one and the same tryptic peptide. Figure 5.3 shows the selective Cys-Cys reduction using 
ECD fragmentation of the quadruply charged m/z=708.097 (tryptic peptides 
TGTVDIC*QGPMELIFSVSR and WTEIC*K), whereas Figure 5.4 shows the mass shift 
of 1.005 at the doubly charged m/z= 757.851 caused by TCEP induced reduction of the 
internal Cys-Cys bond of tryptic peptide C*PVPQFNC*TITHR. 
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Figure 5.3. Mass spectrum of a disulfide-linked tryptic peptide confirms the C16-
C171 disulfide bond. FT-MS/MS spectrum after electron capture dissociation (ECD) 
fragmentation of the quadruply charged m/z=708.097. ECD induced a fragmentation of 
the disulfide bond yielding the singly charged fragment m/z=779.375 and the doubly 
charged fragment m/z=1027.007, corresponding to the tryptic peptides 
TGTVDICQGPMELIFSVSR and WTEICK, respectively. ECD also resulted in further 
peptide fragmentation revealing the sequence tag FSVS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Mass spectra of C*PVPQFNC*TITHR peptide before and after 
reduction with TCEP confirmed the C101-C108 disulfide bond. Mass shift of 1.005 
at the doubly charged peptide m/z=757.851 indicated addition of two protons after 
reduction of internal Cys-Cys bond in tryptic peptide CPVPQFNCTITHR. 
 
TGTVDIC*QGPMELIFSVSR 
 
    WTEIC*K   
C*PVPQFNC*TITHR 
m/z 
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The α3 domain of m153 has a C2 type Ig-fold, which is characterized by a more 
compact domain and shorter intercysteine spacing than the C1 or V type fold (Halaby 
and Mornon, 1998). The A, B and E strands make up one sheet of the domain and the C, 
C’, F and G strands make up the opposite sheet (Figure 5.2A). The canonical Ig-domain 
disulfide bond (C203-C255) connects strands B and F. Searches against the DALI 
database (Holm and Sander, 1996) identified m144, also with a C2 type Ig-fold, and 
CD1d as proteins with α3 domains that are structurally most closely related to m153. 
The difference between the strand dispositions in the α3 domains of m153 and m157 is 
indicated by the relatively high r.m.s.d. of 2.3 Å for the superposition of 67 Cα atoms. 
The α3 domain of m153 has longer β-strands that exhibit the characteristic β-sandwich 
twist, whereas the m157 α3 domain has strands that are shorter and form flatter sheets 
(Figure 5.5C). The terminal residues that were modeled in both structures adopt different 
conformations, in m153 they form a short α-helix, whereas in m157 the C-terminal 
strand forms a circular loop that contacts both sheets of the α3 domain (Adams et al., 
2007). 
 
In Figure 5.5 we compare the α1α2 domain of m153 chain B to that of m157, H-2Kb 
(Fremont et al., 1992), rat FcRn (Burmeister et al., 1994a), and the NKG2D ligand Rae-
1β (Li et al., 2002). The α1 and H2b helices of m153 and m157 are in equivalent 
positions, whereas their α2 helices differ. The N-terminal end of the m157 α2 helix was 
not modeled due to lack of electron density (Adams et al., 2007). The m153 α2 helix 
starts with two full turns (residues 140-146), followed by an extended region that 
stretches along the platform ending in two turns of helix before bending sharply 
downward to continue as the H2b helix.  
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The maximal distance between the α1 and α2 helices of m153 is 8.1 Å compared to 16.8 
Å in H-2Kb  (Figure 5.5A). Surface representations of the α1α2 domains of m153 and H-
2Kb (Figure 5.5B) illustrate the lack of a peptide-binding groove in m153. The groove 
region of m153 is comparable to that of Rae-1β and FcRn, two molecules that also do 
not bind peptide. The maximal distance between Cα atoms of the α1 and α2 helices of 
Rae-1β and FcRn are 8.2 Å and 9.2 Å respectively. The α1 helices of m153, Rae-1β, and 
FcRn have a similar arrangement on the platform but the m153 helix is shorter. The 
m153 platform has seven strands compared to the eight found in classical MHC-I 
proteins (Figure 5.5A). 
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Figure 5.5. Comparison of m153 with m157, H-2Kb, Rae-1β  and rat neonatal FcR. 
A) Ribbon diagrams of the platform domains of m153, m157, Rae-1β, FcRn and H-2Kb. 
The width of the groove of each molecule is indicated in Å and was measured at both 
ends and in the middle at comparable residues of the α-helices. B) Surface representation 
of the peptide-binding domain of H-2Kb (groove shown without any peptide) and the 
corresponding region of m153. Black rectangles indicate the groove.  C) Comparison of 
m153 chain B with m157 and H-2Kb. The α1α2 and H2b-helices, α3-domain, and N- 
and C-termini are labeled. PDB accession codes: 2NYK, 2VAA, 1JFM and 3FRU for 
m157, H-2Kb, Rae-1β and rat FcRn, respectively. 
 
 
The hinge angle between α1α2 and α3 of m153 chain B is 76º, which is within the range 
of the MHC-I molecules H-2Kb, CD1d and T22 (71-74º), but is smaller than that of 
m157 (81º), MICA (116º) and m144 (98º) (Table 5.2). The m153 α3 domain makes 
extensive contacts with the H2b helix, with the loop connecting strands β2 and β3 of the 
platform as well as with the loop connecting β3 and α1. The buried surface area between 
α1α2 and α3 of m153 is 1777 Å2, which is considerably larger than the analogous 
interfaces in m157 (1265 Å2) and H-2Kb (455 Å2).   
 
Table 5.2.  Hinge angle between the α1α2 and α3 domains of viral, MHC-Ia and 
MHC-Ib molecules.  
Protein PDB code  Angle (degrees) Associated subunits 
m153  2O5N 76 m153 
m157 2NYK 81 None 
m144 1U58 98 β2m 
H-2Kb 2VAA 71 β2m, peptide 
CD1d 1ZHN 75 β2m, lipid 
T22 1C16 72 β2m 
ZAG 1TW7 90 β2m 
MICA 1B3J 116 β2m 
Hinge angles were calculated with the HINGE program as described in Chapter 2, 
section 2.14. 
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5.2.2 The m153 dimer  
 
Size exclusion chromatography (SEC) of the insect cell expressed extracellular portion 
of m153 indicated that the molecule formed a stable non-covalent homodimer (Chapter 
4, Figure 4.5), an observation confirmed by velocity sedimentation (Chapter 4, Figures 
4.6 and 4.7). The crystal structure reveals the details of the mode of dimerization. Two 
MHC-I-like chains of m153 are organized in a head-to-tail arrangement forming a 
compact dimer (Figure 5.6A). The two chains are almost identical (r.m.s.d. of 0.624 Å 
for superposition over 268 Cα atoms). The interaction of the platform domain of one 
subunit with the α3 domain of the other imparts a coronal shape forming a central cavity 
with a volume of about 9500 Å3.  The conical cavity measures 46 Å x 35 Å at the top 
narrowing down to 22 Å x 18 Å. It is closed off at the bottom where the K115 sidechains 
of each subunit are only 4 Å apart. We propose an orientation of the m153 dimer with 
respect to the plasma membrane shown in Figure 5.6B. The subunits lie with their long 
axes parallel to the membrane and with the α1 helices closest to the membrane. In this 
orientation the C-termini of both chains point towards the membrane (Figure 5.6B – 
lower). The 37 C-terminal residues for which no electron density was observed in either 
chain may form a flexible stalk connecting the ectodomain to the transmembrane region. 
m153 conserves only two of the 31 β2m-contacting residues present in H-2Kb. It is 
evident from the dimer orientation of m153 that association with β2m would be 
sterically hindered, an observation consistent with the β2m independence of m153 
expression (Chapter 3, Figure 3.2).  
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Figure 5.6. Overall structure of the m153 dimer. A) Ribbon diagram of the m153 
dimer as viewed from the top. Chain A - salmon, Chain B - cyan. The α1α2 helices, the 
α3 Ig-like domains and N- and C-termini are labeled. Dashed line in chain A indicates a 
disordered loop. Blue sticks - carbohydrates observed in the crystal structure, Yellow 
sticks - N-linked glycosylation sites confirmed by mass spectrometry.  B) Two 90º 
rotations reveal different side views of the m153 dimer, and its proposed orientation on 
the cell membrane. C) Top and bottom views of the electrostatic surface representation 
of the m153 dimer (red – acidic; blue – basic).   
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Three sugar moieties were modeled in the m153 structure (at N107 in chains A and B 
and N252 in chain B). These all point upward from the dimer away from the cell surface. 
Mass spectrometry indicated glycosylation at five of the six predicted N-linked 
carbohydrate addition sites and one additional site (Chapter 4, Table 4.1). These sites 
occur in both α1α2 and α3, and are distributed around the periphery of the m153 dimer, 
with none in the central cavity or at the proposed membrane proximal face of the 
molecule (Figure 5.6A). The electrostatic surface of the m153 dimer reveals four nearly 
symmetrical basic patches inside the central cavity, and two highly acidic regions on the 
bottom surface that are formed by the loop that connects the A and B strands of the α3 
domain and the C-terminal α-helical fragment (Figure 5.6C). 
 
The m153 dimer interface is formed by parallel β-strand interactions between the 
platform (β8’ strand) of one subunit and the α3 domain (C’ strand) of the second subunit 
(Figure 5.7A), resulting in two extended, twisted β-sheets of 12 strands each that form 
the core of the dimer. The two interfaces are not perfectly symmetrical as 21 residues of 
chain A and 22 residues of chain B are involved in dimerization. There are 16 hydrogen 
bonds at the interface, most of which represent backbone interactions (Figure 5.7B). In 
addition there are 114 non-bonded contacts. The area buried at the dimer interface is 
1088 Å2 (Figure 5.7C), which is larger than that observed in HLA-G (676 Å2), which 
forms a disulfide-linked MHC-Ib dimer. The shape complementarity (Sc) index of the 
dimer was calculated as 0.72, which is higher than that of most antibody-antigen 
interfaces (0.62-0.68), consistent with the stability of the homodimer (Sc=1 represents a 
perfect fit, (Lawrence and Colman, 1993)).  
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To confirm the observed interface we tested the effects of mutating four interface 
residues T128, S131, R225, and S241, all of which form side-chain/side-chain hydrogen 
bonds, to alanine (Figure 5.7C). In a second mutant we introduced an alanine mutation at 
a site distant from the interface (D194A) as a control. Wild-type (wt) m153 and the 
respective mutants were expressed in insect cells and analyzed by chromatography. SEC 
indicated a smaller size for the quadruple interface m153 mutant, whereas the control 
mutant migrated with wt m153 (Figure 5.8A). Analytical ultracentrifugation analysis of 
wt and interface mutant m153 showed that the mutant protein had a smaller 
sedimentation coefficient indicating disruption of the dimer (Figure 5.8B). Thus the four 
mutations destabilized the m153 dimer and confirm the mode of dimerization visualized 
in the structure.   
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Figure 5.7. Dimer interface of m153. A) Chain A-platform/Chain B-α3 interface 
indicated by boxed region. B) Stereo view of the parallel β strand interactions between 
the β8’ strand of chain A (salmon) and the G strand of chain B (cyan). The nine 
hydrogen bonds are shown as black dashes. Oxygen-red, Nitrogen-blue. C) Molecular 
surface representation of m153 dimer (center). At the left and right the two chains were 
rotated 75º out of the plane of the paper to display the buried interaction surfaces (white). 
The positions of the interface residues that were mutated to alanine (T128A, S131A, 
R225A, S241A) are shown in red. 
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Figure 5.8. Mutations at the interface destabilize the m153 dimer. A) Size exclusion 
chromatography analysis of wild type (black), 4-alanine interface mutant (red) and 
control mutant (dashed blue) m153 purified from SF9 insect cells. The interface mutant 
migrates at a slower rate through the column, indicating a smaller size compared to wt 
m153 and the control mutant. B) Sedimentation coefficients of wild type m153 (black – 
0.3 mg/ml) and quadruple mutant m153 (T128A, S131A, R225A, S241A, red – 0.5 
mg/ml, green 0.1 mg/ml) as determined by sedimentation velocity ultracentrifugation. 
For experimental details see Chapter 2, section 2.15. 
 
158 66 44 kDa A 
B 
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5.2.3 Comparison of m153 to the m145 family   
 
m153 is related by sequence to proteins of the mouse and rat CMV 145 families but has 
no direct homolog in the rat virus (Rawlinson et al., 1996; Vink et al., 2000). The m153 
protein is most closely related to m152 (28% identity), a known regulator of MHC-I and 
NKG2D ligands in MCMV-infected cells (Lodoen et al., 2003; Ziegler et al., 1997). 
Figure 5.9 shows a sequence alignment of the m145 family highlighting shared structural 
features. Based on comparison of m153 and m157 we suggest that the core of the viral 
MHC-I-like fold of the m145 family is comprised of the α1α2 domain, the extended 
H2b helix and an Ig-like α3 domain. The number of platform strands, the length of α2 
on top of the platform and the position of some disulfide bonds may vary. A crucial 
stabilizing interaction for this MHC-I-like fold is that between E70 (α1 helix), R166 and 
W167 (H2b helix) (Figure 5.10). Apart from a cysteine in the α3 domain, these three 
residues are the only amino acids that are conserved throughout the mouse and rat 145 
families, emphasizing the importance of this salt-bridge. Stretches of similarities are 
found in α helix and β sheet regions, whereas loop regions and the α3 domain show less 
conservation. The m153 residues involved in dimerization are not conserved in the rest 
of the family consistent with our observation that m151 and m152 do not dimerize in 
solution (unpublished). Thus dimerization may be unique to m153.  Four family 
members (m17, m151, m152 and m155) contain cysteines that align with those of the 
unusual m153 C16-C171 disulfide. The C101-C108 and C203-C255 disulfides are also 
conserved among some of the family members. The limited sequence similarity of the N- 
and C-terminal regions of the extracellular domains of the m145 family members likely 
indicate a structural divergence in these parts of these molecules.  
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Figure 5.9. Amino acid sequence alignment of the m145 family. The predicted 
extracellular domains of all m145 family members (Refseq: NC_004065 (Rawlinson et 
al., 1996)) were aligned using ClustalW (Chenna et al., 2003) and optimized based on 
m153 and m157 structure. Secondary structure elements of m153 are shown above and 
those of m157 shown below the alignment. Cysteines involved in disulfide bonds are 
indicated by red (m153) and blue (m157) squares, and the respective pairs are indicated. 
Cysteines that are not conserved throughout the family, but are predicted to form 
disulfide bonds are boxed in red. Residues involved in a salt bridge (E70 and R166) are 
also indicated. N-linked glycosylation sites are indicated by green stars. The residues 
involved in m153 dimer interface contacts are indicated by blue ovals. The figure was 
generated with ESPRIPT (Gouet et al., 1999). 
 
 
 
 
           
 
Figure 5.10. Conserved interaction between E70, R166 and W167 connects α1 and 
H2b helices. B chain of m153 (cyan), disulfides (yellow). Inset, E70, R166 and W167 
are labeled, hydrogen bonds shown in black.  
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5.3 Discussion 
 
MHC-I molecules play a crucial role in the protection of the host against virus infection. 
Not only are MHC-I molecules essential for the detection of infection and priming of the 
cytotoxic CD8+ T cell response, but their presence on the cell surface protects healthy 
cells from attack by natural killer cells. Viral molecules with an MHC-I-like structure are 
likely to be excellent decoys for inhibitory natural killer receptors and may be able to 
interact with numerous molecules involved in the immune response. It is therefore not 
surprising that herpesviruses have incorporated MHC-I-like molecules in their arsenal of 
immunoevasins. Human, mouse and rat CMV encode MHC-I-like molecules that exhibit 
different levels of similarity to MHC-Ia molecules (Rawlinson et al., 1996; Vink et al., 
2000). HCMV encodes the MHC-I homolog UL18 which binds both β2m and peptide 
and engages the inhibitory receptor LIR-1 (Cosman et al., 1997). It also encodes UL142, 
which functions to inhibit NK cell lysis, has less sequence similarity to MHC-I and is 
predicted to consist of only the MHC-I α1α2 domain (Wills et al., 2005). MCMV 
encodes proteins like m144 that can associate with β2m, and others like m153 and m157, 
members of the m145 family, that are expressed without β2m. It is likely that several 
host genes have been captured by viruses during the course of coevolution (Alcami and 
Koszinowski, 2000). In the case of the MHC-I viral homologs it is probable that the 
closely related MHC-I genes like m144 and r144 were originally acquired from the host 
and that the distantly related m145 and r145 families arose via gene duplication and 
expansion of an ancestral 144 gene shaped by the selective pressures of the host immune 
response.  
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The crystal structure of MCMV m153 provides an example of the versatility of the 
MHC-I fold and is the first report of an obligate non-covalent dimer composed of two 
MHC-I-like chains. Together with the recently reported m157 structure, it highlights 
both the conserved and divergent features of the m145 family. The m153 monomer 
retains the core MHC-I characteristics, a β-sheet platform that supports two α-helices 
and an Ig-like α3 domain, but it exploits several structural adaptations to yield a stable 
molecule in the absence of peptide and β2m. Three main features combine to stabilize 
the m153 monomer: 1) the closely spaced α1 and α2 helices on the platform do not form 
a groove and alleviate the need for peptide binding; 2) the extended H2b helix bridges 
the α1α2 domain to the α3 domain; and 3) numerous interdomain contacts and two 
unique disulfide bonds (C16-C171 and C101-C108) stabilize the structure. Some of these 
features are shared among the other members of the m145 family. Whereas m157 is GPI-
linked and functions as a monomer (Arase et al., 2002), m153 has a bona fide 
transmembrane region and a large (47 amino acid) intracellular domain. We have shown 
that m153 is a stable dimer when expressed in mammalian cells, and the crystal structure 
of the soluble ectodomain reveals the mode of dimerization.  
 
Dimerization is unusual for MHC-I molecules. Although dimers of some classical MHC-
I molecules have been reported i.e., HLA-B27 (Bowness, 2002) and HLA-G (Shiroishi et 
al., 2006), these are disulfide-linked and their physiological relevance remains unclear. A 
non-disulfide linked dimer has been observed in crystals of the rat FcRn. Unlike m153, 
the two MHC-I molecules of the FcRn interact via their α3 and β2m domains, utilizing 
extensive protein-protein and protein carbohydrate interactions at the interface 
(Burmeister et al., 1994a). In the m157 crystal, a dimer of the same orientation as m153 
is formed with one of the symmetry related molecules. In m157 this dimer interface is 
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formed by anti-parallel beta strand interactions between the β6 strand of the platform and 
the D strand of the α3 domain. Thus the same chain orientation but an opposite sheet of 
the α3 domain (ABED) is utilized in the observed crystal packing.  
 
To gain insight into possible ligand binding sites on m153 we have examined regions 
corresponding to known interaction sites on murine MHC-I like molecules. These 
include the CD8αα binding site (α3 domain residues 220-228 and residues of the α1α2 
domain platform), the Ly49A NK receptor binding site (“site 2” including residues from 
the α3 domain, the α1α2 domain platform, and key residues of β2m), and the region of 
the FcRn-Fc interaction site (N-terminal portions of the α2 domain and of β2m) 
(Margulies et al., 2007). The compact nature of the m153 dimer, its lack of β2m 
association, and the regions that are masked by dimerization make it unlikely that any of 
the above mentioned sites are available for ligand binding. 
    
Since m153 is clearly related to other immunoevasins by both amino acid sequence and 
structure, it may be expected also to function to subvert the host immune response. 
Several features strongly indicate that m153 has a significant role in the viral life cycle. 
1) Several regions of the m153 sequence are conserved among related molecules with 
known immunoregulatory function. m152 and m155 conserve the C16-C171 disulfide, 
and m152 and m145, as well as m157, conserve the β5’-β6’ C101-C108 disulfide. 2) 
This is a readily expressed viral glycoprotein easily detected both intracellularly and at 
the cell surface in MCMV-infected fibroblasts. 3) Heteroduplex mobility assay (HMA) 
and DNA sequence analysis have been used to examine the levels of sequence variation 
of a number of MCMV genes of isolates from wild mice and laboratory strains. The 
MHC-Iv immunoevasins m144, m155 and m157 have significant variation, while m152 
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is highly conserved (Smith et al., 2006; Voigt et al., 2003). m153, like m152, is highly 
conserved among many strains showing little variation by both HMA and sequencing 
(Personal communication: Lee Smith and Alec Redwood, University of Western 
Australia). Such conservation implies not only a role in viral survival, but suggests that 
m153, like m152, may interact with an invariant site on a host molecule (Smith et al., 
2006). 
 
The following chapter presents our approach to the identification of ligands for m153 
and describes the identification of mouse spleen cells that express a putative m153 
ligand.  
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   CHAPTER 6 
 
 
IDENTIFICATION OF SPLEEN CELL SUBPOPULATIONS THAT ENCODE A 
PUTATIVE LIGAND FOR MCMV m153 
 
6.1  Introduction 
 
Virus-encoded proteins that are expressed at the surface of infected cells may serve a 
variety of different functions. Some are incorporated in the mature virus particles of 
enveloped viruses and facilitate adhesion and entry of viruses into uninfected cells and 
thereby enable the virus to spread. Other surface expressed viral proteins interact with 
and manipulate cells of the host immune response to create a favorable environment for 
virus survival. m153 forms part of a family of glycoproteins of which four have 
described immunevasion functions. The functions of m145, m152 and m155 are related 
in terms of their interaction with three different MHC-I-like NKG2D ligands. m152 also 
downregulates host MHC-I and m157 interacts with activating and inhibitory NK cell 
receptors. The MHC-I fold that was predicted for the m145 family has been proven for 
m153 (Chapter 5, (Mans et al., 2007)) and m157 (Adams et al., 2007). Thus it seems 
likely that the m145 family members share a similar MHC-I-like fold. The members with 
established function all interact with molecules that are either structurally related to 
MHC-I or interact with MHC-I molecules under normal physiologic circumstances. 
Since there are many examples of proteins with the MHC-I fold that have functions other 
than antigen presentation to T cells, just having a structure similar to MHC-I does not 
suggest an obvious function for any given protein. Since we have shown that m153 does 
not bind peptide or β2m it is clear that it would not function like traditional MHC-I 
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molecules. To evaluate whether m153 could have the same function as other m145 
family members we have tested the effect of transfected m153 on the cell surface levels 
of MHC-I, and have observed only a small effect on MHC-I surface levels at very high 
overexpression levels of m153 (Chapter 3). Immunoprecipitation studies of m153 in 
metabolically labeled MCMV-infected cells did not detect any binding partner (data not 
shown). To elucidate the function of MCMV m153 one can approach the problem in 
several different ways. An m153 deletion mutant can be constructed and the effect of the 
deletion evaluated in different mouse models of MCMV infection. Should a clear 
phenotype be observed, the organ and cell types in which the deletion has its greatest 
effect can be studied. In another approach, the viral molecule can be generated in 
recombinant form and used as “bait” to identify cell lines or cell types that express a 
ligand. Once a target population is identified, cDNA expression cloning can be used to 
find the ligand. The C-type lectin-related ligands for the NKRP1 family of NK cell 
receptors have been identified by a similar approach using NKRP1 reporter cells to 
screen tumor cells for ligands (Iizuka et al., 2003).  
 
We have used the reporter cell strategy to initiate the search for ligands of MCMV m153. 
In this chapter we will describe the generation of an m153-reporter cell line and the 
identification of mouse spleen cell populations that specifically stimulate the reporter 
cells.  
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6.2  Results 
 
6.2.1 Generation of m153z_43.1 and m144z_43.1 reporter cell lines 
 
In order to follow a reporter cell strategy to identify a ligand for m153, we generated an 
m153-reporter cell line using the 43.1 T cell line. The 43.1 cell line was established by 
Ohtsuka and colleagues (Ohtsuka et al., 2004). They transfected an NFAT-GFP cassette 
in the 2B4 T cell hybridoma and selected a clone that produced GFP upon crosslinking 
of the TCR. We fused the extracellular domain of m153 to the transmembrane and 
intracellular domains of the human zeta chain. This fusion protein construct was then 
introduced in 43.1 cells using a retrovirus. Approximately 71% of the 43.1 cells were 
infected and expressed detectable m153-zeta fusion protein at the cell surface (Figure 
6.1). We constructed a control m144-43.1 reporter cell line using the same strategy. We 
observed lower infection efficiency with the m144-zeta fusion protein virus and obtained 
a reporter cell population in which 45% of the cells express the m144-zeta fusion protein 
(Figure 6.1).  
 
 
 
 
 
 
 
 
 
 
 
123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Infection of 43.1 reporter cells with GFP-, 153z- and 144z-retroviruses. 
Upper panel – Unstained uninfected 43.1 cells (left), unstained control GFP-virus 
infected 43.1 cells (right) 55% of cells express GFP. Middle panel – Uninfected 43.1 
cells (left) and 153z-virus infected 43.1 cells (right) stained for m153 expression with 
mAb153.16 and anti-mouse IgG-APC. Seventy-one percent of 43.1 cells were infected 
with m153z. Lower panel – Uninfected 43.1 cells (left) and 144z-virus infected 43.1 cells 
(right) stained for m144 expression with mAb 15C6 and anti-mouse IgG-APC. Forty-
five percent of 43.1 cells were infected with 144z. For experimental details see Chapter 
2, section 2.17. 
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To establish whether the 153z_43.1 and 144z_43.1 reporter cell lines could produce GFP 
in response to crosslinking of m144 or m153, we cultured the reporter lines and the 
parental 43.1 cells on plates coated with monoclonal antibodies to the TCR (H57), m144 
(15C6) and m153 (mAb153.16). The 153z_43.1 cells responded very weakly to antibody 
coated at 1 µg/ml on plates. Therefore we titrated the m153.16 antibody (Figure 6.2) and 
found that 4 µg/ml is the optimal concentration for plate-bound antibody stimulation of 
153z_43.1. The 43.1 and 144z_43.1 cell lines could be triggered to produce GFP by 
antibody concentrations of 1 µg/ml (Figure 6.3). 
 
Between 80-90% of all three reporter cell types produced GFP in response to plate-
bound H57 anti-Vβ5. The numbers of 144z_43.1 cells that produced GFP corresponded 
to the proportion of cells that express m144 (45%) at the cell surface (Figures 6.1 and 
6.3). The 153z_43.1 cells were slightly less responsive and between 50 and 60% of the 
cells produced GFP, although 70% of the cells express the 153-zeta fusion protein 
(Figures 6.1 and 6.3). This response was specific since both reporter lines did not 
produce significant levels of GFP after culture on the non-specific antibodies (Figure 
6.3).  
 
 
Figure 6.2. Titration of mAb153.16 in a plate-
bound 153z_43.1 stimulation assay. 144z_43.1 
and 153z_43.1 were cultured overnight on plates 
coated with increasing concentrations of m153 
specific monoclonal antibody mAb153.16. The 
number of GFP positive cells was measured by 
FACS and represents the percentage reporter cell 
stimulation. Experimental details are described 
in Chapter 2, section 2.18. 
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Figure 6.3. Antibody-specific triggering of GFP production in 43.1, 144z_43.1 and 
153z_43.1 reporter cells. Reporter cells (1 x 105) were stimulated overnight with plate-
bound H57 (1µg/ml), 15C6 (1 µg/ml) or mAb153.16 (4 µg/ml). The percentage of GFP+ 
cells was determined by FACS and represents the reporter cell stimulation. For more 
details see Chapter 2, section 2.18. 
 
 
6.2.2 Freshly isolated mouse splenocytes stimulate GFP production in  
 153z_43.1 cells 
 
We performed overnight co-culture assays to screen several mouse cell lines of different 
tissue origin for reporter cell stimulation. None of the cell lines tested stimulated 
significant GFP production in 153z_43.1, 144z_43.1 or 43.1 cells (Figure 6.4). However, 
when we tested freshly isolated total spleen cells from B6 mice we observed GFP 
production in 10% of the 153z_43.1 reporter cells, whereas only 0.85% of the parental 
43.1 and 1% of the 144z_43.1 cells respectively produced GFP.  
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Figure 6.4. Mouse spleen cells stimulate GFP production in 153z_43.1 reporter 
cells. Coculture assays of 43.1, 144z_43.1 and 153z_43.1 reporter cells with a panel of 
cell lines and freshly isolated spleen cells. Reporter cells (1 x 105) were cocultured 
overnight with 1x106 test cells. The number of GFP+ cells was determined by FACS. 
Reporter cells were discriminated from stimulator cells by forward and side scatter 
gating. Freshly isolated spleen cells from C57BL6 mice induced GFP expression in 10% 
of 153z_43.1 cells. Control stimulation was performed with plate-bound mAb 15C6 
(144z_43.1) or mAb m153.16 (153z_43.1). Experimental details can be found in Chapter 
2, sections 2.19-2.20. 
 
To determine whether the stimulation we observed with freshly isolated spleen cells was 
dose responsive we titrated the number of spleen cells in a coculture assay. The 
stimulation of the 153z_43.1 reporter cells by mouse spleen cells was clearly dose-
dependent (Figure 6.5). Both the parental 43.1 and control 144z_43.1 cells did not 
respond significantly to stimulation with total spleen cells.  
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Figure 6.5. Dose response curve of spleen cell stimulation of 153z_43.1 reporter 
cells. The different reporter cells were cultured overnight with B6 splenocytes at a 1:10 
reporter to stimulator ratio. The percentage GFP+ cells was determined by FACS. 
Experimental details can be found in Chapter 2, section 2.19. 
 
Addition of the soluble ectodomain of m153, expressed in insect cells, to spleen 
cell/153z_43.1 cocultures blocked reporter cell stimulation by 40% (Figures 6.6 and 6.7). 
Thus the stimulation of 153z_43.1 by mouse spleen cells is dose dependent and can be 
partially blocked by soluble m153.  
 
 
 
Figure 6.6. Soluble m153 partially blocks 
stimulation of 153z_43.1 reporter cells 
by mouse splenocytes. Mouse splenocytes 
(B6) were cocultured overnight with 43.1, 
153z_43.1 or 144z_43.1 reporter cells at a 
ratio of 1:10 reporter to stimulator. The 
soluble extracellular domain of m153 was 
added to the cultures at a concentration of 
128 µg/ml. Experimental procedures are 
detailed in Chapter 2, section 2.19. 
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In a first attempt to identify the spleen cell population/s that stimulate 153z_43.1 reporter 
cells, we depleted mouse spleen cells with beads specific for MHC class II, DX5 and 
CD11c. Although the depletion was incomplete (data not shown), we observed that 
depletion of CD11c+ cells reduced the number of GFP+ cells obtained by total spleen cell 
stimulation from 9.86% to 5.69%. Depletion of MHC II or DX5 positive cells had a 
smaller effect and reduced the percentage of GFP+ cells to between 7.3-7.4%. When we 
tested the CD11c+ enriched population in a coculture assay with 153z_43.1 (at a ratio of 
1 : 4 reporter to stimulator) we observed a significant increase in GFP+ cells (9.86% to 
22.6%). These results suggested that the stimulating population might be CD11c+ cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7. CD11c+ enriched spleen cells increases 153z_43.1 reporter cell 
stimulation.  153z_43.1 cells (1 x 105) were cocultured with no stimulation, positive 
control mAb153.16 or 1 x 106 total mouse (B6) spleen cells, total spleen cells + soluble 
m153, MHC II depleted spleen cells, NK cell (DX5) depleted spleen cells, CD11c 
depleted spleen cells or 4 x 105 CD11c+ enriched cells. After overnight culture the 
number of GFP+ cells was determined by flow cytometry (the percentage GFP+ cells is 
indicated in each gate). CD11c+ cell depletion reduced 153z_43.1 stimulation from 9.9% 
to 5.7% and the CD11c+ enriched population increased the number of GFP-expressing 
reporter cells to 22.6%. Experimental details are described in Chapter 2, section 2.19. 
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6.2.3 Generation of reporter cell lines 153z_43.1_H and 144z_43.1_H 
 
Since the number of reporter cells that were stimulated by total spleen cells was 
relatively low, we wanted to increase the sensitivity of the coculture assay. The original 
m144- and m153-specific 43.1 reporter cell lines did not express the viral proteins on all 
cells in the respective populations (Figure 6.1). Therefore, we attempted to isolate 
reporter cell populations in which the majority of the cells expressed the m144- or m153-
zeta fusion proteins. We performed limiting dilution experiments and were able to 
generate new cell lines with higher and more homogeneous expression of the viral fusion 
proteins. The new cell lines were designated 153z_43.1_H and 144z_43.1_H. Surface 
staining of these cell lines indicated that approximately 90% of 144z_43.1_H cells 
expressed m144-zeta and 98% of 153z_43.1_H cells expressed m153-zeta. (Figure 6.8A 
and C). When tested in a stimulation coculture assay, the capacity of the 153z_43.1_H 
cells to produce GFP in response to total spleen cell stimulation (1:10 reporter : 
stimulator) increased approximately two-fold (Figure 6.8B). The new reporter cell lines 
were used in all subsequent stimulation assays.  
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Figure 6.8. 144z_43.1_H and 153z_43.1_H reporter cells. A) m153-zeta surface 
expression on the original 153z_43.1 reporter cell population  (left, 74% m153+) and the 
153z_43.1_H cells (right, 98% m153+). Cells were surface stained with mAb153.16 and 
anti-mouse IgG-APC. B) Comparison of GFP production in 153z_43.1 and 153z_43.1_H 
cells. The respective reporter cells (1 x 105) were cultured overnight with 1 x 106 total 
spleen cells from BALB/c mice. The number of GFP positive cells was determined by 
FACS. C) Surface expression of m144-zeta on the original 144z_43.1 and the new 
144z_43.1_H cells. Cells were stained with m144 specific mAb 15C6 and anti-mouse-
PE. Experimental details are described in Chapter 2, sections 2.17 and 2.19. 
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6.2.4 Dendritic cells are the major population in mouse spleen that stimulates 
153z_43.1_H reporter cells 
 
Based on the initial results of the CD11c+ depletion experiments, we isolated CD11c+ 
cells by positive selection and tested these cells in a coculture assay with 153z_43.1_H 
and 144z_43.1_H. To obtain the highest numbers of dendritic cells from spleen the 
single cell suspensions were prepared by enzymatic disaggregation. This resulted in 
increased yields of CD11c+ cells. The results in Figure 6.9A show that total spleen cells 
prepared by this method showed increased stimulation of 153z_43.1_H cells of ~ 30%. 
This represents a two-fold increase in the stimulation that was observed with 
mechanically aggregated spleen cells (Figure 6.8B). Purified CD11c+ cells induced GFP 
production in approximately 70% of 153-specific reporter cells but did not cause 
significant GFP production in the control 144z_43.1_H cells (Figure 6.9A). Spleen cells 
that were depleted of about half of the original number of CD11c+ cells had a reduced 
capacity to stimulate the 153z_43.1_H cells when compared to total spleen cells (18% 
versus 30%). Taken together these results show that CD11c+ cells are potent and specific 
stimulators of 153z_43.1_H cells and therefore could encode a ligand for m153.  
 
To establish whether additional spleen cell populations have the ability to stimulate 
153z_43.1_H reporter cells we isolated CD11b+ (monocytes/macrophages), DX5+ (NK) 
and CD19+ (B) cells by positive selection and CD4+ and CD8+ T cells by negative 
selection and tested them in coculture assays. In Figure 6.9B the percentage reporter cell 
stimulation relative to CD11c+ stimulation (which was set to 100%) is shown.  
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Figure 6.9. CD11c+ cells are the most potent stimulators of 153z_43.1_H reporter 
cells. A) Total BALB/c spleen cells, CD11c+ cells or CD11c+-depleted spleen cells were 
cocultured overnight with 153z_43.1_H or 144z_43.1_H at a 1:10 ratio of reporter to 
stimulator. B) 144z_43.1_H or 153z_43.1_H cells were stimulated overnight with 
CD11c+ cells, CD11b+ cells (monocytes/macrophages), NK cells (DX5), B cells (CD19) 
or T cells (CD4 or CD8) (1:10 ratio reporter to stimulator). The purity of the respective 
stimulator populations is indicated in parentheses. In both A) and B) the reporter cells 
were stained with an anti-Vβ3-PE antibody, to facilitate discrimination between the 
reporter and stimulator cells. The number of Vβ3 and GFP double positive cells was 
determined by FACS and represents the percentage reporter cell stimulation. In B) the 
A 
B 
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stimulation observed by CD11c+ cells was set at 100% and the other values normalized 
to that level. Details on the isolation of the spleen cell populations and the coculture 
assay can be found in Chapter 2, sections 2.19 and 2.21.  
 
 
Compared to CD11c+ cells, only CD11b+ cells and NK cells caused significant 
stimulation of GFP production in 153z_43.1_H cells (Figure 6.9B). In mice, CD11b is 
expressed on monocytes/macrophages and is present at lower levels on granulocytes, NK 
cells and subsets of DCs. The CD11b population that was isolated for testing against the 
153z_43.1_H reporter cells was 80% positive for CD11b. Sixteen percent of this 
population expressed both CD11b and CD11c and represents DCs. Thus the stimulation 
observed could in part be due to contaminating DCs. The purity of the NK cells was 70% 
based on DX5 expression. There was a substantial amount of CD11c+ cell contamination 
(data not shown) in the NK cell preparation. To obtain a purer NK cell isolation we 
isolated NK cells by first performing negative selection and then enriching that 
population for DX5+ cells using positive selection. Using this combination we obtained 
91% pure DX5+ NK cells (1-2% CD11c+ DC contamination). When compared to 
CD11c+ cells in a stimulation assay these NK cells could induce GFP production in 20% 
of the reporter cells, whereas 76% of the 153z_43.1_H cells responded to CD11c+ cell 
stimulation (Figure 6.10). The low level of DC contamination in the NK preparation 
could not account for this stimulation, therefore it is likely that a ligand for m153 is 
present at low levels or only on a subset of NK cells. It is clear however, that B and T 
cells do not encode a ligand for m153, since even cell populations of high purity could 
not induce substantial GFP production in the 153z_43.1_H reporter cells.  
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Figure 6.10. Comparison of 153z_43.1_H reporter cell stimulation by CD11c+ DCs 
and DX5+ NK cells. 153z_43.1_H reporter cells (1 x 105) were cocultured overnight 
with 9 x 105 DCs or NK cells. The cells were analyzed by FACS as described in the 
legend to Figure 6.9. Filled grey histogram – NK cells + 153z_43.1_H, blue line – DCs 
+ 153z_43.1_H.  
 
Another dendritic cell type that occurs at a low frequency in the spleen is the 
plasmacytoid dendritic cell (pDC). Since conventional dendritic cells were strong 
stimulators of m153-specific reporter cells, we isolated pDCs from mouse spleens and 
tested them for stimulation of the 153z_43.1_H cells. Our results in Figure 6.11 reveal 
that pDC are even more potent stimulators of 153z_43.1_H reporter cells. Compared to 
the ~ 70% GFP+ cells induced by conventional CD11c+ DCs, ~ 89% of the reporter cells 
produced GFP after overnight coculture with pDCs (Figure 6.11A). The control 
144z_43.1_H cells did not produce any GFP in response to coculture with pDCs, 
confirming the specificity of the stimulation (Figure 6.11B). In summary, only cells of 
the innate immune system are capable of stimulating 153z_43.1_H cells. cDC and pDC 
CD11c+ cells NK (DX5+) cells 
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are the most potent stimulators, macrophages and NK cells provide much weaker 
stimulation and B and T cells no significant stimulation at all.  
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Figure 6.11. Plasmacytoid DC and bone marrow-derived CD11c+ DC stimulate 
153z_43.1_H reporter cells. A) GFP production in 153z_43.1_H reporter cells 
cocultured overnight with BALB/c CD11c+ DCs (left) or pDCs (right) at a 1 : 7 ratio of 
reporter to stimulator cell. Reporter cells were stained for Vβ3 and analyzed for GFP 
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expression by FACS. Double positive cells (Vβ3+GFP) represent the number of 
stimulated cells. B) Histogram representation of GFP production in A with addition of 
the control cells 144z_43.1_H.  C) GFP production in parental 43.1 and 153z_43.1_H 
reporter cells in response to overnight stimulation with splenic CD11c+ cells (left) and 
BM-derived CD11c+ cells (right). The cells were gated on Vβ3 expression and the 
percentage of GFP+ cells was determined by FACS. Experimental details in Chapter 2, 
sections 2.21.2 and 2.22.  
 
 
To establish whether dendritic cells derived from bone marrow cultures could stimulate 
153z_43.1_H reporter cells we cocultured reporter cells with CD11c+ cells isolated from 
six- day old bone marrow (BM)-GM-CSF cultures. BM-derived CD11c+ cells stimulated 
153z_43.1_H reporter cells as potently as CD11c+ cells isolated from the spleen (Figure 
6.11C).  
 
 
We next titrated the number of spleen CD11c+ cells in a coculture assay and determined 
that the stimulation we observed resembled a specific interaction and could be saturated. 
Maximal stimulation of the 153z_43.1_H reporter cells was observed with 5 x 105 
CD11c+ cells (Figure 6.12A). To ascertain that the reporter cell stimulation we observed 
was due to a specific interaction of MCMV m153 with a ligand/ligands on dendritic cells 
we pre-incubated splenic CD11c+ cells with increasing concentrations of soluble m153, 
and soluble m152 as a negative control, and then performed the overnight coculture 
assay. Soluble m153, but not soluble m152, reduced the reporter cell stimulation from 
56% to 29% (Figure 6.12B) indicating that the stimulation is m153 specific. In addition 
we show that the stimulation of 153z_43.1_H reporter cells by spleen CD11c+ cells is 
cell contact dependent (Figure 6.12C). In a standard 24 well coculture assay, 52% of 
153z_43.1_H cells produce GFP in response to CD11c+ cells, whereas less that 1% 
parental 43.1 cells produce GFP. When the cocultures are performed using transwell 
inserts (0.4 µm membrane) that separate the stimulator cells from the reporter cells, the 
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reporter cell stimulation is abolished. Thus, CD11c+ cells stimulate 153z_43.1_H 
reporter cells in a dose-, m153-specific and cell contact-dependent fashion. We conclude 
that both conventional and plasmacytoid DC potently and specifically stimulate 
153z_43.1_H reporter cells and thus express a ligand for MCMV m153.  
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Figure 6.12. The stimulation of 153z_43.1_H reporter cells by CD11c+ cells is m153- 
specific and dose- and cell contact-dependent. A) Percentage reporter cell stimulation 
after overnight coculture of parental 43.1 cells or 153z_43.1_H reporter cells (1x105) 
with increasing numbers of BALB/c spleen-derived CD11c+ cells (0.625 – 10 x 105). 
Reporter cells were stained for TCR (Vβ3) expression and the percentage of TCR/GFP 
double positive cells represents stimulation. B) BALB/c CD11c+ cells (5 x 105) were pre-
incubated with either 100 or 200 µg soluble MCMV m152 or m153 for 30 min. at 37 °C 
before addition of 1 x 105 153z_43.1_H reporter cells and overnight coculture. Reporter 
cell stimulation was decreased from 56% in the PBS control to 38% (100 µg) and 29% 
(200 µg) after m153 pre-incubation. m152 pre-incubation did not affect reporter cell 
stimulation significantly (around 53% stimulation at both concentrations). C) Coculture 
of 1.2 x 106 BALB/c CD11c+ cells with 5 x 105 43.1 or 153z_43.1_H reporter cells 
(upper panels) and transwell cocultures of 1.2 x 106 CD11c+ cells with 5 x 105 
153z_43.1_H reporter cells (lower panels). Reporter cells were stained for TCR 
expression to facilitate discrimination from stimulator cells. TCR/GFP double positive 
cells represent the fraction of activated reporter cells. The cell-cell contact assay is 
described in Chapter 2, section 2.23. 
 
 
6.2.5 Dendritic cells from a variety of mouse strains stimulate 153z_43.1_H 
reporter cells 
 
We have screened several mouse strains to establish how widely the m153 ligand is 
expressed. Total spleen cell populations and purified CD11c+ cells from eight different 
strains were tested. DCs from all strains were able to stimulate the 153z_43.1_H reporter 
cells specifically although some strains were more potent than others (Figure 6.13). 
Further experiments were performed with cells isolated from BALB/c mice, since cells 
from this strain caused strong stimulation of the 153z_43.1_H reporter cells.   
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Figure 6.13. Splenocytes and CD11c+ cells from eight mouse strains stimulate 
153z_43.1_H reporter cells. Total spleen cells (1 x 106) or positively selected CD11c+ 
cells (1 x 106) from each strain were cocultured overnight with 1 x 105 153z_43.1_H 
reporter cells or parental 43.1 cells as a control. The reporter cells were stained for TCR 
(Vβ3) and analyzed by FACS. The TCR/GFP double positive cells represent stimulated 
reporter cells. Details on the isolation of total spleen and CD11c+ cells as well as the 
coculture protocol can be found in Chapter 2, sections 2.19-2.21.  
 
We also tested total splenocytes and splenic OX62+ dendritic cells isolated from Wistar 
rats for stimulation of the 153z_43.1_H reporter cells (Figure 6.14) but observed no 
significant GFP production. These results indicate that the m153 ligand is expressed in a 
range of mouse strains but not in the rat.  
 
 
 
153z_43.1_H 43.1 
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Figure 6.14. Rat OX62+ dendritic cells do not stimulate the 153z_43.1_H reporter 
cells. Total spleen and dendritic cells were isolated from mice or rats and cocultured 
overnight with 153z_43.1_H reporter cells. The reporter cells were stained for TCR 
(Vβ3) expression and analyzed by FACS. The percentage of Vβ3 cells that express GFP 
represent the stimulated fraction. Details on the cell isolation and cocultures can be 
found in Chapter 2, sections 2.19-2.21. 
 
6.2.6 Analysis of the surface phenotype and migration of CD11c+ DCs after 
exposure to 153z_43.1_H reporter cells or plate-bound m153  
 
We have shown that coculture of CD11c+ DCs and 153z_43.1_H can induce GFP 
production in the m153-specific reporter cell line. These results imply an interaction of 
m153 with one or several unknown ligands on the surface of mouse DCs. Dendritic cells 
undergo rapid phenotypic changes linked to their maturation and function. We have 
examined whether the interaction of CD11c+ DCs with 153z_43.1_H reporter cells 
specifically affects the expression levels of the DC surface markers CD40, CD80, CD86 
and MHC class II. Dendritic cells were either cultured alone, with control 43.1 cells or 
with 153z_43.1_H reporter cells at a 1 : 1 ratio to optimize cell-cell interactions. The cell 
cultures were then stained for CD11c and the respective cell surface markers as shown in 
Figure 6.15.  
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Figure 6.15. CD11c+ surface phenotype is not specifically affected by coculture with 
153z_43.1_H cells.  The levels of CD40, CD80, CD86 and MHC II on the surface of 
BALB/c CD11c+ cells were determined after overnight culture of CD11c+ cells alone or 
with 43.1 or 153z_43.1_H reporter cells (at a 1:1 ratio). Grey – isotype control, black – 
CD11c+ cells alone, blue – CD11c+ + 43.1, red – CD11c+ + 153z_43.1_H. Cells were 
stained for CD11c and gated on this population before analysis of the surface marker 
staining. Experimental details in Chapter 2, section 2.25. 
 
 
Coculture of dendritic cells with the control 43.1 cells or 153z_43.1_H cells caused 
significant upregulation of CD40, CD80 and CD86 and slight upregulation of MHC class 
II in both cultures. Since the parental control cell line and 153z_43.1_H cells induced 
comparable upregulation in DC surface markers the effect is not specific to m153. 
Therefore the m153/DC interaction does not seem to specifically affect the surface levels 
of CD40, CD80, CD86 and MHC class II on dendritic cells. 
 
Next we examined the effect of m153 on the migration capacity of CD11c+ cells. 
Purified CD11c+ cells were cultured overnight on plates coated with recombinant m153 
or m152 as a negative control. The cells were then transferred to transwell chambers 
with 5 µm polycarbonate membranes in wells containing the chemokine MIP-
3β (CCL19). The number of cells that had migrated was quantified by FACS after 5 
hours of incubation.  
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In comparison to the PBS treated control DCs, the cells that were grown on plate-bound 
m152 or m153 exhibited a reduced capacity to migrate in response to MIP-3β (Figure 
6.16). Therefore this effect was not specific to MCMV m153. DCs treated overnight with 
LPS showed only a slight decrease in migration.  
 
Figure 6.16 Migration of dendritic cells in response to MIP-3β  (CCL19) is not 
affected by MCMV m153. BALB/c CD11c+ cells were cultured overnight on plates 
coated with PBS, PBS + 1µg/ml LPS in the medium, m152 or m153 (10 µg/ml). The 
migration of the control and treated DCs was assessed in a migration assay in 5 µm 
transwell plates as described in Chapter 2, section 2.24. The migration index represents 
the ratio of number of cells migrating in chemokine (MIP-3β)/ number of cell migrating 
in medium.  
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6.3 Discussion 
 
We have identified dendritic cells as a cell type that encodes a potential ligand for 
MCMV m153. By using the recombinant extracellular domain of m153 fused to the 
transmembrane and signaling chains of human zeta, we have created a reporter cell line 
(153z_43.1_H) that expresses GFP upon cross-linking of the m153-zeta fusion protein. 
 
CD11c+ dendritic cells derived both from the spleen and the bone marrow, as well as 
splenic plasmacytoid DCs, potently stimulate GFP production in the 153z_43.1_H cell 
line. The stimulation was shown to require cell-cell contact and increased in a dose 
dependent manner with increasing numbers of purified CD11c+ DCs. The specificity of 
the interaction was confirmed by two different controls. An m144-specific reporter cell 
line, 144z_43.1_H, constructed in the same way as the m153-specific reporter line, did 
not produce GFP in response to coculture with dendritic cells. In addition, the 
stimulation of 153z_43.1_H cells could be blocked partially by addition of soluble m153. 
These results strongly suggest that an interaction between m153 and one or more 
molecules on DCs triggers GFP production in the m153-specific reporter cells. We were 
however, unable to stain DCs with either the dimer or tetramer of soluble m153 (data not 
shown). This could indicate that it is a low affinity interaction that can occur between 
molecules on the surfaces of interacting cells, but is not strong enough to be detected by 
surface staining.  
 
Dendritic cells from a variety of mouse strains were able to stimulate the 153z_43.1_H 
reporter cells in a specific manner. We also tested rat dendritic cells for reporter cell 
stimulation. These cells were unable to induce GFP expression in the m153 reporter 
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cells. This correlates with the absence of a direct homolog of MCMV m153 in the rat 
CMV (Vink et al., 2000). Different dendritic cell subsets play pivotal roles in 
orchestrating the immune response to virus infections. Therefore it would not be 
surprising if MCMV targets this specific cell type via m153. In our experiments, pDCs 
induced nearly 20% more GFP positive cells than the same number of conventional 
CD11c+ DCs. This could either indicate that the ligand is present at higher 
concentrations on pDCs, or that only a subset of CD11c+ cells express the ligand at 
levels comparable to pDCs. This remains to be investigated. Since a target population 
has now been identified, a viable approach to identify the ligand for m153 is to construct 
a dendritic cell-specific cDNA library and screen this library with the reporter cell line. 
The success of this approach depends on the assumption that the ligand is a single 
molecule.  
 
We have assessed the functional effect of m153 on dendritic cell surface phenotype and 
the ability of the cells to migrate in response to the chemokine MIP3β. Neither the 
surface phenotype nor the migration capacity of CD11c+ dendritic cells was altered 
specifically due to interaction with 153z_43.1_H reporter cells. In contrast to the other 
members of the MCMV m145 family with defined functions, which all target NK cell 
related ligands, our data suggests that m153 targets dendritic cells of various subsets. 
The identification of the ligand for m153 and further functional characterization of the 
interaction should shed light on the mechanism that MCMV uses to manipulate these 
antigen presenting cells to its own advantage.  
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CHAPTER 7 
 
CONCLUDING DISCUSSION 
 
In this study we set out to characterize the m145 glycoprotein family encoded by MCMV 
and test the prediction that these proteins are structurally similar to MHC class I 
molecules, despite very low amino acid similarity between the viral proteins and MHC-I. 
The first MHC-I structure was determined twenty-one years ago (Bjorkman et al., 1987). 
At that time the mechanism of antigen presentation by MHC-I molecules was not well 
understood. The structure revealed the nature of the antigen-binding site and the authors 
correctly predicted that the unidentified electron density in the groove represented 
peptide antigen bound to the heavy chain. The classical role of MHC-I molecules in 
antigen presentation to CD8 T cells has been studied extensively in the past decades. 
However, more recently several examples of MHC-I related molecules with functions 
unrelated to peptide binding and presentation have been described. The neonatal rat Fc 
receptor structure was the first structure of a non-classical MHC-I molecule to be 
determined. The structure revealed a peptide-free, β2m-associated heavy chain in which 
the α1 and α2 helices are situated close together (Burmeister et al., 1994a). The structure 
of the FcRn in complex with Fc showed that a site distinct from the antigen binding 
groove (N-terminal end of α2 helix and β2m) is utilized in binding to Fc (Burmeister et 
al., 1994b). This study illustrated for the first time that the MHC-I fold is utilized for 
functions other than antigen presentation. 
 
Human and mouse CD1 molecules present lipid antigens to NKT cells (Brigl and 
Brenner, 2004). The crystal structure of mouse CD1d revealed an MHC-I-like heavy 
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chain associated with β2m (Zeng et al., 1997). The helices that form the groove are 
longer than in classical MHC-I molecules and closer together and form a deep groove 
lined with hydrophobic residues, which is consistent with binding of lipid antigens. 
Further examples of proteins that have the MHC-I fold but perform functions unrelated 
to antigen presentation are the hemochromatosis gene product (HFE), which plays a role 
in the regulation of iron metabolism (Adams and Barton, 2007), the zinc-α2-
glycoprotein (ZAG), a soluble lipid mobilizing factor involved in the regulation of body 
weight (Gohda et al., 2003) and the mouse M10 proteins, which are pheromone receptor-
associated MHC-like proteins (Olson et al., 2006) that are expressed in the mouse 
vomeronasal organ. Both HFE and M10.5, an M10 family member, associate with β2m. 
Whereas HFE does not have a functional groove (Lebron et al., 1998), M10.5 has a 
groove region that resembles that of classical class I molecules but that was unoccupied 
in the crystal structure (Olson et al., 2005). The M10.5 structure is the first of an MHC-I-
like molecule with an empty, open groove. M10.5 however is thermally unstable, which 
suggests that the groove is normally occupied by an unknown ligand (Olson et al., 2005). 
ZAG does not associate with β2m or peptide but binds a yet unidentified ligand with 
hydrophobic character (McDermott et al., 2006).  
 
The stress-induced ligands Rae-1 (α-γ), MICA, and the viral MHC-I homolog m144 are 
proteins that exhibit more drastic deviations from the classical MHC-I fold. None of 
these molecules bind peptide, Rae-1β consists only of an α1α2 domain (Li et al., 2002), 
MICA and m144 conserve the full-length heavy chain but MICA does not associate with 
β2m (Li et al., 2001) whereas m144 crystallized in complex with β2m, but is also stable 
in recombinant form without β2m (Natarajan et al., 2006). To explore the similarities 
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between classical MHC-I proteins and the members of the MCMV m145 family we 
studied the proteins in transfected mammalian cells. 
 
Initial experiments indicated that some members (m145, m151, m153) localize 
predominantly to the cell surface while others (m17, m152, m155) remain inside the cell. 
The cellular localization possibly reflects the site of action of the viral proteins, although 
not in all cases since m145 is detected readily at the cell surface in spite of the fact that it 
downregulates the NKG2D ligand, MULT-1, from the surface of MCMV-infected cells. 
Experiments in β2m- and TAP-deficient cell lines provided evidence that the surface 
expression of m145, m151 and m153 as well as M37 is independent of β2m or TAP 
activity. These results imply that the MCMV proteins have a modified MHC-I fold.  
 
To generate protein for structural characterization we evaluated recombinant expression 
in bacteria. We were unable to refold any of the MHC-Iv proteins from bacterial 
inclusion bodies. Classical MHC-I proteins are generally refolded easily when the 
denatured heavy chain is added to folded β2m and peptide, which presumably act as 
nuclei for the heavy chain to fold properly. The non-classical MHC-I molecule Rae-
1β was refolded successfully from E. coli inclusion bodies (Li et al., 2002), probably 
since it only consists of the α1α2 MHC-I domain. MICA, in contrast, was expressed in 
insect cells (Trichoplusia ni) to obtain protein for crystallization (Li et al., 2001). We 
expressed M37, m151 and m153 successfully in Drosophila insect cells and we have 
determined the crystal structure of m153. The structure of m157 was also reported 
recently (Adams et al., 2007).  
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The MHC-I fold (α1α2 and α3 domains) is clearly recognizable in both structures and 
the overall shape of the heavy chain is similar for m153 and m157. A most unusual 
feature of m153 is that it forms a stable, non-covalent dimer. In this dimer the two m153 
heavy chains are arranged “head-to-tail” with the platform of one monomer contacting 
the α3 domain of the other. The β8’ strand of the platform domain forms a parallel β 
strand interaction with the C’ strand of the α3 domain. Mutation of four residues that 
contribute to the dimer interface to alanine, abolished the dimerization of m153. 
 
In both m153 and m157 the α1 and α2 helices are positioned close together on the 
platform and no peptide binding groove is formed, reminiscent of Rae-1β and HFE. The 
most distinctive feature of these viral molecules is an extended α2 helix, designated H2b, 
which bends down at the edge of the platform sheet and extends towards the α3 domain. 
The upper part of the H2b helix is tethered to the α1 helix via interactions between three 
highly conserved residues (E70, R166, W167).  
 
m153 and m157 exhibit the biggest differences at their termini. The N-terminus of m153 
is elongated compared to other MHC-I molecules and starts adjacent the α3 domain and 
stretches upwards along the H2b helix until it forms the first strand of the platform sheet. 
A unique disulfide bond links the extended N-terminus to the H2b helix. m157 also has 
an extended N-terminus, but this region folds into a short α-helix, designated α0 that lies 
almost parallel to the α1 and α2 helices. The C-termini of both proteins could not be 
modeled due to a lack of electron density, suggesting flexibility in those parts of the 
proteins. The other members of the m145 family are likely to adopt the same basic fold 
as m153 and m157, with variations at the N- and C-termini. m17, m151, m152 and m155 
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all conserve Cys16 and Cys171, that are involved in the bond stabilizing the extended N-
terminus of m153, suggesting that they have similar N-termini.  
 
m152 and m153 share the largest number of identical amino acids within the m145 
family. An interesting feature of m152 is that it lacks the second conserved cysteine in 
the α3 domain, which is present in all the other m145 and r145 family members. 
Examples of proteins with Ig-like domains lacking the conserved disulfide bond include 
CD2 (Jones et al., 1992) and CD4 (Brady et al., 1993). In domain 1 of CD2 the positions 
of the β strands are not affected by the lack of a disulfide bond and the domain 
superimposes well on domain 1 of CD4, which has a disulfide bond. In domain 3 of rat 
CD4 the absence of the disulfide bond causes expansion of the domain, with greater 
separation between the β sheets. The α3 domain disulfide bond is preserved in the rat 
homolog of m152, which suggests that the MCMV protein may not display a significant 
displacement of the strands. A molecular model of m152, based on the structure of 
m153, could be useful in exploring the interactions of m152 with its cellular ligands.  
 
In conclusion, the structure of m153 reveals yet another adaptation of the MHC-I fold, 
displays a novel mode of dimer formation for β2m-free heavy chains and together with 
the m157 structure it allows the prediction of shared structural features for the other 
m145 family glycoproteins.  
 
The immune modulatory functions of the m145 family members have been discussed in 
detail in previous chapters. We have shown that m153 is expressed on the surface of 
MCMV-infected cells. It is likely that m153 functions by engaging a receptor on host 
cells. To identify host cell populations that express ligands for m153 we constructed a 
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153-reporter cell line that can express GFP in response to cross-linking of an m153-
human zeta fusion protein. Mouse splenocytes stimulated these reporter cells 
specifically. We subsequently isolated different cell types from the spleen and tested 
them for stimulation of the m153-reporter cells. Our results show that cells of the innate 
immune system most likely express a ligand or ligands for MCMV m153. Whilst B and 
T cells were unable to stimulate the m153-reporter cells, CD11c+ and plasmacytoid 
dendritic cells and to a lesser extent CD11b+ cells and NK cells specifically stimulated 
GFP production in the m153-reporter cells. Dendritic cells derived from the spleen as 
well as bone marrow cultures could stimulate the reporter cells. The stimulation was 
dependent on cell-cell contact and could partially be blocked by soluble recombinant 
m153.  
 
Cells of the innate immune system coordinate the initial response to virus infections and 
help to shape the adaptive immune response. Dendritic and NK cells in particular are 
important in combating MCMV infection. Disruption of the activation of NK cells is a 
major target for several MCMV proteins, especially those from the m145 family. 
Dendritic cells can be infected by MCMV and the functional capacity of these cells is 
severely impaired at late times after infection. Due to the central role of DCs in the 
generation of an immune response the virus would benefit from also manipulating 
uninfected DCs. A recent study that investigated the effect of UL18-Fc fusion proteins 
on DCs showed that the UL18/LIR-1 interaction leads to the upregulation of CD83 and 
cytokine production in immature monocyte-derived DCs. UL18 also inhibited the 
chemotaxis of the DCs (Wagner et al., 2008). These results provide evidence that a viral 
MHC-I homolog can modulate DC function in vitro.  
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Our results indicate that MCMV m153 interacts specifically with both conventional and 
plasmacytoid DCs. We could not detect a specific effect of this interaction on the surface 
phenotype or migration ability of CD11c+ DCs. The functional consequences of the 
interaction remain to be further explored. To best understand the function of m153 
during MCMV infection, one needs to identify its ligand in the host. Based on our data, 
both conventional and plasmacytoid DCs present excellent target cell types for ligand 
identification. The m153-reporter cell line will be a useful tool to screen a DC-specific 
cDNA library to identify a ligand.  
 
The m145 family of MCMV encodes a fascinating set of molecules with diverse 
functions that all presumably contribute to successful virus propagation. The original 
structural prediction has now been proven for two family members and it is clear that 
these MCMV proteins form part of the MHC superfamily. Many questions remain and it 
would be of great interest to determine which regions of the MHC-Iv molecules are 
involved in complex formation with their individual ligands. Further study of this 
MCMV family should yield great insight into the mechanisms MCMV and other 
herpesviruses employ to co-exist with their hosts.  
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